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CHAPTER 1
GENERAL INTRODUCTION
Mr. C is a 58-year old man with FSHD diagnosed at the age of 22. Apart from this 
muscle disease, he has always been healthy. He has worked fulltime most of his 
life but, since five years, he has been declared unfit for work. He used to live in 
a home with a garden, together with his wife.  Because he was not able to walk 
stairs anymore, they were forced to move to an apartment with a small balcony. 
Since gardening was his hobby, he lost his main activity which he replaced by 
taking a nap every afternoon. At night, he is frequently awake and in the morning 
he is already fatigued from the beginning of the day. His wife wants him to go with 
her to family and friends, but he is reluctant to do so because he hates talking 
about his disease and getting all sorts of well meant advice. He is afraid that 
exercise might damage his muscles, as he regularly experiences muscle pain after 
physical activity. As a consequence, he has stopped his daily cycling sessions 
on a home trainer. His maximal walking distance has decreased to just a couple 
of hundred meters, which makes him increasingly home-bound. All together, his 
changing condition and circumstances have drawn him into a vicious circle of 
physical inactivity and fatigue, with a great impact on his quality of life.
For patients with facioscapulohumeral muscular dystrophy (FSHD), medical 
involvement often stops after receiving the diagnosis but, from their perspective, 
the need for medical attention has just begun.  Patients, clinicians and researchers 
are searching for a curative treatment but, meanwhile, care for the consequences 
of the disease is just as important, especially in the short turn. Many patients with 
FSHD try to keep up their participation in social life and work. Citing a patient with 
FSHD: “You just want to live your life like everyone else. That should be the aim of 
medical research”. Yet, being physically active is difficult for patients due to muscle 
weakness. The resulting reduction in aerobic capacity further restricts social 
participation. Moreover, more than 60% of the patients with FSHD are severely 
fatigued (1). In the past, fatigue in FSHD has received little attention as it was 
regarded as an untreatable problem patients “just had to live with”. Consequently, 
patients did not often spontaneously complain of fatigue. Still, recognition of 
fatigue in FSHD is important for patients, whereas understanding and treating 
fatigue is a great challenge for researchers and clinicians. Fortunately, medical 
attention for fatigue is increasing. 
FSHD
FSHD is the third-most common muscu lar dystrophy. The estimated prevalence is 
one in 8,000 persons (2). FSHD is an autosomal dominant disease. It is associated 
with subtelomeric contraction of the D4Z4 repeat region at chromosome 4q, with C
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loss of tandem repeat units and toxic expression of the DUX4 gene in muscle 
cells (3). In unaffected individuals, the D4Z4 array consists of 11 to 150 repeats, 
whereas FSHD patients have only 1 to 10 repeats. In general, the disorder is more 
severe in patients with lower numbers of repeats (Figure 1). Individuals genetically 
determined to have FSHD, however, show a wide range of clinical severity, age of 
onset, and rate of disease progression, including some who remain asymptomatic 
throughout their lives. This variability suggests that the disease has a strong 
epigenetic component. 
Figure 1 FSHD is linked to the 4qQ subtelomere and the epigenetic status of 
the 4q35 D4Z4 array
When D4Z4 is composed of many DUX4 copies the DNA becomes ‘locked’. As a result, the 
DUX4 gene is switched off or ‘silenced’. However, if there are only a few DUX4 copies, the 
DNA ‘relaxes’ and becomes accessible. When this happens, the DUX4 gene is switched 
on resulting in carbon copies of the gene being made – called RNA. These contain the 
instructions to build a DUX4 protein. Figure courtesy of Andreas Leidenroth (4).
Epigenetics concerns the mechanisms other than DNA sequence that 
influence gene expression. An example of an epigenetic mechanism is DNA 
methylation, a process by which methyl groups are added to DNA. The more 
methylation, the tighter the chromatin is compacted and the less the gene inside 
is expressed. Conversely, reduced methylation (hypomethylation) relaxes the 
chromatin and increases the likelihood of gene expression. Healthy individuals have 
numerous D4Z4 repeats which are highly methylated (Figure 1) (4). FSHD1-affected 
individuals have few repeats and these are hypomethylated. FSHD1 asymptomatic 
or unaffected individuals also have few repeats, but these have a higher degree of 
methylation (5). Recently, a new subtype of FSHD, type 2, (FSHD2) was identified 
(6). The symptoms of FSHD1 and FSHD2 are similar; the difference between 
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the conditions is their genetic locus and frequency of occurrence (7). FSHD2 
individuals have many D4Z4 repeats, like healthy individuals, but they are severely 
hypomethylated (6).  
FSHD2 is much less prevalent than FSHD1. Current research projects try to identify 
and manipulate the epigenetic regulators of the DUX4 gene expression in both 
FSHD1 and FSHD2 in order to decrease the symptoms of the disease.
FSHD derives its name from the muscle groups that are affected first: facial and 
shoulder girdle muscles. While the disease progresses, humeral, abdominal, pelvic 
girdle and foot dorsiflexor muscles often become involved as well (Figure 2) (8).
Lower abdominal muscles are weaker than the upper abdominal muscles, causing 
a ‘Beevor’s sign’, a physical finding specific for FSHD (Figure 3) (9). 
Figure 2 A visual representation of the muscle groups ordered by degree
of fatty infiltration from red (most often affected) to yellow (least 
affected) (8)
The most commonly described extramuscular manifestations are hearing loss 
and retinal telangiectasias, occurring in 75% and 60% of the affected individuals, 
respectively (10).C
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The heart is not affected in most cases, although asymptomatic arrhythmias 
and conduction defects have been described (11). The median age of onset 
is around 17 years, but the onset of clinical symptoms varies from infancy to 
the seventh decade. The course of FSHD is usually slowly progressive, but the 
severity among patients is extremely variable, even within families, ranging from 
isolated facial weak ness to severe generalized weakness, with approximately 20% 
of patients eventually becoming wheelchair-dependent. Many patients report a 
relapsing course, with long periods of quiescence interrupted by periods of rapid 
deterioration involving a particular muscle group, often heralded by pain in the 
affected limb. Most of the patients have a normal life expectancy (10). 
Figure 3 Beevor’s sign 
Many FSHD patients have a protruding abdomen because the lower abdominal muscles 
are more severely affected than the upper abdominal muscles. This asymmetrical weakness 
leads to Beevor’s sign: upward displacement of the navel while flexing the neck. It is a typical 
finding for FSHD on clinical examination.   
MUSCLE IMAGING IN FSHD
A typical characteristic of FSHD is the asymmetric and individual involvement 
of different skeletal muscles. In the last decade, substantial progress has been 
made in the understanding of the molecular genetics of FSHD (12). However, 
it is still unknown why the weakening of different muscles and muscle groups 
occurs at different rates and times.  Moreover, there are no biomarkers for an 
objective assessment of the severity and progression of FSHD and to establish the 
effectiveness of treatments. Currently, muscle ultrasound is predominantly used 
as a screening tool for patients with suspected neuromuscular disorders, as it can 
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easily visualize intramuscular fibrosis and fatty infiltration. In the past, computer 
tomography (CT) has been used for unbiased and reliable assessments of skeletal 
muscle in FSHD patients (13). Nevertheless, magnetic resonance imaging (MRI) is 
nowadays preferred over CT as determination of therapy effectiveness in follow-
up examinations would require multiple CT scans, with inherent radiation load. 
Furthermore, the sensitivity in the identification of fatty infiltration is higher for MRI 
compared to CT. With MRI a detailed picture of the anatomy of individual skeletal 
muscles or whole muscle groups can be obtained. In FSHD, MRI with T1 weighting 
shows fatty infiltration and changes in muscle volume of affected muscles. T2 
weighted MRI can show inflammation and edema (14). Kan et al. developed a new 
MR method to quantitatively separate muscular and fat content in different muscles 
of the lower limb in patients with FSHD, using differences in T2 relaxation times 
of fat and muscle tissue, to provide an objective biomarker for individual muscle 
involvement (15). By using MRI, clinically useful biomarkers for disease progression 
and response to therapy could be established. 
FATIGUE IN FSHD
Fatigue is one of the most commonly presented symptoms in primary care with 
a prevalence of 5-20% across different patient groups (16). Although chronic 
fatigue can lead to reduced psychosocial functioning, in the past fatigue was 
often neglected as a target for treatment, perhaps because it is difficult to assess 
and manage (17). In contrast to pain, fatigue can be experienced as positive, e.g. 
during and after sports. Such a sensation of fatigue is of short duration and will be 
resolved by rest. In contrast, chronic fatigue often accompanies medical illness, 
lasts longer than six months, is poorly relieved by rest, and is often not related to 
activity (18). Currently, fatigue is increasingly being recognized as a major clinical 
problem in many conditions and evidence-based treatment programs are now 
developed for e.g. patients with cancer, stroke and multiple sclerosis (19-21). 
Fatigue consists of several dimensions and, therefore, it is important to assess 
each dimension and to determine how the different dimensions are related.  
Experienced fatigue is assessed subjectively by means of questionnaires. In the 
absence of a universal definition of fatigue a large number of scales have been 
developed attempting to assess the nature, level and impact of fatigue in several 
populations, so no gold standard is to be expected. In the general literature more 
than 250 questionnaires to assess fatigue have been reported, of which 150 
have been only used once (22).These scales differ from each other mainly in the 
construct that is assessed. For example, in the Fatigue Severity Scale (23) fatigue 
is regarded as a uniform construct as this scale focuses mainly on the experienced C
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impact of fatigue on daily life. However, unidimensional fatigue measures do not 
capture the full spectrum of fatigue as a multidimensional phenomenon. To assess 
fatigue more extensively, especially in research, multidimensional questionnaires 
are applied. An example of a multidimensional instrument is the Checklist Individual 
Strength (CIS), consisting of four subscales: subjective fatigue experience, 
concentration, motivation and subjective physical activity. The subscale 
experienced fatigue of the CIS (CIS-fatigue) assesses the level of experienced 
fatigue and has been frequently used in clinical studies. The CIS-fatigue consists 
of eight questions that have to be answered on a seven-point Likert scale (range 
7-56). Severe fatigue is defined by a cut-off score of 35 or higher (24). The CIS-
fatigue has been used to assess the level of fatigue in patients with FSHD in a 
cross-sectional study by Kalkman et al. It was found that more than 60% of the 
patients with FSHD experienced severe fatigue (1). In addition, being severely 
fatigued was associated with a lower level of social participation. Apparently, 
fatigue is a prevalent and a relevant problem in patients with FSHD.  
REHABILITATION OF FATIGUE IN FSHD
Rehabilitation of people with neurological disabilities is a process aimed at 
enabling them to reach and maintain their optimal physical, sensory, intellectual, 
psychological and social activity level. Rehabilitation provides disabled people with 
the tools they need to attain and maintain independence and self-efficacy (25).
In FSHD, muscle function is impaired and declines over time. A progressive loss 
of muscle strength and muscle endurance often leads to loss of functional abilities 
and mobility. Patients with FSHD identify poor mobility, fatigue and the emotional 
and social burden of the disease as the factors with the greatest impact on their 
lives (26). Fatigue may result in patients altering their lifestyles to avoid activities. 
Low physical activity levels may lead to even deconditioining, greater weakness 
and atrophy of skeletal muscles, which causes a vicious circle of disuse and 
increased fatigue (27).
In a longitudinal study Kalkman et al (28) built a model of perpetuating factors for 
fatigue in patients with FSHD using structural equation modelling. A total of 60 
ambulatory patients were studied twice during an 18-months period. Experienced 
fatigue was assessed with the CIS-fatigue (24), while a multidimensional functional 
assessment was used to identify various dimensions relevant for fatigue: pain, 
muscle strength, physical activity, neuropsychological impairments, psychological 
distress, sleep disturbances, concentration problems, social functioning and 
social support, and quality of life. It appeared that lack of physical activity, sleep 
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disturbances and pain all contributed to experienced fatigue. Loss of muscle 
strength contributed to experienced fatigue through a lower level of physical 
activity. In addition, pain contributed to physical inactivity. Ultimately, experienced 
fatigue and physical inactivity both determined the level of social dependence and 
loss of participation. The model, presented in Figure 4, served as a basis for the 
treatment protocol used in this thesis.
Figure 4 Model of perpetuating factors of fatigue for patients with FSHD
Source: Adapted from Kalkman et al. (28)
It was hypothesized that, in order to preserve functioning at the highest achievable 
level and to prevent the vicious circle of inactivity, two different therapeutic 
approaches can be followed: aerobic exercise therapy to promote physical activity 
and cognitive behavioral therapy to stimulate an active lifestyle yet avoiding 
excessive physical strain.
Aerobic exercise aims at maintaining muscle function and improving 
cardiorespiratory status to optimize physical capacity as a prerequisite for 
executing many activities in daily life. For a long time, individuals with muscle 
degeneration were discouraged to perform physical exercise based on fear for 
exacerbation of disease activity and damage to muscle fibers. However, recent 
studies have shown that exercise in patients with neuromuscular disorders is safe 
and, thus, applicable to patients with FSHD (29). Although the number of exercise 
studies in patients with neuromuscular disorders is increasing, the overall amount 
of studies is still scarce. 
FSHD has a strong impact on psychosocial functioning as patients have to 
periodically re-adapt their daily life activities to living with a progressive illness. 
Illness cognitions and coping style influence the choice and level of activities and, 
hence, quality of life. 
Because a cognitive-behavioral approach influencing illness cognitions and coping 
strategies has been proven successful for chronic fatigue syndrome (30) and post-
cancer fatigue (19), it was expected to be efficacious for chronic fatigue in patients 
with FSHD as well. No previous studies used cognitive behavioral therapy to treat 
fatigue in FSHD.
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THE FACTS-2-FSHD STUDY
Since there is still a long way to go before a treatment is expected that will 
decelerate or perhaps even cease disease progression in FSHD, interventions 
to treat the consequences of the disease are particularly important. This thesis 
reports the results of the FACTS-2-FSHD study (acronym for Fitness And Cognitive 
behavioral TherapieS for Fatigue and ACTivitieS in FSHD) which is the first model-
based randomized clinical trial that evaluates the effects of aerobic exercise 
training (AET) and cognitive behavioral therapy (CBT) on chronic fatigue in patients 
with FSHD. These interventions are based on the above-mentioned model of 
chronic fatigue. The primary objective of this study was to evaluate the effect of 
both interventions on chronic fatigue in patients with FSHD as assessed with the 
subscale fatigue of the Checklist Individual Strength. The secondary objective 
was to evaluate the effects of each intervention on the known perpetuating factors 
of chronic fatigue in FSHD based on secondary outcome measures covering all 
domains of the International Classification of Functioning, Disability and Health 
(ICF). In addition, it was aimed to find clinically useful MRI biomarkers of disease 
progression and response to therapy in patients with FSHD. 
The FACTS-2-FSHD study is one of the studies conducted within the FACTS-2-
NMD consortium. FACTS-2-NMD stands for Fitness And Cognitive behavioral 
TherapieS for Fatigue and ACTivitieS in NeuroMuscular Diseases (www.facts2nmd.
nl), a consortium funded by the Dutch Public Fund for Neuromuscular Disorders 
(Prinses Beatrix Spierfonds) and the Netherlands Organization for Health Research 
and Development (ZonMw) (grant nr 89000003). 
17
AIMS AND OUTLINE OF THE THESIS 
This thesis consists of two parts. The first part gives an overview of the 
prevalence, measurement and treatment of fatigue in neuromuscular disorders. 
The second part presents the results of the FACTS-2-FSHD study. 
The following research questions will be addressed:
PART 1 FATIGUE IN NEUROMUSCULAR DISORDERS
1. What is the prevalence and relevance of fatigue in patients with muscular 
dystrophy?
Chapter 2 gives an overview of the prevalence of fatigue and consequences in 
muscular dystrophies.
2. How can we assess fatigue in patients with neuromuscular disorders?
Chapter 3 provides a core set of instruments for measuring fatigue in patients 
with neuromuscular disorders. 
3. What is the evidence for exercise in muscle disease?
A Cochrane review regarding the effects of strength training and aerobic 
exercise therapy in patients with muscle disease is reported in chapter 4.  
PART 2 FACTS-2-FSHD STUDY
4. What are the effects of aerobic exercise therapy and cognitive behavioral 
therapy on chronic fatigue in patients with FSHD? 
The protocol of the FACTS-2-FSHD trial, which aims to decrease experienced 
fatigue by AET and CBT, is described in Chapter 5. The main results of the trial 
are presented in Chapter 6.
5. Can we discover structural abnormalities in skeletal muscle of FSHD patients 
that may serve as biomarkers for disease progression and response to 
therapy?
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In chapter 7, MRI measurements are used to provide more information about 
the underlying pathobiology of FSHD. Chapter 8 describes the effects of AET 
and CBT on the progression of fatty infiltration in the thigh muscles of patients 
with FSHD.
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PART 1
FATIGUE IN NEUROMUSCULAR DISORDERS
Fatigue
CHAPTER 2
MUSCLE FATIGUE IN MUSCULAR DYSTROPHIES
Nicoline B.M. Voet
Alexander C.H. Geurts
Gijs Bleijenberg 
Machiel J. Zwarts 
George W. Padberg
Baziel G.M. van Engelen 
Published in: Williams C., Ratel S. Human muscle fatigue. 
Oxon: Routledge. 285-312 (2009)
OBJECTIVES 
The aim of this chapter is to provide an overview on:
the prevalence and assessment of fatigue in muscular dystrophies
the pathophysiological determinants of fatigue in muscular dystrophies
the possible treatment options of fatigue in muscular dystrophies
INTRODUCTION 
The aim of this chapter is to provide an update on the prevalence, relevance, 
causes and treatment of fatigue in muscular dystrophies. In a study by  McDonald 
et al., the three problems most frequently cited as “very significant” by patients 
with slowly progressive neuromuscular disease (n = 811) were muscle weakness 
(57%), difficulty exercising (43%), and fatigue (40%) (1). In a study by Kalkman 
et al., 61% of patients with facioscapulohumeral dystrophy (n = 139) and 74% 
of patients with myotonic dystrophy (n = 322) were “severely fatigued” (2). The 
muscular dystrophies are an inherited group of more than 30 distinct progressive 
disorders resulting from defects in a number of genes required for normal muscle 
structure and function. They are characterized by progressive loss of muscle 
strength and integrity and they have a variable distribution and severity (3). We 
will, however, limit our review to those main types of diseases which are most 
frequent: Duchenne and Becker muscular dystrophy, myotonic dystrophy type 1, 
facioscapulohumeral muscular dystrophy and the limb girdle muscular dystrophies. 
A more extensive overview of muscular dystrophies can be found in Engel and 
Franzini-Armstrong (4).
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In this chapter, we will distinguish two main types of fatigue (Table 1): 
Table 1 Dimensions and definitions of fatigue as used in this chapter
Muscle fatigue, or physiological fatigue, can objectively be assessed in a 
laboratory setting and is defined as the total amount of voluntary loss of force 
during a sustained maximal voluntary muscle force (MVC). It contains both 
peripheral and central components, a distinction that is based on whether the 
loss of capacity to generate force originates from the muscle system or the 
central nervous system.
Peripheral fatigue can be determined as the loss of force during constant 
electrical stimulation, applied to the motor nerve or motor endplate during a 
sustained MVC.
Central fatigue can be determined as an increase in central activation failure 
during exercise. Central activation failure (CAF) is defined as submaximal central 
activation. CAF can be measured by the “twitch interpolation technique”. If the 
central activation is submaximal, the electrical stimulation, applied to the motor 
nerve or motor endplate during a sustained MVC, will result in an increased 
exertion of force compared to exertion of force without electrical stimulation, 
demonstrating CAF. CAF can be present already at the start of a sustained MVC 
(Schillings et al. 2007).
Experienced fatigue is by definition a subjective entity and can be assessed 
only by self report, for example with the subscale fatigue of the Checklist 
Individual Strength, and does not necessarily correlate with physiological fatigue. 
Experienced fatigue has many dimensions: for example activity limitations in daily 
life, physical inactivity, sleep disturbances, concentration problems, loss of social 
participation, psychological distress, sense of control over fatigue, cognitions 
about the possible cause of fatigue, and pain.
Physiological fatigue, or muscle fatigue, which has been defined as a reduction 
in MVC during exercise. Experienced fatigue, on the other hand, is the subjective 
feeling of fatigue. Muscle fatigue is not necessarily accompanied by experienced 
fatigue, or vice versa.
High-quality studies about fatigue in muscular dystrophy are scarce. Nevertheless, 
after a general introduction on muscular dystrophies, addressing both clinical and 
pathophysiological aspects, the prevalence of experienced fatigue in muscular 
dystrophies in the literature will be critically reviewed and the putative underlying 
pathophysiological mechanisms of muscle fatigue and experienced fatigue will 
be outlined. Finally, literature about treatment of muscle fatigue and experienced 
fatigue in muscular dystrophies will be reviewed and recommendations for future 
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research will be made. Throughout the chapter, the scientific knowledge will be 
illustrated by a clinical case report that describes the experienced fatigue of a 59 
year old man with facioscapulohumeral dystrophy, Mr. A.
DYSTROPHINOPATHIES 
Duchenne muscular dystrophy (DMD) is the most common form of the human 
muscular dystrophies. Becker muscular dystrophy (BMD) is a less frequent and 
more benign form of the disease. The incidence of DMD is approximately 1 in 
3.500 live male births. By comparison, BMD is found in 1 in 30,000 male births (5). 
Both are X-linked recessive disorders and are caused by a mutation in the DMD 
gene which is located on chromosome Xp21 and encodes for the production of 
dystrophin. One third of the cases are due to spontaneous mutations (6). 
The primary abnormality in DMD is the lack of dystrophin. In BMD, the protein 
is reduced in amount or abnormal in size. Dystrophin is a 427 kiloDalton protein 
normally found at the cytoplasmic face of the muscle cell surface membrane, 
functioning as a component of a large, tightly associated glycoprotein complex (7). 
In its absence, the glycoprotein complex is digested by proteases. This may initiate 
the degeneration of muscle fibers, resulting in muscle weakness and potential 
mechanical injury from tissue stress in rest and during exercise (8-10).
Diagnosis is suspected by characteristic clinical findings among which progressive 
symmetrical muscle weakness is the most important, affecting proximal limb 
muscles more than the distal muscles. Initially, only lower limb muscles are affected 
accompanied by pseudohypertrophy of the calf muscles. Common musculoskeletal 
complications are kyphoscoliosis and muscle contractures. Because dystrophin 
is also found in the heart, brain, and the smooth muscles, frequent concomitant 
manifestations are cardiomyopathy and mental retardation (11).
In DMD, the clinical symptoms first present between 3 and 5 years of age, and 
patients generally lose ambulation between 7 and 12 years. In the past, death 
usually occurred from cardiac or respiratory causes in the late teens or early 
twenties. But recently, respiratory support can prolong survival into the fourth 
decade (12). The diagnosis is supported by a family history suggestive of X-linked 
recessive inheritance (4) or by dystrophin immunostaining of muscle tissue (6, 
13, 14) Serum creatine phosphokinase (CK) level is generally increased to levels 
that are 50-100 times the reference range (i.e. as high as 20,000 mU•mL-1). The 
diagnosis is confirmed by identifying abnormalities in the dystrophin gene by 
mutation analysis of DNA from peripheral blood leukocytes (6).
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In BMD, the distribution of muscle wasting and weakness is closely similar to that 
in DMD, but the course of the disease is more benign and far less predictable, 
with first clinical symptoms presenting around 12 years. Many patients remain 
ambulatory into adult life (3, 6). 
No curative treatment is available for both diseases, although first attempts are 
made: the gene transfer technique by intramuscular injection of an antisense 
oligonucleotide is under development (15), but several hurdles still need to be taken 
(16). Therefore, emphasis currently is on respiratory care, treatment of cardiological 
complications and optimizing the quality of life by symptomatic physiotherapeutic 
and medical treatments (17). There is evidence that corticosteroid therapy in DMD 
can reduce speed of decline of muscle strength and function (18, 19).
MYOTONIC DYSTROPHY  
Myotonic dystrophy (DM) is the second most common muscular dystrophy. 
There are two major forms: DM1, also known as Steinert’s disease, and DM2, a 
multisystem disease, also known as Proximal Myotonic Myopathy (PROMM). In this 
chapter, we will limit the discussion to DM1, which is more frequent. 
DM1 is divided into congenital, classical, and minimal phenotypes according to the 
age of the symptom onset and disease severity. The congenital form of DM1 will 
not be further considered in this chapter, see Engel and Franzini-Armstrong (4). The 
prevalence of DM1 is approximately 1 in 8,000 in the general population (20). DM1 
is an autosomal-dominant disorder, of which the molecular basis is expansion of an 
unstable repeat sequence in a non-coding part of the dystrophia myotonica protein 
kinase gene (DMPK gene) on chromosome 19. The repeat expansion enlarges with 
each generation, which leads to earlier onset and increased severity of symptoms 
with each affected generation, a phenomenon which is known as “anticipation” 
(21). There is increasing support for the theory that disruption of RNA metabolism, 
which has effects on many other genes, explains the multisystemic nature of the 
disease (22). 
DM1 is clinically characterized by muscle weakness of the distal limbs, progressing 
to the proximal limbs with gradual occurrence of myotonia (delayed relaxation 
after muscle contraction). Weakness occurs most frequently in facial muscles, the 
distal muscles of the forearm, and the ankle dorsiflexors with onset of symptoms in 
the second, third or fourth decade (23).  Associated findings include muscle pain, 
cognitive and psychological changes, cataract, cardiac conduction defects and 
endocrine disorders (20, 24, 25). Excessive daytime sleepiness is found in about 
one-third of patients (26, 27). 
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The diagnosis can be suspected clinically by a positive family history and 
by identifying the symptoms mentioned above. Specific genetic testing to 
demonstrate the presence of an expanded CTG repeat in the DMPK gene is the 
gold standard for the diagnosis of DM1 (20). Life expectancy is reduced for patients 
with DM1. Respiratory insufficiency and cardiac diseases are the most common 
causes of death (28-30). There is no disease-modifying therapy available for the 
treatment of DM1. Therefore, treatment is symptomatic (31).  
FACIOSCAPULOHUMERAL DYSTROPHY
Facioscapulohumeral dystrophy (FSHD) is the third most common muscular 
dystrophy. The estimated prevalence is 1 in 20,000 persons (32). FSHD is an 
autosomal dominant disease. It is associated with subtelomeric contraction of 
chromosome 4q, with loss of tandem repeat-units. In general, the disorder is more 
severe in a patient with a lower number of repeats. The pathogenetic mechanisms 
in FSHD are unknown. The presence of some extramuscular manifestations in 
FSHD suggests the involvement of a gene with pleiotropic effects or, alternatively, 
the involvement of multiple genes (33). FSHD derives its name from the muscle 
groups that are mainly affected first: facial and shoulder girdle muscles. During 
disease progression humeral, abdominal, pelvic girdle and foot-extensor muscles 
can become involved as well (32). Lower abdominal muscles are weaker than the 
upper abdominal muscles, causing a “Beevor’s sign”, a physical finding specific 
for FSHD (34). Most commonly described extramuscular manifestations are the 
high-frequency hearing loss and retinal telangiectasias, occurring in 75% and 60% 
of affected individuals, respectively (33). The heart is not affected in most cases, 
though arrhythmias and conduction defects have been described (3). 
The median age of onset is around 17 years, but the onset of clinical symptoms 
varies from infancy to the seventh decade (32).
Although the exact gene defect or genetic mechanism is not yet known, a DNA test 
is available for FSHD which detects a specific deletion in chromosome 4q35. This 
diagnostic test is abnormal in 95 to 98 percent of typical FSHD cases (35-37). 
The course of FSHD is usually slowly progressive but the severity among patients 
is extremely variable, ranging from isolated facial weakness to severe generalized 
weakness, with approximately 20 % of patients eventually becoming wheelchair-
dependent (32). Many patients report a relapsing course with long periods of 
quiescence interrupted by periods of rapid deterioration involving a particular 
muscle group, often heralded by pain in the affected limb. Most of the patients 
have a normal life expectancy (33). C
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Currently, there is no genetic or pharmaceutical curative treatment available for 
FSHD. Only two randomized controlled trials have been published. Recent trials 
of albuterol, also known as salbutamol (38, 39), folic acid and methionine (40), and  
creatine, a dietary supplement for building muscle (41), did not confirm or refute a 
significant effect of either of these treatments (42). The mainstay of management 
is, therefore, treatment of symptoms, prevention of secondary problems, and 
improvement of functional abilities and quality of life (33).
LIMB GIRDLE MUSCULAR DYSTROPHIES  
The limb girdle muscular dystrophies (LGMD) are a group of disorders which are 
historically grouped together because of the shared clinical feature of predominant 
involvement of the “limb-girdle” (pelvic and shoulder) musculature. However, 
it is recognized that there is a broad heterogeneity of presentation and muscle 
involvement in the LGMD group (43). The overall frequency has been estimated to 
be 1: 14,000 – 1: 200,000 (5). Most cases of LGMD are inherited in an autosomal 
recessive fashion (44). However, families with an autosomal dominant pattern of 
inheritance have also been described, which probably account for about 10% of 
all LGMDs (45). The emergence of a LGMD phenotype can result from mutations 
in any of, at least, 19 different genes (46). The discovery of genetically distinct 
subtypes has redefined the classification of LGMD and has led to a nomenclature 
designating the autosomal dominant form as LGMD1A, 1B, 1C, etc, and the 
autosomal recessive form as LGMD2A, 2B, 2C, etc (45). The proteins causing 
LGMD have a wide range of localization across the muscle fiber, from sarcolemma 
to nuclear envelope, with various functions (43, 46). 
Weakness may affect proximal muscles of the shoulder girdle (scapulohumeral 
type), the pelvic girdle (pelvifemoral type), or both. Neck flexor and extensor 
muscles may be concurrently involved. Facial weakness, when present, is usually 
mild and, in most cases, totally absent. Even in mild cases, there is preferential 
weakness and atrophy of the biceps muscle. 
Distal muscle strength is usually preserved, even at the late stage of the disease. 
Selectivity of muscle involvement and clinical characteristics such as hypertrophy 
of the calves or tongue, and late stage cardiac complications are associated more 
or less specifically with each of the different forms (4).
The single constant biochemical abnormality in LGMD is the elevation of the CK 
level. In autosomal recessive types of LGMD, serum CK is always increased, up 
to 200 times the normal range. DNA analysis to detect a mutation in the affected 
gene(s) is the gold standard of diagnosis (47). Reported age of onset of LGMDs 
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varies among the different mutations and is between 1 and 50 years, although 
some patients may be asymptomatic. Compared with the autosomal dominant 
type, autosomal recessive LGMD is usually associated with earlier age of onset, 
more rapid progression, and relatively high CK values. Morbidity and mortality rates 
vary, but with early onset the course is generally rapid (4). Treatment is supportive 
and consists of physical therapy, assistive devices and monitoring of respiratory 
function and cardial complications. Treatment is generally aimed at prolonging 
survival and improving quality of life (46).  
Clinical case: disease description 
Mr. A is a 59 year old man who broke his clavicle in a football game when he was 
18 years old. A year after the accident he went back to his general practitioner, 
because symptoms of pain and decreased functioning of his shoulder did not 
disappear. He was referred to a neurologist, who clinically diagnosed a “muscle 
disease” when he was 19 years old. At that time, he knew that his mother, who 
was wheelchair-dependent, had a “muscle disease”, but neither the diagnosis, 
nor the prognosis of her condition was known. Decades later, his neurologist 
told him he had a muscle disease which was known as “Landouzy–Dejerine”, 
the former name of FSHD. The diagnosis FSHD was genetically confirmed 
30 years later. At that time, an autosomal dominant inheritance pattern could 
be recognized in his family. Many persons in every generation appeared to be 
affected by the disease.  
Mr. A experiences a relapsing course of FSHD with long stable periods followed 
by periods of clear deterioration. Currently, facial, shoulder girdle, humeral, 
abdominal, pelvic girdle and foot-dorsiflexor muscles are involved. He is still 
ambulant but his unaided walking distance is restricted to approximately 100 
meters. Outdoor he uses a rollator, which increases his walking distance to 250 
meters. He is very afraid of becoming wheelchair-dependent, just like his  mother. 
Mr. A lives together with his wife in an apartment at ground level. He works four 
days a week as an IT specialist and spends a lot of time in volunteer activities. 
He plays the saxophone in a band.
EXPERIENCED FATIGUE  
ASSESSMENT OF EXPERIENCED FATIGUE  
Distinguishing experienced fatigue from muscle weakness, the key feature 
in muscular dystrophy, may be difficult. Asking patients to describe their C
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fatigue will lead to several descriptions, varying from sleepiness, weakness, 
exercise intolerance to exhaustion. Hence, experienced fatigue is, therefore, a 
multidimensional concept with possible contributions of, for example physical, 
cognitive and motivational factors (Table 1). Although experienced fatigue is 
difficult to define, it still is a valuable concept which can be reliably measured by 
using questionnaires. An often used questionnaire for the experience of fatigue 
and its behavioral consequences is the Checklist Individual Strength (CIS). The 
CIS is consists of four subscales: one scale for experienced fatigue, so called 
“CIS-fatigue”, and three scales for reduction in motivation, physical activity and 
concentration, respectively. Higher scores indicate higher levels of fatigue, more 
concentration problems, a greater decrease in motivation and lower levels of 
activities (48). The Abbreviated Fatigue Questionnaire (AFQ) is another short, 
reliable, and easy-to-use instrument to determine the intensity of a patient’s 
experienced fatigue. It consists of four questions that have to be answered on a 
7-point Likert scale. A lower total score indicates a higher degree of fatigue (49).  
PREVALENCE AND IMPACT OF EXPERIENCED FATIGUE  
Kalkman et al. measured the prevalence of “severe experienced fatigue” in of 598 
neuromuscular patients, among which 139 patients with FSHD and 322 patients 
with DM. Both patient groups experienced high levels of fatigue (2). The mean CIS- 
fatigue score in the FSHD group was 36.5 (SD 12.5) and in the DM group 40.4 (SD 
11.8). In the FSHD group 61% of patients were “severely fatigued” (determined by 
a CIS-fatigue score equal or above 35). In the DM group, this percentage was 74. 
In both groups, age showed low but significant correlations with fatigue severity, 
indicating that, in general, older patients experienced somewhat greater fatigue. 
Severely fatigued patients scored lower on all Short Form-36 (SF-36) scales than 
the non-severely fatigued patients, suggesting a relation between experienced 
fatigue and activity limitations. There appeared to be several differences between 
DM and FSHD patients. Patients with DM had higher scores for experienced 
fatigue, reported greater problems with concentration, and had more difficulties 
with initiative and planning than patients with FSHD. In FSHD patients and DM 
patients, social functioning was related to fatigue severity. 
Irrespective of its cause, fatigue has a major impact on daily functioning and 
quality of life (50, 51). For example, in a study by van der Werf in patients with DM 
(n = 32) and FSHD or LGMD (n = 20), severe fatigue was associated with greater 
levels of psychological distress and more physical and psychosocial limitations, as 
measured with the Sickness Impact Profile (SIP), the Symptom Checklist-90 (SCL-
90) and the Beck Depression Inventory Primary Care (BDI-PC) (52). In the study by 
Kalkman et al. severely fatigued patients with FSHD or DM also had lower scores 
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on all subscales of the SF-36, which monitors disease burden. 
This suggests a relation between experienced fatigue and the level of activity and 
social participation (4). Apparently, fatigue is not only a frequent, but also a relevant 
problem in muscular dystrophy.
Clinical case: experienced fatigue
Mr A has suffered from fatigue since the age of 40. He considers his fatigue and 
muscle pain to be the most relevant and disabling consequences of his disease. 
He defines his fatigue as a lack of energy which restrains him from activities. 
After walking approximately 100 m, he has to stop because of severe fatigue 
and muscle pain. These symptoms are comparable with the exhaustion he felt 
after playing football in his younger years. That type of exhaustion, however, felt 
positive, in contrast to the negative feeling associ ated with the present fatigue. 
Fatigue has a significant and deleterious impact on his life that goes beyond the 
other symptoms of FSHD. It takes almost two hours to prepare himself for work 
every morning. After he has dressed, he often falls asleep due to exhaustion. He 
can only travel by car because other forms of transport are too strenuous. He 
describes himself as a “healthy mind in an aged body”. 
DETERMINANTS OF FATIGUE
As fatigue in muscular dystrophy is a multidimensional concept, (see assessment 
of experienced fatigue and Table 1), it is important to understand factors that 
contribute to fatigue. Based on such an analysis, preventive and therapeutic 
interventions can be developed. The critical pathophysiological determinants of 
muscle fatigue and experienced fatigue will, therefore, be described in the next 
section. 
PATHOPHYSIOLOGICAL STUDIES OF MUSCLE FATIGUE
Because of practical reasons, pathophysiological studies depend to a large extent 
on animal models. A review of Wineinger et al. summarizes the literature regarding 
the physiological fatigue characteristics of skeletal muscles in animal models 
of muscular dystrophy (53). Muscle fatigue in animal studies was expressed as 
a percentage of initial force, i.e. physiological fatigue. Force was measured by 
recording the action potential (AP) of muscles and muscle-evoked tension. Two 
rodent models (mdx mouse and dystrophic hamster) have been studied most 
extensively. The dystrophic hamster, lacking normal sarcoglycan, was used as a C
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model for LGMD. The mdx mouse lacks dystrophin, and was therefore considered 
a model for DMD.
Significant variability has been observed before in studies of muscle fatigue 
in dystrophic animals, which may be due to different experimental conditions. 
Because of this variability, it is difficult to evaluate muscle fatigue in animal models 
of muscular dystrophy. Still, some trends can be recognized (Table 2).
Table 2 The difference in fatigability of dystrophic animal muscles 
 compared to healthy animal muscles can be explained by 
 differences in muscle fiber types 
Muscle fiber type Fatigability dystrophic animal muscles 
compared to healthy animal muscles. 
Type I (slow-twitch,  oxidative) ↓/ =
Type IIA ( fast-twitch, oxidative) =
Type IIB  (fast-twitch, glycolytic) ­↑
The dystrophic soleus muscle fatigued more slowly or at the same rate as that of 
healthy animals. The soleus is largely composed of slow-twitch type I oxidative 
muscle fibers and is considered to be fatigue resistant. Histological studies showed 
an increase in the proportion of type I muscle fibers in the dystrophic soleus 
muscle, which could explain the increased resistance to fatigue. The dystrophic 
extensor digitorum longus (EDL) was weaker than in healthy animals and generally 
more fatigable. The EDL muscle has a majority of type IIB fibers which are easily 
fatigable. Pagala et al. described that type IIB dystrophic muscle fibers are more 
susceptible to degeneration, in contrast to type I muscle fibers (54). No difference 
was found in fatigability between healthy and dystrophic diaphragm muscles. The 
diaphragm is composed of fast oxidative IIA muscle fibers, which are relatively 
fatigue resistant. It appears that difference in fatigability of dystrophic animal 
muscles compared to muscles of healthy animals can largely be explained by 
differences in muscle fiber types (Table 2).
Apparently, type I, in contrast to type II muscle fibers of dystrophic animal muscles 
have the potential to regenerate. Because aerobic training increases the proportion 
of type I muscle fibers and, with that, fatigue resistance of healthy muscles, aerobic 
training could be effective in decreasing fatigability of dystrophic muscles, as well 
through the same mechanism (55).
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Increased muscle fatigue has often been attributed to a decrease in the metabolic 
potential of the individual muscle fibers. It is known that the levels of some energy 
metabolites like creatine are decreased in muscular dystrophies such as DMD 
(56, 57) which may aggravate muscle weakness and muscle fatigue. Interestingly, 
in some types of LGMD, in which muscles are less severely affected, creatine 
does not seem to be decreased, indicating that the level of creatine may serve 
as a biomarker for the severity of muscle weakness and muscle fatigue (58). 
Furthermore, the decrease in concentrations of other metabolites such as choline 
and lactate was less severe in LGMD compared to DMD suggesting that these 
metabolites could also be potential biomarkers (57).
In summary, these reports indicate that abnormal metabolite profiles could serve as 
specific biomarkers to characterize the severity of muscular dystrophies. 
PERIPHERAL VERSUS CENTRAL FATIGUE  
Until recently, the emphasis in clinical research in muscular dystrophies was on 
peripheral fatigue (Table 1). However, not only peripheral impairments, but also 
changes within the central nervous system could be responsible for increased 
fatigue. Schillings et al. first investigated central aspects of physiological fatigue 
in patients with muscular dystrophy (59). Both peripheral and central aspects of 
fatigue were determined during a sustained maximum voluntary contraction (MVC) 
of elbow flexion in patients with FSHD (n=65) and DM (n=79) (Figure 1). 
Unexpectedly, overall physiological fatigue and peripheral fatigue were smaller in 
neuromuscular patients compared with healthy controls. Moreover, in patients with 
FSHD and DM, physiological fatigue did not correlate with the level of experienced 
fatigue. In contrast, Schulte-Mattler et al. described excessive peripheral fatigue in 
a mixed group of neuromuscular disorders, among which FSHD and DM (60). This 
discrepancy may be explained by a difference in the exercises. The type of exercise 
in the study by Schillings et al., i.e. isometric contraction at maximal force level, is 
hardly ever required in daily life and may also decrease blood supply. 
Schulte-Mattler et al. elicited fatigue by intermittent and non-tetanic contractions 
to avoid blood vessel occlusion. This type of exercise may be clinically more 
relevant and valid for measuring physiological fatigue. CAF and central fatigue in 
the study by Schillings et al. were measured by the twitch interpolation technique 
(See chapter 2) (61). Central fatigue was minimal in all groups and did not differ 
between groups nor did it have any relation with experienced fatigue. Remarkably, 
CAF at the start of sustained MVC was enlarged in patients compared to controls. 
CAF in patients was related to the level of experienced fatigue. An increased C
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CAF further decreases the maximal voluntary force in patients with muscular 
dystrophy. The cause of this decreased central activation cannot be determined by 
currently available techniques. It could be that the activation pattern of the central 
nervous system is not able to compensate for the peripheral problems in muscular 
dystrophies. The increased CAF could also be considered a beneficial adaptation, 
which prevents the affected muscles from excessive fatigue.
Figure 1 Schematic representation of peripheral and central fatigue 
The figure shows the decline over time (within 2 min) of the maximum voluntary force (on 
the Y-axis), which is peripheral fatigue. The arrows indicate the moments of superimposed 
electrical endplate stim ulation. The twitch interpolation may induce increments in muscle 
force with examples of a negligible (†) and a large CAF (#). A (near) absent response indicates 
a full voluntary activa tion of the muscle. The “at-rest twitches” are visible before (*) and 
following (**) the contrac tion, with the post-experimental twitch being clearly lower, indicative 
of peripheral fatigue. Source: Adapted from Zwarts et al., 2008. This figure is not the 
registration of an individual patient.
VICIOUS CIRCLE OF PHYSICAL INACTIVITY
Fatigue may result in patients altering their life-styles to avoid activities. Low 
physical activity levels may lead to even greater weakness and atrophy of skeletal 
muscles, which causes a vicious circle of disuse and weakness. Physical inactivity 
in turn can lead to chronic cardiovascular and muscle deconditioning and 
increased cardiovascular health risks (1). For example, the maximal oxygen uptake 
(VO2max) is abnormally low in patients with muscular dystrophy (62).
39
Body-composition measurements in muscular dystrophy patients by various 
methods indicate reduced fat-free mass (FFM) and increased adiposity in these 
patients relative to able-bodied control subjects of comparable ages and body 
weights (63, 64). The excess body fat of muscular dystrophy patients additionally 
impairs mobility and further increases the risk of cardiovascular disease.
In a study by McCrory et al., resting energy expenditure (REE) and total daily 
energy expenditure (TEE) were measured by indirect calorimetry and heart rate 
monitoring, respectively (65). Relatively active muscular dystrophy patients (FSHD, 
LGMD, DM and BMD) did not differ in REE, but had a lower estimated TEE. They 
also had a higher energy cost of physical activity than able-bodied subjects of the 
same gender who were similar in age and weight, even after adjustment for FFM 
differences. It is possible that the lower amount of time spent in physical activity 
by muscular dystrophy patients can be attributed to the higher energy cost. An 
alternative explanation is that persons with muscular dystrophy avoid physical 
activity, because of the widespread belief that too much strain on the muscles will 
accelerate the disease process (overwork weakness). Fear of physical activity, or 
fear to damage the muscle, may also contribute to the reduced central activation 
in patients with muscular dystrophy as described in the section peripheral versus 
central fatigue. Irrespective of its cause, physical inactivity should be discouraged 
in muscular dystrophy patients, because of an increasing risk of cardiovascular 
disease and muscle deconditioning.
PERPETUATING FACTORS OF EXPERIENCED FATIGUE
Experienced fatigue can be regarded as a multimodal concept, with a wide 
variety of contributing factors in patients with muscular dystrophy. These factors 
can be categorized into predisposing, precipitating and perpetuating factors. 
Predisposing factors include the presence of muscular dystrophy, whereas 
precipitating factors include acute physical stresses such as a concomitant disease 
or a period of relatively deterioration of muscle function. These factors cannot be 
treated, in contrast to perpetuating factors, which contribute to the continuation of 
experienced fatigue. Kalkman et al. used a longitudinal design to investigate the 
perpetuating factors of experienced fatigue in patients with FSHD (n = 60) and DM 
(n = 70) (66). Structural equation techniques, also referred to as “causal modeling” 
were used.  Based on longitudinal data, separate models for FSHD and DM were 
developed. The model of perpetuating factors of experienced fatigue in FSHD 
differed from the model for DM, the main difference being physical (in)activity and 
pain. The model fit was best for FSHD (Figure 2).
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Figure 2 Adjusted model of perpetuating factors of experienced fatigue in 
patients with FSHD (n = 60)
Severe muscle strength, (self-reported) physical inactivity, pain and sleep disturbances were 
significantly associated with the level of experienced fatigue. 
In FSHD, the level of physical (in)activity has a central place in the model. Lower 
levels of physical activity contribute to higher levels of experienced fatigue and, 
through that, to restrictions in social participation. The level of physical activity 
is directly and negatively influenced by loss of muscle strength. In addition, pain 
complaints influence levels of experienced fatigue both directly and indirectly by 
decreasing physical activity. In contrast, in DM, physical activity and pain did not 
differ between patients with and without severe experienced fatigue and, therefore, 
did not significantly contribute to experienced fatigue. 
Yet, sleep disturbances lead to higher levels of experienced fatigue in both FSHD 
and DM patients. The observed patterns of perpetuating factors are unique 
for FSHD and DM, and are different from the model of experienced fatigue in 
chronic fatigue syndrome (48). They can be used as a basis to develop evidence-
based interventions to reduce fatigue. Specific attention should be paid to 
sleep disturbances in both patient groups. Specifically in FSHD, treatment of 
fatigue should also be directed at increasing physical activity and reducing pain 
complaints.
EXPERIENCED FATIGUE AND PSYCHIATRIC DISORDERS 
Fatigue is a characteristic of a number of affective disorders, and an association 
between experienced fatigue and psychiatric symptoms has been reported in 
a number of central nervous system disorders, including Parkinson’s disease 
and multiple sclerosis (67, 68). In this perspective, it is relevant to know whether 
psychiatric comorbidity is associated with fatigue severity in muscular dystrophies. 
Although in the study by Kalkman et al. (see section on prevalence and impact 
of experienced fatigue) severe experienced fatigue was related to higher levels of 
psychological distress in both patients with FSHD and DM, most of the severely 
fatigued patients did not fulfill the operational criteria of depression (4). The authors 
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argued that severe experienced fatigue can, therefore, not be seen as merely a 
sign of depression. In a later study by Kalkman et al. using the Structured Clinical 
Interview for DSM-IV axis 1 disorders, and Beck Depression Inventory (BDI) 
lifetime and current psychiatric disorders (mood disorders, anxiety disorders and 
substance-related disorders) were equally prevalent in a large cohort of DM and 
FSHD patients, and were equally or even less present than these disorders in the 
general (Dutch) population (69, 70). The most common psychiatric disorders were 
depression and phobias. Psychiatric comorbidity was not associated with fatigue 
severity or muscle strength in the various neuromuscular disorders. In conclusion, 
psychiatric comorbidity is not an explanation for experienced fatigue in FSHD and 
DM.
Clinical case: perpetuating factors of fatigue
Mr A experiences fatigue during activities of daily life, work and leisure, but also 
when reading a book due to concentration problems. He easily falls asleep by 
day. At night, his sleep is often disturbed by muscle pain. In the past, when 
he was less physically disabled, he exercised at a low intensity. In his youth, 
he played football. In adult life, he practised swimming once a week and, later 
on, physical fitness, but avoided excessive training because of fear of overuse. 
Nevertheless, many years ago he altered his lifestyle. He stopped swimming 
and playing football. Currently, he is physically inactive and in a vicious circle of 
disuse and weakness. His physical inactivity results in muscle and cardiovascular 
deconditioning and obesity. Altogether, he is at risk for cardiovascular disease. 
Seven years ago, he experienced an ischemic cerebrovascular incident, which 
further increased his experienced fatigue.
TREATMENT OF FATIGUE 
Most treatment studies in patients with muscular dystrophy do not describe the 
efficacy of the intervention in terms of decreasing muscle fatigue or experienced 
fatigue. Nevertheless, we will provide a critical overview of the possible treatment 
options with respect to fatigue in these patients. Treatment strategies that will 
be reviewed include physical exercise training, drug treatment and cognitive 
behavioral therapy.
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TRAINING STUDIES IN ANIMALS
Extrapolating data from animal studies to humans must be done with caution, 
because there are large differences in biomechanical properties and phenotypic 
expression of the dystrophic disorder between humans and, for example, the mdx 
mouse. Nevertheless, it may still be valuable to consider animal studies first, since 
unique information can be obtained (53, 71). Exercise training in animals mainly 
consisted of high-repetition aerobic-type activities like swimming, treadmill running 
or voluntary-wheel running. Two reviews described that dystrophic animals had a 
normal (and beneficial) adaptation to mild, voluntary submaximal aerobic exercise, 
which generally included an increase in muscle strength per cross-sectional area 
of muscle tissue and a reduction in muscle degeneration. The oxidative capacity 
and the proportion of oxidative fibers were increased, especially in slow-twitch 
muscles and in the muscles that were not severely affected by the dystrophy (53, 
72). Aerobic training apparently increases the amount of type I muscle fibers, as 
hypothesized earlier in this chapter (see section on pathophysiological studies of 
muscle fatigue). Younger animals tend to benefit more from exercise studies than 
older animals. The muscles of young dystrophic mdx mice have a greater rate 
of recovery of force production than those of older mdx mice. Histological and 
contractile studies suggest that this difference is due to an increased regenerative 
capacity in young dystrophin-deficient mdx mice, which is lost in older mdx mice 
(71, 73).
Carter et al. reviewed studies of exercise training and contraction-induced 
muscle-injury in animal models of muscular dystrophy (72). A majority of the 
studies in both normal and dystrophic animals showed that untrained eccentric 
exercise (lengthening of the muscle during contraction) may injure the contractile 
and cytoskeletal components of the muscle fibers. During eccentric exercise, 
sarcomeres are stretched and the actin and myosin filaments are pulled apart, 
leading to disruption of the thick and thin filament array and subsequent damage 
to cytoskeletal proteins. The inability to quickly repair a disruption of the membrane 
causes an elevation in intracellular calcium concentration, which triggers calcium-
activated degradation pathways and further structural damage. This damage 
results in fiber degeneration followed by inflammation and, eventually, fiber 
regeneration. Probably because of their increased regenerative capacity, muscles 
of younger mdx mice recovered more rapidly than those of older mdx mice (74-
77). Based on these animal studies, one can conclude that submaximal aerobic 
exercise training can be beneficial. However, eccentric exercise training should be 
avoided.
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TRAINING STUDIES IN MUSCULAR DYSTROPHY PATIENTS
In the past, many patients with muscular dystrophy were advised not to exercise 
because of the belief that too much exercise might lead to “overuse weakness” 
(78-80). Yet, in their Cochrane review on muscle strength training and aerobic 
exercise training for patients with muscle diseases, van der Kooi et al. concluded 
that moderate intensity strength training in DM and FSHD appeared not to be 
harmful, although there was insufficient evidence to establish its benefit (81). This 
conclusion was based on merely two randomized clinical trials (RCTs) (38, 82).  
When RCTs are scarce, evidence from nonrandomized studies and other designs, 
such as pre-post studies or case-control studies, may be particularly relevant (83). 
For this reason, Cup et al. reviewed not only RCTs, but also controlled clinical trials 
and other designs of sufficient quality, using the list by van Tulder et al. (84, 85).  
All types of exercise therapy and other physical therapy modalities were included 
for patients with muscular dystrophy, among which patients with FSHD, LGMD, 
DM and DMD. Cup et al. also concluded that exercise training is not harmful in 
muscular dystrophies (85). However, based on the reviewed studies, there was 
insufficient evidence for the effectiveness of muscle strengthening exercises, 
although there were some indications that aerobic exercises may have a positive 
effect on body functions as well as on activities and participation.  
There are several limitations to consider when reviewing training studies in 
muscular dystrophies. First of all, there are only very few randomized controlled 
trials, each small in sample size. Second, studies are not immediately comparable 
because they have used training protocols which differ regarding the intensity 
and duration of the training, targeted muscle groups, type of strength training, 
i.e. isometric or isokinetic, and type of controls. The majority of exercise training 
studies have evaluated non-supervised home programs of relatively short duration, 
using submaximal, low-intensity training levels. The short duration of most 
strengthening studies does not allow differentiation between neural training effects 
versus muscle fiber hypertrophy, which generally occurs after six weeks. Third, 
the compliance of patients, especially during non-supervised home protocols, is a 
possible confounding factor in all training studies. Fourth, because of the scarcity 
of patients of each muscular dystrophy, studies have often grouped together 
several disorders. Persons with different types of muscular dystrophy may however 
respond very differently to exercise (86). Fifth, some studies used the contralateral 
non-exercised muscle as a control in muscle strengthening interventions (87-89).  
The problem with this study design is that there may be confounding cross-over 
effect in the non-exercised muscles. Moreover, one can hardly expect meaningful 
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effects of a single-limb training program on a patient’s activities, participation 
and well-being (86). Olsen et al. (90) investigated the effect of aerobic training in 
8 patients with FSHD. Twelve weeks of low-intense aerobic exercise improved 
maximal oxygen uptake and workload with no signs of muscle damage. The 
authors conclude that aerobic training is a safe method to increase exercise 
performance in patients with FSHD. Most importantly, only one study described the 
effect of strength training for experienced fatigue (39) (see section on medication 
for muscle fatigue and experienced fatigue). 
To conclude, aerobic exercise training appears not to be harmful in muscular 
dystrophies and could have a positive effect on functioning, activities and 
participation, but the number of high quality studies is low.  
MEDICATION FOR MUSCLE FATIGUE AND EXPERIENCED FATIGUE
No curative pharmacological interventions are available, nevertheless, many 
agents have been proposed as a potential pharmacological treatment for 
decreasing muscle fatigue in muscular dystrophies. Creatine and β2- agonists 
have been studied most frequently. Creatine is a well known nutritional supplement 
among athletes because it increases muscle force and lean body mass (91). 
Supplementation of creatine monohydrate might enhance muscle performance 
in patients with muscular dystrophy, as they tend to have lower skeletal muscle 
creatine levels (see section on pathophysiological studies off muscle fatigue). 
A recent systematic review on creatine for treating muscle disorders concluded 
that short- to intermediate-term supplementation with creatine monohydrate in 
patients with muscular dystrophy may result in a significant, but minimal increase 
in maximal isometric force of approximately 8.5% in quantitative muscle testing. 
Most of the potentially clinically relevant effects in muscular dystrophies were seen 
in dystrophinopathies (92).
Other investigators expected a positive effect of β2- agonists in decreasing muscle 
fatigue as high doses of β2- agonists have muscle anabolic properties. In animals 
and healthy volunteers, β2-adrenergic agonists, such as clenbuterol and albuterol, 
increase muscle strength and muscle mass, in particular when combined with 
strength training (93, 94). Based on the model by Kalkman et al. (see section on 
perpetuating factors of experienced fatigue) we might expect that these drugs 
can decrease experienced fatigue, as many of them are aimed to increase muscle 
strength. However, in the study by van der Kooi et al., albuterol and a strength 
training program did not have any effect on experienced fatigue (39). Moreover, 
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β2- agonists are often associated with numerous undesirable side effects including 
increased heart rate and muscle tremor, factors that have limited their therapeutical 
potential. Consequences of prolonged use are presently unclear (38, 39).
Thus, although creatine and albuterol appear to be effective in increasing muscle 
strength in healthy subjects, they seem to have little effect on muscle strength and 
experienced fatigue in muscular dystrophies. 
COGNITIVE BEHAVIORAL THERAPY
Muscular dystrophies have a large impact on psychosocial functioning as patients 
must continuously adapt to their progressive illness. Illness cognitions and coping 
styles influence the level of physical activity and, consequently, experienced fatigue 
and restrictions in social participation. Hence, changing illness cognitions and 
coping style may lead to a better quality of life. A cognitive-behavioral approach 
has been proven successful in the chronic fatigue syndrome (95, 96) and for post 
cancer fatigue (97, 98) and may be effective in patients with muscular dystrophy as 
well. Cognitive behavioral therapy in FSHD should, for instance,  be focused on the 
known perpetuating factors of experienced fatigue as described by Kalkman et al., 
i.e. sleep disturbances, pain complaints and, physical inactivity (66, 99) (see section 
on perpetuating factors of experienced fatigue). Therapy should be adapted to the 
life of each individual, resulting in an individualized treatment approach. Altogether, 
cognitive behavioral therapy seems a rational, promising treatment for fatigue in 
muscular dystrophies.
Clinical case: treatment of fatigue
Mr A. has never used any drug for alleviating his fatigue. It has simply not been 
mentioned by any clinician. He believes that physical exercise is beneficial for 
decreasing his fatigue. In this perspective, he regrets that it is very difficult for 
him to exercise because of his obesity and poor cardiovascular condition. He 
is convinced that exercise at a maximum level will lead to overuse. He regards 
cognitive behavioral therapy as a promising intervention for him.
Clinical case: Experienced fatigue in clinical setting
Mr. A. regrets that his experienced fatigue has never been asked for, nor treated 
by health workers. He regards his fatigue as an essential disability, whereas his 
physician has focused on the genetical aspects and diagnosis of the disease. He 
is happy that fatigue is now on the research and on the medical agenda.C
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CONCLUSION
Fatigue is not only a frequent, but also a very relevant symptom in patients 
with muscular dystrophy. Based on the content of this chapter, several 
recommendations for clinical practice and research can be made. Clinicians 
should actively ask their patients about the presence of fatigue and its individual 
characteristics. The nature of the experienced fatigue gives directions to its primary 
cause. In particular, affective disorders need to be diagnosed or ruled out. The CIS-
fatigue questionnaire can be used to measure the severity of experienced fatigue.
The history taking should cover the possible perpetuating factors of fatigue and the 
perceived disabilities in daily life. 
Based on these perpetuating factors, a therapeutic intervention can be proposed. 
Both in DM and FSHD, specific attention should be paid to sleep disturbances. 
Specifically in FSHD, the level of physical activity should improve.
Aerobic exercise training appears to be a safe intervention to increase physical 
activity. It may also be effective in maximizing functional ability and preventing 
chronic physical complications of inactivity. High-resistance and eccentric strength 
training should be avoided, particularly in muscular dystrophies caused by defects 
in structural proteins in the dystrophin-glycoprotein complex, i.e. LGMD, BMD and 
DMD. 
In the future, research on fatigue in muscular dystrophies needs to investigate 
each type of muscular dystrophy separately, both pathophysiologically and 
therapeutically. All treatment strategies will ultimately depend on pathophysiology, 
but the absence of hard evidence should not prevent clinicians and researchers 
from investigating treatment options based on credible hypotheses.
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FIVE KEY PAPERS THAT SHAPED THE TOPIC AREA
Study 1. Wineinger, M.A., Walsh, S.A. and Abresch, T. (2002). Muscle fatigue in 
animal models of neuromuscular disease. American Journal of Physical Medicine 
and Rehabilitation, 81, S81-S98.
A review of Wineinger et al. showed that difference in fatigability between 
dystrophic animal muscles and muscles of healthy animals can largely be explained 
by differences in muscle fiber types. The dystrophic soleus muscle, which is largely, 
composed of slow-twitch type I oxidative muscle fibers, fatigued more slowly or 
at the same rate as that of healthy animals. Yet, the dystrophic extensor digitorum 
longus (EDL), which has mainly type IIB fibers, was weaker than in healthy animals 
and generally more fatigable. No differences in fatigability were found between 
healthy and dystrophic diaphragm muscles. The diaphragm is composed of fast 
oxidative IIA muscle fibers, which are relatively fatigue resistant (Table 2). 
Study 2. Kalkman, J.S., Schillings, M.L., Zwarts, M.J., van Engelen, B.G. and 
Bleijenberg, G. (2007b). The development of a model of fatigue in neuromuscular 
disorders: a longitudinal study. Journal of Psychosomatic Research, 62, 571-579.
Kalkman et al. investigated the perpetuating factors of experienced fatigue in 
patients with FSHD (n = 60) and DM (n = 70) (Figure 2). Only in FSHD, the level 
of physical (in)activity had a central place in the model. Lower levels of physical 
activity contributed to higher levels of experienced fatigue and, through that, to 
restrictions in social participation. The level of physical activity was directly and 
negatively influenced by loss of muscle strength. In addition, pain complaints 
influenced levels of experienced fatigue, both directly and indirectly, by decreasing 
physical activity. 
Study 3. Vignos, P.J., and Watkins, M.P. (1966). The effect of exercise in muscular 
dystrophy. The Journal of the American Medical Association, 197, 843-848.
The first controlled study of strengthening exercise in muscular dystrophies used 
a regimen with gradual increase in weight resistance in patients with DMD (n=14), 
FSHD (n=4) and LGMD (n=6) over a one-year period. The authors reported strength 
improvement throughout the first four months of exercise regardless of type of 
dystrophy. The degree of improvement was related to the initial strength of the 
exercised muscle. Therefore, they concluded that exercise programs should begin 
early in the course of the disease. 
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Study 4. Florence, J.M. and Hagberg, J.M. (1984). Effect of training on the exercise 
responses of neuromuscular disease patients. Medicine and Science in Sports and 
Exercise, 16, 460-465.
Because the hallmark of muscular dystrophy is motor weakness, more studies 
have been conducted looking at muscle strength training than at aerobic exercise 
training. Only in 1984,  Florence et al. first described a positive effect of aerobic 
exercise training on the exercise responses of neuromuscular disease patients 
among which patients with LGMD (n=3) and FSHD (n=1). All patients completed a 
12-week cycle ergometry training program, three days per week. The increase in 
VO2max in the patients was almost the same as that of the healthy subjects (n=4).  
The authors concluded that patients can develop relatively normal adaptations to 
training. No definitive deleterious effects of training were demonstrated in these 
patients. 
Study 5. Lindeman, E., Leffers, P., Spaans, F., Drukker, J., Reulen, J., Kerckhoffs, 
M. and Koke, A. (1995). Strength training in patients with myotonic dystrophy and 
hereditary motor and sensory neuropathy: a randomized clinical trial. Archives of 
Physical Medicine and Rehabilitation, 76, 612-620.
The number of recent studies on the effect of training in muscular dystrophy 
lacking a randomized controlled design is striking. Lindeman et al.  first conducted 
a randomized clinical trial on the effects of strength training in muscular dystrophy. 
This trial compared the effect of 24 weeks of strength training of the thigh muscles 
versus no training in 36 adult patients with myotonic dystrophy. The participants 
trained 3 times a week for 24 weeks with weights adjusted to their force. In the 
DM patients, none of the outcomes showed any training effect. No serious side 
effects of the training occurred. Training loads could be gradually increased in 
all patients, because the repetition maximum improved. Three rather weak DM 
patients were unable to perform the exercises according to the training instructions. 
Most of the differences in muscle strength outcomes (isometric, dynamic and 
endurance) between groups showed small, non-significant positive effects in 
favor of the training group. Only changes in the endurance measure (13.1 s longer 
maximum duration of an isometric contraction; 95% CI 2.2 to 24.0) reached 
statistical significance. No signs of overuse, such as a decline in strength or a rise 
in parameters of muscle membrane permeability were seen. However, this study 
imposed merely a controlled strain for a relatively short period.
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INTRODUCTION 
This European Neuromuscular Centre (ENMC) care workshop was attended by 
19 professionals working in the field of neuromuscular disorders (NMD) (pediatric 
and adult), pain or fatigue from 8 different countries (USA, Great Britain, Germany, 
France, Italy, Sweden, Denmark and the Netherlands), and 3 patient representatives 
coming from the Netherlands. This ENMC organized workshop aimed to achieve 
consensus on the definition of pain and fatigue in NMD, to define a core set of 
measurement instruments for pain and fatigue in NMD, and to discuss possible 
interventions. Prior to the workshop, all participants received a questionnaire on the 
assessment instruments and interventions that they regularly used to, respectively, 
assess and treat pain and fatigue. Two experts on (chronic) pain and fatigue in 
general (Henriët van Middendorp and Hans Knoop) were invited to present an 
overview of definitions, mechanisms, and measurement instruments for pain 
and fatigue. Next to that, several participants presented data on the prevalence 
of pain and fatigue in the various NMD populations. Through group discussions 
with all participants, consensus was reached on the definition and core set of 
measurement instruments for use in future research and clinical practice in NMD.  
BACKGROUND 
Pain and fatigue are common symptoms in neuromuscular disorders (NMD) with a 
prevalence of 30–90%, present in all types of NMD, both in adults and children (1-
6). Pain and fatigue have a strong impact on many activities of daily life, including 
mobility, work, school, leisure, and sleep (4, 7). The differences in reported 
prevalence could be due to different definitions of pain and fatigue, and various 
types of measurements. In order to develop effective treatment approaches, both 
definitions and methods to measure pain and fatigue should be agreed on.  
QUESTIONNAIRES 
Questionnaires were sent to all participants prior to the workshop to get an 
overview of the questionnaires on pain and fatigue that are currently used in 
research and practice in NMD (8). In addition, the various interventions used to treat 
pain and fatigue were investigated. To assess pain in adults, nearly all participants 
used the SF-36 (items related to pain), a Likert scale, visual analog scale (=VAS), 
numeric rating scale (=NRS), and the McGill Pain Questionnaire. For neuropathic 
pain, more specific scales were mentioned, such as the Douleur Neuropathic 4 
(=DN4), Neuropathic Pain Symptom Inventory (=NPSI), or ID-pain. In children, all C
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used the VAS or the Faces Pain Scale (of which there are many different versions), 
few used body images to indicate the site of pain or the PedsQol (pain items), and 
one used the San Salvadour scale for severely handicapped children or the Douleur 
Enfant Gustav Roussy Scale for children between 2 and 6 years of age. 
For fatigue in adults, most of the participants used the Fatigue Severity Scale 
(=FSS), Borg CR-10 scale, NRS for fatigue, and some used the Modified Fatigue 
Impact Scale or the Checklist Individual Strength (=CIS). Specific for Myotonic 
Dystrophy type 1 (DM1), the following sleepiness scales were reported: Daytime 
Sleepiness Scale (DSS), Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness 
Scale (ESS), and Unnalinna Narcolepsy Scale (UNS). For children, the (modified) 
Borg scales were reported and the six minute walking test for ambulant children. 
As possible interventions for pain, all participants mentioned guidance and 
advice for daily activities with special attention for overuse, physical therapy, and 
possible drugs such as pregabalin, citalopram, duloxetine, amitriptyline, creatine 
monohydrate, and paminodrate. 
For fatigue, possible interventions that were reported included polysomnography 
to evaluate nocturnal hypoventilation and treatment, guidance and advice for 
daily activities with special attention for overuse, physical therapy, and cognitive 
behavioral therapy. Only for DM1 drugs to treat sleepiness were mentioned such as 
modafinil, citalopram, and Ritalin. 
The level of evidence for the efficacy of the interventions is low; available evidence 
is restricted to drug treatment for neuropathic pain and sleepiness and fatigue in 
DM (see Cochrane reviews). 
PARTICIPANTS’ RESEARCH ON PAIN AND 
FATIGUE IN NMD 
Baziel van Engelen reported on several studies in NMD populations, consisting of 
cross-sectional data of adult DM1 (n = 322), DM type 2 (n = 29), OculoPharyngeal 
Muscular Dystrophy (OPMD) (n = 35), Chronic Progressive External 
Ophthalmoplegia (CPEO) (n = 28), Facioscapulohumeral muscular dystrophy 
(FSHD) (n = 139), and Charcot Marie Tooth (CMT) (n = 137), as well as longitudinal 
data of adult DM1 (n = 79), FSHD (n = 65), and CMT (n = 73). To assess pain and 
fatigue in these studies, the McGill pain questionnaire and VAS were used for pain, 
and the CIS and SF-36 for fatigue. The reported fatigue was between 54% (OPMD) 
and 68% (CPEO), with significant impact on daily functioning. The pain scores were 
between 47% (DM1) and 96% (CPEO), with a different distribution pattern for each 
specific type of NMD. Pain scores were independent of age, impairments, physical 
activity level, or muscle force. The longitudinal study in FSHD (n = 60) and DM1    
61
(N = 75) resulted in an FSH health status model and a DM1 health status model. 
Pain and fatigue were main determinants of health status in both diseases (7). 
These models enable to rationally develop treatment strategies in FSHD and DM1 
and form the starting point of the study presented by Nicoline Voet: the protocol 
of the FACTS-2-FSHD trial. In this recently finished study, aerobic exercise training 
is compared to cognitive behavioral therapy (data currently in analysis). Pain and 
fatigue are measured by CIS, VAS for pain, 6 min walking test, and SF36. 
Birgit Steffensen reported on a study of self-reported pain and fatigue in patients 
with FSHD and their healthy relatives or caregivers. The FSS and VAS were used 
to assess fatigue; pain was measured on a 1–7 scale as adapted from the FSS, by 
VAS, and by localization on a body image. 
Pain and fatigue scores were significantly higher in patients than in healthy 
persons, there was no statistical difference between patients who were still able to 
walk and those who were not, and there was a tendency towards higher pain and 
fatigue scores in patients with less muscle strength. 
Marie Kierkegaard reported the results of a cross-sectional study on 70 persons 
with DM1. The ICF checklist was used for self-rating of perceived pain. Fatigue and 
excessive daytime sleepiness was evaluated with the FSS and ESS, as well as with 
the ICF checklist. Fatigue, daytime sleepiness and pain were rated as a problem 
in 76%, 80% and 51%, respectively. The impact of the cut-off level for fatigue and 
excessive sleepiness when using the FSS and ESS was stressed. For example, 
with a score equal or above 4 in FSS 52% are classified as experiencing fatigue 
compared to 17% when a cut-off score equal or above 5 is used. 
Cornelia Kornblum discussed her study of 22 patients with DM1, 22 with DM2, and 
22 controls. The FSS, DSS, ESS, PSQI, and UNS were used to assess fatigue and 
sleepiness as part of a more extensive psychological test set. DM1 showed more 
sleepiness and fatigue in all measurements compared to the other groups; only 
the mean KFSS-, DSS-, and PSQI-scores were above the cutoff for pathological 
performing. The DM2-patients showed more fatigue and a lower sleep quality 
(mean KFSS- and PSQI-scores were above the cut-off for pathological performing); 
no differences were found in daytime sleepiness. DM1 and DM2 patients were both 
more fatigued than healthy controls, and DM1 more than DM2. 
Luca Padua showed the results of a study in 392 patients with peripheral nerve 
diseases, in which the Neuropathic Pain Symptom Inventory (NPSI), VAS, ID-pain, 
and DN4 were assessed. In 60% of the patients, the VAS-pain was 3 or higher, 
and approximately 30% had a VAS of 5 or higher. On ID-pain and DN4, 50–60% 
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had symptoms of neuropathic pain. The NPSI showed no statistical difference 
between the different symptoms of neuropathic pain, in which paraesthesias had 
the highest score. In another study on 65 patients with FSHD, the SF-36, VAS-
pain, and ID-pain were assessed. According to the ID-pain, 7% of the patients had 
very probable neuropathic pain, 20% probable neuropathic pain, 24% possible 
neuropathic pain, 33% no pain, and 16% joint pain exclusively. 
Bernard Wuyam showed the preliminary results of an ongoing study on the 
assessment of neuromuscular dysfunction by means of magnetic nerve stimulation 
in muscular dystrophies and CMT, and the effect of exercise. 
Ulla Werlauff showed results of studies on the perception of pain and fatigue in 
persons with spinal muscular atrophy (SMA) (52 persons: 7.8–72.6 years) and 
congenital myopathies (95 persons: 5.5–75.2 years). The PedsQoL (generic, 
specific), SF-36, Egen classification 2 scale, FSS, and Modified Fatigue Impact 
Scale were used to measure pain and fatigue. In congenital myopathies, pain was a 
problem in all muscles (overload?) whereas in SMA-type 2 it was not, or related to 
an event like surgery. 
In this study, fatigue was a problem in congenital myopathies but not in SMA. From 
her results, Ulla Werlauf concluded that PedsQoL, SF-36 and Modified fatigue 
impact scale were not very sensitive or conclusive. The recommended scale would 
be the FSS. 
Imelda de Groot showed results of former studies in adults with SMA and ALS and 
an ongoing study in DMD. In an open questionnaire study in 99 adult SMA patients, 
divided into two groups (SMA type1–2 and type 3), neck pain was most prevalent 
in both groups (38% in SMA1-2, and 34% in SMA3); fatigue was reported in 64% 
in SMA3, in contrast to 34% in SMA1-2. In a study in 74 persons with ALS, no 
correlations were found between functional abilities (measured with ALS-FRS), and 
pain or fatigue (measured with SF-36). In the ongoing study in boys with DMD (N 
= 30) and training, the preliminary results show that boys with DMD have similar 
adaptations to physical exercise (heart rate and EMG-adaptations) as healthy age-
matched controls (N = 99) and comparable subjective fatigue (measured by OMNI 
scale), but that some boys can perceive/ experience fatigue in rest. 
Yaacov Anziska showed preliminary results of two studies: one study in children 
with NMD (7 with myopathy/limb girdle muscular dystrophy, 9 with DMD, 3 
with CMT, and 2 with myasthenia gravis; age range 5– 19 years). The Epworth 
Sleepiness Scale, the Vignos, and Brooke ratings scales, the Children’s Depression 
Inventory, and the PedsQoL 3.0 Neuromuscular Module for Patients and Parents 
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were used. Except for the myopathy/DMD-group, there was no correlation between 
PedsQOL-scores of the patients and those of their parents. There was evidence of 
mild abnormal mood disorders and mild-moderate sleepiness. A study of 31 adults 
(5 patients with DM1-2, 14 with LGMD, 5 with CMT, 5 with motor neuron diseases, 
2 with myasthenia gravis) in which the SF-36 was used gave similar results. 
Carole Bérard showed results of a study in 22 boys with DMD with pain and 
osteopenia (7 ambulant, and 15 non-ambulant). In 21 of the 22 boys, a moderate 
to severe pain was measured with NRS, most of the boys (21) experienced 
pain during physiotherapy; 11 also spontaneously, 9 during the night and 5 
(nonambulant) during transfers. There was no correlation between the NRS-pain 
score and osteopenia. 
Anna-Karin Kroksmark shared some practical experiences on pain and fatigue 
in children with DMD from studies performed at her centre. In these studies, 
PedsQoL, Multidimensional Fatigue Scale, Sleep Quality Index, and questions 
about pain and tiredness were used. Pain has an increasing interest in the network 
in Sweden and a national survey is now being performed. Adapted Faces Scales 
were shown. 
Caron Coleman showed her work on establishing how to measure pain in children: 
one size does not fit all! Due to the different developmental stages the following 
measurements were recommended for clinical utility: 0–5 years and cognitive or 
learning difficulties observation and parent/caretaker report; 5–7 years-faces and 
questions to child and parents regarding location, frequency, quality (if possible) 
and impact on function; 8+ years-combination of faces/NRS and questions as 
above; 13+ years Brief Pain Inventory/faces/NRS. 
Heinz Jungbluth gave an overview of different childhood NMD in which exertial 
myalgia with or without rhabdomyolysis is a common primary or secondary feature. 
One of the open questions that need to be addressed in future research is whether 
the different mechanisms underlying these features in distinct disorders will require 
different treatment approaches. 
Marion Main shared some thoughts on pain and fatigue in children with NMD. Pain 
can be caused by secondary complications of the disorder, such as contractures, 
cramps, muscle soreness etc. A warning was given that the physiotherapist can be 
a cause of pain due to treatments like stretching. 
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She pointed at the lack of knowledge on the topic of fatigue with regard to the role 
of weakness in the development of fatigue and the important role of exercise in the 
management of pain and fatigue. 
Finally, Jo Auld gave advices on the psychometric properties that outcome 
measures on pain and fatigue should encompass.  
CONCLUSIONS 
Pain as well as fatigue are currently measured by various methods and several 
NMDs have been studied so far. It can be concluded that pain and fatigue are 
highly prevalent and important problems, both in adults and children. It is important 
to differentiate pain and fatigue from sleepiness, depression, de-conditioning, and 
side effects of drugs. Specific types of pain and fatigue, related to the underlying 
NMD and/or stage of the NMD can be distinguished. These should be differentiated 
from aspecific pain and fatigue, which are not primary related to NMD. 
Fatigue can have physiological features, such as loss of voluntary force or 
endurance during exercise/activity (both of peripheral and central origin). This type 
of fatigue is activity-related. This aspect of fatigue is also applicable for cognitive 
fatigue, defined as a reduction in cognitive performance over time. 
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PROPOSED DEFINITIONS 
As presented by the experts on pain and fatigue, both pain and fatigue are 
multidimensional concepts and include the following aspects: 
Characteristics: acute or chronic (“long lasting”), intensity, frequency, 
location, quality.
Cause(s). 
Consequences or impact on: body function(s), activities of daily life, 
and participation. 
Cognitive behavioral factors (predisposing and/or perpetuating). 
The proposed definition of pain in NMD is from the International Association of 
Study on Pain (IASP): pain is an unpleasant sensory and emotional experience 
associated with actual or potential tissue damage, or described in terms of such 
damage. 
Fatigue can have many definitions. The proposed one is: experienced/subjective 
fatigue is lack of energy or the existence of weakness or exhaustion – mentally, 
physically or both. 
PROPOSED MEASUREMENT CORE-SETS  
Several instruments to measure pain and fatigue in NMD were discussed with 
experts in the research field (8). Two types of measurement core-sets are proposed: 
one to use in daily practice and one for research purposes. 
For pain the following core-sets are proposed: 
Core-set (daily practice): 
Numeric Rating Scales (faces for children)/Face Legs Activity Cry Consolability 
(FLACC) in young children. 
Modified Brief Pain Inventory. 
Hospital Anxiety and Depression Scale (HADS). 
Pay attention to organic/biomechanical causes/ neuropathic pain (if the latter is 
suspected: use ID-pain or DN4). 
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Research (extended screening): 
Pain Disability Index (PDI) or Brief Pain Inventory (BPI). 
SF-36. 
HADS and/or Beck’s Depression Index (BDI). 
Cognitive behavioral factors. 
In case of neuropathic pain, use ID-pain or NPSI.   
For fatigue: 
Core set (daily practice): 
NRS. 
Checklist Individual Strength (CIS) (norms, multiple dimensions), or if CIS is 
not available fatigue severity scale (FSS) (impact of fatigue). 
Look for organic/biomechanical causes/forced vital capacity. 
Extended/research: 
Physical activity (e.g. actography, activlim). 
Disability scale (e.g. SIP, SF-36). 
Psychological distress (e.g. Hospital Anxiety and Depression Scale). 
Sleep disturbances. 
Social support scale.
Fatigue-related cognitions. 
Pain. 
FUTURE PLANS 
This workshop only covers discussions and proposals for definitions of pain and 
fatigue in NMD and the core set of measurements for daily practice and research. 
The management of pain and fatigue is still a point to discuss in the future. It 
was decided to collaborate on the use of the core-sets and share data with each 
other in order to get more insight in the possible contributing factors of pain and 
fatigue in NMD. Based on these results, possible management approaches can be 
discussed in a next workshop on Management of pain and fatigue in NMD. 
Participants: 
Yaacov Anzsika, SUNY Downstate medical center, Brooklyn NY, USA. 
Jo Auld, King’s College Hospital, London, GB. 
Carole Bérard, Centre Hospitalier, Lyon, Fr. 
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Caron Coleman, Evelina Childrens Hospital, London, GB. 
Baziel van Engelen, Radboud University Nijmegen medical centre, 
Nijmegen, NL. 
Imelda de Groot, Radboud University Nijmegen medical center, Nijmegen, NL. 
Heinz Jungbluth, King’s College, London, GB. 
Marie Kierkegaard, Karolinska Institute, Stockholm, Sw. 
Hans Knoop, Radboud University Nijmegen medical center, Nijmegen, NL. 
Cornelia Kornblum, University Hospital of Bonn, Bonn, Ger. 
Anne-Karin Kroksmark, Queen Silvia’s Children’s hospital, Gothenburg, Sw. 
Marion Main, Great Ormond street Children’s hospital, London, GB. 
Henriët van Middendorp, Radboud University Nijmegen medical center, 
Nijmegen, NL. 
Luca Padua, Universita Cattolica del Sacro Cuore, Rome, It. 
Jes Rahbek, Rehabiliteringscenter for Muskelsvind/ Muskelvindfonden, 
Aarhus, Dk. 
Birgit Steffensen, Rehabiliteringscenter for Muskelsvind/Muskelvindfonden, 
Aarhus, Dk. 
Nicole Voet, Radboud University Nijmegen medical center, Nijmegen, NL. 
Ulla Werlauff, Rehabiliteringscenter for Muskelsvind/ Muskelvindfonden, 
Aarhus, Dk. 
Bernard Wuyam, Université Joseph Fourier, Grenoble Fr. 
Patient representatives: 
Paul Hölzenspies, NL. 
Joanna Kleiverda NL. 
Stephanus Kuijpers NL. 
ENMC: 
Annette Boersen
Annelies Zittersteijn
Maarten Rector
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Aerobic exercise
Strength training
CHAPTER 4
STRENGTH TRAINING AND AEROBIC EXERCISE TRAINING FOR 
MUSCLE DISEASE 
Nicoline B.M. Voet 
Elly L. van der Kooi 
Ingrid L. Riphagen 
Eline Lindeman ƚ
Baziel G.M. van Engelen 
Alexander C.H. Geurts 
Published in: Cochrane Database of Systematic Reviews 2013, Issue 6. 
Art. No.: CD003907. DOI:10.1002/14651858.CD003907.pub4.
ABSTRACT 
Background
Strength training or aerobic exercise programs might optimize muscle 
and cardiorespiratory function and prevent additional disuse atrophy and 
deconditioning in people with a muscle disease. This is an update of a review first 
published in 2004.  
Objectives 
To examine the safety and efficacy of strength training and aerobic exercise training 
in people with a muscle disease. 
Search methods 
We searched the Cochrane Neuromuscular Disease Group Specialized Register 
(July 2012), CENTRAL (2012 Issue 3 of 4), MEDLINE (January 1946 to July 2012), 
EMBASE (January 1974 to July 2012), EMBASE Classic (1947 to 1973) and 
CINAHL (January 1982 to July 2012). 
Selection criteria 
Randomized or quasi-randomized controlled trials comparing strength training or 
aerobic exercise programs, or both, to no training, and lasting at least six weeks, 
in people with a well-described diagnosis of a muscle disease. We did not use the 
reporting of specific outcomes as a study selection criterion. 
Data collection and analysis 
Two authors independently assessed trial quality and extracted the data obtained 
from the full text-articles and from the original investigators. We collected adverse 
event data from included studies. 
Main results 
We included five trials (170 participants). The first trial compared the effect of 
strength training versus no training in 36 people with myotonic dystrophy. The 
second trial compared aerobic exercise training versus no training in 14 people 
with polymyositis and dermatomyositis. The third trial compared strength training 
versus no training in a factorial trial that also compared albuterol with placebo, in 
65 people with facioscapulohumeral muscular dystrophy (FSHD). The fourth trial 
compared combined strength training and aerobic exercise versus no training in 18 
people with mitochondrial myopathy. The fifth trial compared combined strength 
training and aerobic exercise versus no training in 35 people with myotonic 
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dystrophy type 1. In both myotonic dystrophy trials and the dermatomyositis 
and polymyositis trial there were no significant differences between training and 
non-training groups for primary and secondary outcome measures. The risk of 
bias of the strength training trial in myotonic dystrophy and the aerobic exercise 
trial in polymyositis and dermatomyositis was judged as uncertain, and for the 
combined strength training and aerobic exercise trial, the risk of bias was judged 
as adequate. In the FSHD trial, for which the risk of bias was judged as adequate, a 
+1.17 kg difference (95% confidence interval (CI) 0.18 to 2.16) in dynamic strength 
of elbow flexors in favor of the training group reached statistical significance. In 
the mitochondrial myopathy trial, there were no significant differences in dynamic 
strength measures between training and non-training groups. Exercise duration 
and distance cycled in a submaximal endurance test increased significantly in the 
training group compared to the control group. The differences in mean time and 
mean distance cycled till exhaustion between groups were 23.70 min (95% CI 2.63 
to 44.77) and 9.70 km (95% CI 1.51 to 17.89), respectively. The risk of bias was 
judged as uncertain. In all trials, no adverse events were reported. 
Authors’ conclusions 
Moderate-intensity strength training in myotonic dystrophy and FSHD and aerobic 
exercise training in dermatomyositis and polymyositis and myotonic dystrophy 
type I appear to do no harm, but there is insufficient evidence to conclude that 
they offer benefit. In mitochondrial myopathy, aerobic exercise combined with 
strength training appears to be safe and may be effective in increasing submaximal 
endurance capacity. Limitations in the design of studies in other muscle diseases 
prevent more general conclusions in these disorders. 
PLAIN LANGUAGE SUMMARY
STRENGTH TRAINING OR COMPREHENSIVE AEROBIC EXERCISE 
TRAINING FOR MUSCLE DISEASE 
Strength training, which is performed to improve muscle strength and muscle 
endurance, or aerobic exercise programs, which are designed to improve 
cardiorespiratory endurance, might optimize physical fitness and prevent 
additional muscle wasting in people with muscle disease. However, people with 
muscle disease and some clinicians are still afraid of overuse and have a cautious 
approach to training. This updated review (most recent date of search 2 July 2012) 
included two eligible trials of strength training in people with facioscapulohumeral 
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muscular dystrophy (FSHD) and myotonic dystrophy (101 participants), two trials 
of strength training combined with aerobic exercise in people with mitochondrial 
myopathy (18 participants) and myotonic dystrophy type I (35 participants) and 
one trial of aerobic exercise in people with polymyositis and dermatomyositis 
(14 participants). These trials showed that moderate-intensity strength training in 
people with myotonic dystrophy or with FSHD, and aerobic exercise training in 
people with dermatomyositis or polymyositis appear not to harm muscles. Strength 
training combined with aerobic exercise appears to be safe in myotonic dystrophy 
type I and may be effective in increasing endurance in people with mitochondrial 
myopathy. Evidence suggests that strength training is not harmful in people in 
FSHD, myotonic dystrophy, mitochondrial disorders and dermatomyositis and 
polymyositis, but further research is needed to determine potential benefit.
BACKGROUND
The term ’muscle disease’ comprises a large group of conditions. Skeletal muscles 
are primarily affected but in some disorders other organ systems may also be 
involved. Most conditions are progressive, causing the muscles to gradually 
weaken over time. When a person is diagnosed as having a muscle disease, 
questions arise about the prognosis, possible interventions and genetics. However, 
people with muscle disease are usually also concerned about everyday issues 
such as participation in sports, work and hobbies. We cannot give evidence-based 
advice about these issues, because we do not know how physical exercise affects 
the diseased muscular system or the cardiorespiratory system. To answer these 
questions, controlled trials of aerobic exercise and strength training in people with 
a muscle disease are needed. 
Weakness and impaired cardiorespiratory function are common in people with 
muscle disease; pain and fatigue may also be common symptoms, all of which 
contribute to a decreased quality of life. In healthy persons the best intervention 
to improve strength and cardiorespiratory function is physical training. Strength 
training or aerobic exercise programs in people with muscle disease might 
maximise muscle and cardiorespiratory function and prevent additional disuse 
atrophy (1). However, reports of progression of weakness after exercise in people 
with myopathies have encouraged a cautious approach to training (2-4). Therefore, 
many people with a muscle disease were advised to avoid physical exertion (3). 
Thus the benefit from strength training or aerobic exercise training in muscle 
diseases is still not clear (5). 
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The relative rarity of many muscle diseases has led researchers to group 
participants with different neuromuscular disorders together in one study, 
including myopathies, neuropathies and motor neuron disease (6-13). As the 
pathophysiology of these disorders differs, their reaction to an intervention might 
also be different. Therefore, conclusions about the effect of training derived from 
these mixed populations cannot readily be extrapolated to people with specific 
muscular disorders (14). 
In this review we systematically analyzed randomized controlled trials (RCTs) of 
these interventions for people with specified muscle diseases. This review was first 
published in 2004, with the most recent update of the searches in 2012. 
Objectives 
To examine the safety and efficacy of strength training and aerobic exercise training 
in people with a muscle disease. 
METHODS
CRITERIA FOR CONSIDERING STUDIES FOR THIS REVIEW 
Types of studies 
We included all RCTs or quasi-RCTs that made any of the following comparisons: 
strength training versus no training; 
aerobic exercise training versus no training; 
combined strength training and aerobic exercise versus no training. 
Quasi-RCTs are trials that allocate participants to experimental or control groups 
based on a method that is not truly random, for example, hospital record number or 
date of birth. 
Types of participants 
We selected all trials that included participants with a well-described diagnosis 
of a muscle disease, such as inflammatory myopathies, metabolic myopathies, 
muscular dystrophies, muscle diseases with myotonia and other well-defined 
myopathies. We decided not to include studies looking at strength training or 
aerobic exercise training for people in whom muscle weakness was not the primary 
feature, but might have been secondary to chronic renal insufficiency, chronic 
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heart failure, renal or heart transplantation, or corticosteroid use. We did not review 
the effects of respiratory muscle training. We did not include studies regarding 
aerobic exercise training for McArdle disease because there is a separate Cochrane 
review available for this metabolic myopathy (15). We excluded studies in which 
participants had a variety of muscle diseases if we could not obtain results for each 
condition separately. We assessed the diagnostic criteria of each study; diagnosis 
has to be confirmed by muscle biopsy or genetic testing. 
Types of interventions 
To date, there is no evidence or recommendation for a minimum duration of training 
in muscle disease. However, in the first six weeks, the change in muscle strength or 
aerobic capacity is generally caused by neural adaptation. Therefore, we included 
all forms of strength training and aerobic exercise training lasting at least six weeks. 
We excluded all studies using a within-subjects design with the non-exercised limb 
as a control. If exercises are performed to increase muscle strength on one side of 
the body, voluntary strength can increase on the contralateral side. This concept is 
called cross-education, and has been described with different forms of exercises. A 
meta-analysis of 16 randomized studies concluded that, on average, the magnitude 
of cross-education is eight per cent of the initial strength of the untrained limb (16). 
Neural adaptations to training and learning effects due to testing are postulated 
as explanations (17-20). Moreover, the results may well be confounded by the 
presence of asymmetric weakness of both limbs, as the absolute gain in muscle 
strength resulting from strength training is related to pre-exercise muscle weakness 
(21). For this reason, a non-exercised limb is not an appropriate control, even if 
training is randomly assigned. For this reason, we have excluded studies using 
such a within-subjects design. 
Definitions
Training or physical fitness training: a planned, structured regimen of regular 
physical exercise deliberately performed to improve one or more of the 
following components of physical fitness: cardiorespiratory fitness, body 
composition, muscle strength and endurance, and flexibility (22). 
Strength training: a systematic program of exercises designed to increase an 
individual’s ability to exert or resist force using, for example, weights, weight 
machines or elastic cords (22).
Aerobic exercise training or cardiorespiratory fitness training: training that is 
designed to improve the capacity and efficiency of aerobic energy-producing 
systems and is effective for improving cardiorespiratory endurance. It consists C
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of an activity or combination of activities that uses large muscle groups, that 
can be maintained continuously, and is rhythmical and aerobic in nature, for 
example walking, running, cycling, aerobic dance exercise or swimming (22). 
TYPES OF OUTCOME MEASURES  
Primary outcomes 
The primary outcome measure for strength training was: 
change in muscle strength, expressed in measures of static (that is, isometric) 
or dynamic strength between baseline and six weeks. 
The primary outcome measure for aerobic exercise training was:
change in aerobic capacity, expressed in measures of work capacity between 
baseline and six weeks. 
Secondary outcomes 
The secondary outcome measure specific to strength training was:
change in muscle endurance muscle endurance or muscle fatigue between 
baseline and six weeks. 
The secondary outcome measure specific to aerobic exercise training was: 
change in aerobic capacity, expressed in measures of oxygen consumption, 
parameters of cardiac function or parameters of respiratory function between 
baseline and six weeks. 
Secondary outcome measures applicable to both strength training and aerobic 
exercise training showing a change from baseline and six weeks were:  
timed-scored functional assessments of muscle performance, such as a six-
minute walk test (23); 
quality of life measures, such as the Short Form 36 (SF-36) Health Survey (24); 
parameters of muscle membrane permeability (serum creatine kinase level, 
myoglobin level) to assess safety; pain assessed by an analogue pain scale 
(25); 
experienced fatigue assessed by questionnaires, e.g. Checklist Individual 
Strength (CIS-fatigue) (26); 
adverse effects requiring withdrawal of the participant from the study: acute 
rhabdomyolysis, increasing muscle pain, injury, etc; 
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We compared data on outcome measures at baseline with those obtained after at 
least six weeks of training. When there were assessments at more than one time 
(during the intervention, after cessation of the intervention), our preference was for 
data on outcome measures obtained at the end of the intervention. 
SEARCH METHODS FOR IDENTIFICATION OF STUDIES 
We searched the following databases: the Cochrane Neuromuscular Disease Group 
Specialized Register (July 2012), the Cochrane Central Register of Controlled Trials 
(CENTRAL, in The Cochrane Library 2012, Issue 7 of 12), MEDLINE (January 1946 
to July 2012), EMBASE (January 1974 to July 2012), EMBASE Classic (1947 to 
1973) and CINAHL (January 1982 to July 2012). We reviewed the bibliographies 
of the trials identified and other reviews of the subject, and contacted some of the 
authors in the field to identify additional published and unpublished data.
DATA COLLECTION AND ANALYSIS 
Selection of studies 
Two review authors (Voet, van der Kooi) checked the references identified by 
the search strategy. We obtained the full text of all potentially relevant studies 
for independent assessment by both authors. We decided which trials fitted the 
inclusion criteria. 
Data extraction and management
Two review authors (Voet, van der Kooi) independently extracted the data from the 
included trials onto a specially designed data extraction form, and graded the risk 
of bias and certain other aspects of the design of the included trials. 
Assessment of risk of bias in included studies 
We assessed the risk of bias and other aspects according to the Cochrane 
approach using the updated guidance in the Cochrane Handbook for Systematic 
Reviews of Interventions (27). 
We assessed the included studies for randomization sequence generation, 
allocation concealment, blinding (participants and outcome assessors), incomplete 
outcome data, selective outcome reporting and other sources of bias. When there 
was uncertainty, we contacted authors for clarification. We resolved disagreements 
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about fulfillment of inclusion or quality criteria by discussion between the two 
authors. We made a judgement on each of the ’Risk of bias’ criteria, of “High risk of 
bias”, “Low risk of bias” or “Unclear risk of bias”. Whenever characteristics of study 
design or drop-out rates were likely to cause a higher risk of bias, we planned to 
make a note of this and investigate the possibility of differences in treatment effects 
varying with the degree of this problem. 
Data synthesis 
We intended to combine trial results for appropriate pairings of treatments by 
calculating a mean of the difference between their effects using the Cochrane 
statistical package Review Manager 5 (RevMan) (28). Because pooling of the 
results of trials in different muscle diseases is usually not appropriate, we 
expressed, when possible, the results per muscle disease as mean differences 
(MDiff) with 95% confidence intervals (CI) for continuous outcomes, and risk ratios 
(RR) with 95% CI for dichotomous outcome measures. The intended testing for 
heterogeneity, and consequent actions, turned out to be unnecessary. 
Subgroup analysis and investigation of heterogeneity  
We decided, in advance, not to perform subgroup analyses based on sex or 
age because we anticipated that the differences in muscle disease severity 
would have a much bigger influence on outcome than sex or age. Moreover, the 
American College of Sports Medicine stated in their Position Stand (22) that relative 
improvements resulting from aerobic and strength training are similar for young and 
old, male and female. We presented data for individual muscle diseases separately. 
As the pathophysiology of each muscle disease differs, we considered that their 
reaction to training might be different. If in future data are available for meta-
analysis, we will consider investigating the effect of different durations of exercise 
or training intervention. 
RESULTS
DESCRIPTION OF STUDIES 
In this review, the search retrieved approximately 7400 records. After assessing the 
titles and abstracts, we identified 61 studies for potential inclusion: 26 completed 
trials that studied strength training as an intervention, 20 trials studying aerobic 
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exercise training, and 15 trials studying combined strength training and aerobic 
exercise, sometimes incorporated in more comprehensive rehabilitation programs. 
Most strength training trials included people with the following muscle diseases: 
slowly progressive dystrophies (mostly myotonic dystrophy, limb-girdle dystrophies, 
facioscapulohumeral muscular dystrophy (FSHD)) and in the older studies, non-
specified progressive muscular dystrophies and inflammatory myopathies. 
Studies on the effects of aerobic exercise training included mainly people with 
slowly progressive dystrophies and metabolic myopathies (mostly unspecified 
mitochondrial myopathies). 
Studies have generally been limited by small sample sizes. We excluded 48 studies 
because there was no randomized controlled comparison between training and 
non-training participants and six studies because of a within-subjects design (see 
Table 2: Characteristics of excluded studies). 
Table 1 Characteristics of included studies  
Cejudo 2005 
Methods Parallel group RCT
Participants 20 adults with mitochondrial myopathy, diagnosed on the basis 
of clinical, familial and muscle biopsy data
Interventions Strength training and aerobic exercise training versus no training 
Type of training and exercise Endurance bicycle training, 
dynamic isotonic with weights  
Intensity Aerobic training: individualized work rate, 30 min leg 
exercise on an ergo cycle, 70% of the peak work rate; strength 
training: one set dynamic and isotonic of 10 to 15 repetitions 
at 50% 1RM load, to 2 or 3 sets. Adjustments on workload 
changed every 2 weeks  
Frequency 3 times/week  
Duration Session: approximately 60 min. Program: 24 weeks  
Muscle groups Shoulder, upper back,  arm, pectoralis major, 
biceps brachii and brachialis muscles Supervision Supervised 
training program by specialized nurses and a physiatrist 
specialist in a rehabilitation unit on an outpatient basis
Outcomes Primary: exercise capacity - expressed in measures of oxygen 
uptake (ie. VO2 max), endurance time and distance walked in 
the shuttle walking test. Secondary outcomes were: peripheral 
muscle strength (1RMtest), quality of life, symptoms of myalgia, 
cramps and fatigability and functional exercise capacity
Notes -
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Risk of bias
Bias Authors’ 
judgement
Support for judgement
Random sequence 
generation (selection 
bias)
Low risk Quote: “Patients were randomly assigned to a 
training group or control group”  
Comment: no published information on the 
sequence generation. The author (Cejudo) 
informed us that patients were randomly 
assigned according to a computer generated 
randomization list
Allocation conceal-
ment (selection bias)
Unclear risk Quote: “Patients were randomly assigned to a 
training group or control group”  
Comment: no published information on the 
allocation concealment. The author (Cejudo) 
informed us that patients were randomly 
assigned according to a computer generated 
randomization list
Blinding (performance 
bias and detection 
bias) All outcomes
High risk Comment: no published information on 
the blinding of the outcome assessors and 
personnel. The author (Cejudo) told us that the 
evaluators knew to which group each patient 
was assigned
Incomplete outcome 
data (attrition bias) 
All outcomes
High risk Quote: “...one patient in each group failed to 
finish the study for personal reasons” 
Comment: baseline outcome data assessed, but 
not available for these patients. So 1/10 missing 
from intervention group and 1/ 10 missing from 
control group
Selective reporting 
(reporting bias)
High risk No primary and secondary outcome(s) defined in 
the article
Other bias Low risk No risk of bias from other sources detected
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Kierkegaard  2011
Methods Evaluator blind, parallel group RCT
Participants 35 adults with myotonic dystrophy type 1, genetically confirmed
Interventions Strength training and aerobic exercise training versus no training 
Type of training and exercise Strength training, aerobic 
exercise, balance exercises 
Intensity Strength exercises for arm, leg, back and abdominal 
muscles 16-20 repetitions, for 6- 7 min, balance exercises for 
3-4 min, aerobic activities for 11-12 min at 60-80% of maximum 
heart rate. Once a week a 30-min brisk walk 
Frequency 2 times/week and once a week a brisk walk 
Duration Session: 60 min and a 30-min walk. Program: 
14 weeks 
Muscle groups Arm, leg, back and abdominal muscles 
Supervision All sessions were supervised by a specialized 
physiotherapist
Outcomes Primary: distance walked in the 6-min walk test Secondary: 
timed-stands test, timed up-and-go test
Notes Participants were stratified before randomization by their results 
in the 6-min walk test
Risk of bias
Bias Authors’ 
judgement
Support for judgement
Random sequence 
generation 
(selection bias)
Low risk Quote: “The lots were drawn by a person who 
was not involved in any other part of the study”
Allocation 
concealment 
(selection bias)
Low risk Quote: “Patients were randomly assigned to a 
training group or control group”  
Comment: no published information on the allo-
cation concealment. 
Blinding 
(performance bias 
and detection bias) 
All outcomes
Low risk Quote: “Data was collected before and after the 
intervention by two independent experienced 
physiotherapists, blinded to group allocation 
and each assessing the same participants on 
both occasions”
Incomplete outcome 
data (attrition bias) 
All outcomes
Low risk Quote: “one person in the control group did not 
attend the data collection after the intervention”
Selective reporting 
(reporting bias)
Low risk No evidence found for selective reporting
Other bias Low risk No risk of bias from other sources detected
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Lindeman 1995 
Methods Evaluator blind, matched-control RCT
Participants 36 adults with myotonic dystrophy (2 congenital form, 
34 classical adult type), diagnosis not verified
Interventions Strength training versus no training 
Type of training and exercise Dynamic strength training with 
weights
Intensity Individualized progressive overload, 3 sets from 25 
repetitions at 60% of 1RM, via 15 repetitions at 70%, to 10 
repetitions at 80% 
Frequency 3 times/week 
Duration Session: within 30 min. Program: 24 weeks 
Muscle groups Knee extensors and flexors, hip extensors and 
abductors 
Supervision Supervised home training program
Outcomes Primary: muscle strength by isokinetically measured knee 
torques and isometrically as MVIC. Main secondary outcomes 
were: endurance by maximum duration of contraction at 80% 
of MVIC, functional performance by timed motor performance 
tests and by questionnaires. Serum myoglobin levels to detect 
changes in muscle fiber membrane permeability
Notes Participants were matched based on muscle strength (knee ex-
tension torque/bodyweight) and on performance in a stair-climb-
ing test. Only complete pairs were analyzed
Risk of bias
Bias Authors’ 
judgement
Support for judgement
Random sequence 
generation (selection 
bias)
Low risk Comment: there was no published information 
on the sequence generation but the author 
(Lindeman) informed us that 2 independent 
persons drew a sealed lot per matched pair and 
allocated it by tossing a coin to the training or 
non-training group
Allocation 
concealment 
(selection bias)
Low risk Comment: there was no published information 
on the method of allocation concealment 
but the author (Lindeman) informed us that 2 
independent persons allocated the training, after 
tossing the coin, to the training or nontraining 
group
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Blinding 
(performance bias 
and detection bias) 
All outcomes
Low risk Quote: “observers of the outcome measure-
ments were blinded for treatment allocation” 
Comment: approximately 20% of the myotonic 
dystrophy participants revealed information to 
the clinical evaluators that resulted in unblinding 
during the course of the trial
Incomplete outcome 
data (attrition bias) 
All outcomes
High risk 3 of the initially 36 randomized participants with-
drew before disclosure of treatment allocation. 
The 33 participants starting the trial made 15 
matched pairs. During the trial 1 person dropped 
out. Because of the matched pair design only 
complete pairs were analyzed, therefore eventu-
ally 28 of the initial 36 randomized participants 
were analyzed. Follow-up was therefore incom-
plete and analysis was not by intention-to-treat. 
However, the flow path of participants was well 
documented
Selective reporting 
(reporting bias)
Low risk No evidence found for selective reporting
Other bias Low risk No risk of bias from other sources detected
Van der Kooi 2004
Methods Evaluator blind, parallel group, RCT
Participants 65 adults with FSHD, genetically confirmed
Interventions Strength training versus no training (and as add-on in a double 
blind randomized controlled design albuterol or placebo) 
Type of training and exercise Dynamic and isometric strength 
training with weights
Intensity Individualized progressive overload, 2 sets dynamic 
from 10 repetitions at 10RM, via 8 repetitions at 8RM, to 5 repe-
titions at 5RM, and 30s isometric with same weight 
Frequency 3 times/week 
Duration Session: Within 30 min. Program: 52 weeks 
Muscle groups Elbow flexors, ankle dorsiflexors 
Supervision Supervised home training program
Outcomes Primary: difference in muscle strength of elbow flexors and an-
kle dorsiflexors after 52 weeks using the MVIC. Main secondary 
outcomes were muscle endurance (MVIC Force-Time Integral) 
and dynamic muscle strength (1RM). Other measures included 
functional tests and timed motor performance tasks
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Notes Outcomes are presented for the 4 treatment groups (i.e. the 
4 combinations of training versus non-training, and albuterol 
versus placebo). Effect sizes are presented by intervention as 
well
Risk of bias
Bias Authors’ 
judgement
Support for judgement
Random sequence 
generation 
(selection bias)
Low risk Quote: “...participants were randomly assigned 
to one of the four treatment groups according to 
a computer generated randomization list”
Allocation 
concealment 
(selection bias)
Unclear risk Quote: “information on the assignment to 
training or non-training was disclosed to the 
participants by the physical therapist”
Blinding (performance 
bias and detection 
bias) All outcomes
Low risk Quote: “The RM measurements were performed 
by the physical therapist, who was not blinded 
for the allocation to training or non-training, as 
this specific measurement carried too great a 
risk of unblinding the clinical evaluator” 
Comment: adequate although one of the 
main secondary outcome measures, the 1RM 
measurement for assessing dynamic strength, 
was performed by the physical therapist, who 
supervised the training, and was therefore not 
blinded to the allocation to training or non-train-
ing. Unblinding during the trial was adequately 
registered. Allocation to training or non-training 
was unmasked in 3 cases, due to unintentional 
remarks
Incomplete outcome 
data (attrition bias) 
All outcomes
Low risk Quote: “One patient stopped training because 
of recurring, training-related muscle soreness 
and fatigue. Four participants stopped using 
their study medication because of side effects. 
Data for the participants who discontinued 
an intervention were analyzed in the assigned 
treatment group” Comment: complete follow-up 
of all participants
Selective reporting 
(reporting bias)
Low risk No evidence found for selective reporting
Other bias Low risk No risk of bias from other sources detected
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Wiesinger 1998
Methods Parallel group RCT
Participants 9 adults with dermatomyositis and 5 adults with polymyositis 
Diagnosis of primary inflammatory muscle disease was defined 
by the criteria of Bohan and Peter
Interventions Aerobic exercise training versus no training 
Type of training and exercise Endurance bicycle training, 
endurance step aerobics 
Intensity Bicycle training: 30min, slowly increased on an 
individual basis. Resistance was increased until a heart rate of 
60% of maximum. Step aerobics: 30 min
Frequency During the first 2 weeks, twice weekly, during the 
remaining 4 weeks, 3 times weekly 
Duration Session: 60 min. Program: 6 weeks 
Muscle groups Not applicable 
Supervision Supervised by a physiotherapist
Outcomes No primary outcome or secondary outcomes defined. Study 
outcomes: activities of daily living score, peak isometric torque 
of knee extensors and hip flexors, peak oxygen consumption 
and creatine kinase and aldolase levels
Notes Outcomes are not presented separately for the dermatomyositis 
and polymyositis patients
Risk of bias
Bias Authors’ 
judgement
Support for judgement
Random sequence 
generation 
(selection bias)
Unclear risk Quote: “Distinct randomization lists were used”. 
Comment: there was no information about 
the generation of the list. It is not clear what is 
meant by “distinct randomization lists”
Allocation 
concealment 
(selection bias)
Unclear risk Comment: there was no published information 
on the method of allocation concealment
Blinding (performance 
bias and detection 
bias) 
All outcomes
Unclear risk Quote: “Muscle strength assessments were 
carried out by the same person who was 
unaware of the group to which the individual 
patients belonged”. 
Comment: there was no published information 
about blinding of the assessor of the other 
measurements
Incomplete outcome 
data (attrition bias) All 
outcomes
Low risk Comment: complete follow-up of all participants
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Selective reporting 
(reporting bias)
High risk Comment: no primary or secondary outcomes 
are defined
Other bias Low risk No risk of bias from other sources 
detected. Outcomes are not presented for 
dermatomyositis and polymyositis separately
MVIC: maximum voluntary isometric strength, RCT: randomized controlled trial 
RM: repetition maximum, VO2 max: maximal oxygen uptake  
Only seven studies were RCTs making a comparison between training and 
non-training participants (7, 14, 29-33). Regrettably, the extension of the 
initially randomized, controlled six-week aerobic exercise study in people with 
dermatomyositis and polymyositis by Wiesinger et al (32) lost its randomized 
controlled design due to a decision of the ethics committee. The randomized 
controlled strength training combined with aerobic exercise trial which compared 
eight weeks of walking and strengthening exercises versus no training in 20 
participants with different muscle diseases (7) has been excluded as both study 
groups consisted of participants with various muscle diseases and the outcome 
measures were not presented for each muscle disease separately. As the 
pathophysiology of each muscle disease differs, their reaction to training might 
be different. It is not known if the effect of strength training and aerobic exercise 
training is the same for every muscle disease. Therefore, data should be presented 
and analyzed for each disease individually, and the power should be sufficient for 
each individual disorder. For this reason, no conclusions can be drawn with regard 
to the effect of exercise training for each specific muscle disease in the trial. Finally, 
no specific details about the exercise program were provided and the risk of bias of 
the trial was high. 
In conclusion, we included two strength training trials (14, 31), one aerobic exercise 
trial (33) and two strength training combined with aerobic exercise trials (29, 30) 
(see Table 1 Characteristics of included studies). 
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Table 2 Characteristics of excluded studies
Study Reason for exclusion
Abramson 1952  Not a RCT
Aitkens 1993  Not a RCT. Exercised versus non-exercised control limb 
(randomly assigned) and patients versus healthy volunteers
Aldehag 2005  Not a RCT
Alexanderson 1999  Pilot study. Not a RCT
Alexanderson 2000  Extension of a pilot study. Not a RCT
Alexanderson 2007  Not a RCT
Arnardottir 2003  Not a RCT
Chung 2007  No non-exercising control group
Dastmalchi 2007  Not a RCT
Dawes 2006  Excluded because of serious insufficiencies in the study design
De Lateur 1979  Not a RCT. Exercised versus non-exercised control limb 
(randomly assigned)
Escalante 1993  Not a RCT
Florence 1984a  Not a RCT
Florence 1984b  Not a RCT
Fowler 1965  Not a RCT. Exercise combined with medication
Heikkila 2001  Not a RCT. Training program duration of 3 weeks
Hicks 1989  Not a RCT. Training program duration of 1 month
Hoberman 1955  Not a RCT. 3 drugs added to a comprehensive regimen of 
therapies, including breathing and resistive exercises
Jeppesen 2006  Not a RCT
Jeppesen 2009a  Not a RCT
Johnson 2007  Not a RCT
Johnson 2009  Not a RCT
Kelm 2001  Not a RCT
Kilmer 1994  Not a RCT. Exercised versus non-exercised control limb 
(randomly assigned) and patients versus healthy volunteers
Kilmer 2005  Not a RCT. Training program duration for participants with 
muscle disorders ranged from approximately 1 to 21 months
Lenman 1959  Not a RCT. Training program duration for participants with 
muscle disorders ranged from approximately 1 to 21 months
Mate-Munoz 2007  Not a RCT
McCartney 1988  Not a RCT. Exercised versus non-exercised control limb       
(randomly assigned)C
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Mielke 1990  Not a RCT
Milner-Brown 1988a  Not a RCT. Training program duration for participants with 
muscle disorders ranged from approximately 2 to 48 months
Milner-Brown 1988b  Not a RCT. Intervention is not training versus non-training, but 
training added to electric stimulation or electric stimulation only 
in 1 limb versus a non-stimulated, non-exercised control limb
Milner-Brown 1990  Not a RCT. Intervention is not training versus no training, but 
amitriptyline added to strength training
Murphy 2008  Not a RCT
Na 1996  Not a RCT. Intervention is not training versus non-training, but 
training and daily quinine sulfate
Nader 2010  Not a RCT
Olsen 2005  Not a RCT
Omori 2010  Not a RCT
Orngreen 2005  Not a RCT
Scott 1981  A RCT that makes a comparison between 2 different training 
regimes. No comparison of training versus non-training 
participants
Siciliano 2000  Not a RCT
Spector 1997  Not a RCT
Sunnerhagen 2004  Not a RCT
Sveen 2007  Not a RCT
Sveen 2008  Not a RCT
Taivassalo 1998  Not a RCT
Taivassalo 1999  Not a RCT
Taivassalo 2001  Not a RCT
Taivassalo 2006  Not a RCT
Tollbäck 1999  Not a RCT. Exercised versus non-exercised control limb 
(randomly assigned)
Trenell 2006  Not a RCT
Varju 2003  Not a RCT. Training program duration of 3 weeks
Vignos 1966  Not a RCT
Wiesinger 1998b  A non-randomized extension of a RCT (Wiesinger 1998a)
Wright 1996  Not a RCT
Yildirim 2007  Not a RCT
RCT: randomized controlled trial
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The first strength training trial compared the effect of 24 weeks of training versus 
no training in 36 adults with myotonic dystrophy and 30 adults with hereditary 
motor and sensory neuropathy types I or II (14). As this review is concerned 
with muscle disease, we will not discuss the results of the hereditary motor and 
sensory neuropathy participant group. The aerobic exercise trial compared six 
weeks of cycle and step aerobics exercise with no training in nine adults with 
dermatomyositis and five adults with polymyositis (33). The second strength 
training trial compared 52 weeks of strength training versus no training in a factorial 
trial that also compared albuterol with placebo after the first 26 weeks of training in 
65 adult participants with FSHD (30). Only the results for the comparison strength 
training versus no training will be discussed in this review. The first combined 
aerobic exercise and strength training trial compared 12 weeks of cycle exercises 
and dynamic and isokinetic strength training versus no training in 18 people with 
mitochondrial myopathy (29) (see Table 1 Characteristics of included studies). The 
second combined aerobic exercise and strength training trial compared 14 weeks 
of balance exercises, aerobic activities, flexibility exercises, strength exercises and 
a brisk walk versus no training in 35 people with myotonic dystrophy type I. (30). 
RISK OF BIAS IN INCLUDED STUDIES  
Strength training trial in myotonic dystrophy  
In the first myotonic dystrophy trial (14), participants with myotonic dystrophy were 
individually matched for muscle strength and performance in a stair-climbing test. 
Within each matched pair, participants were randomly assigned to the training or 
control group. 
There was no published information on the method of randomization or on 
allocation concealment but the first author (Lindeman) informed us that two 
independent persons drew one sealed name per matched pair and allocated it 
to the training or non-training group by tossing a coin. We graded the intention 
to blind the clinical evaluators as adequate, although approximately 20% of the 
myotonic dystrophy participants revealed information to the clinical evaluators that 
resulted in unblinding during the course of the trial. The authors considered the 
baseline comparability of the groups as suboptimal because the training group had 
longer time scores for stair climbing (a measure of functional ability) and had higher 
knee torques (a measure of muscle strength). They argued that the first three items 
could have resulted in an underestimation of the training effect, whereas the last 
item could have resulted in an overestimation of the training effect. They concluded 
that the differences in experimental group composition did not seem to explain the 
absence of differences in outcomes between treatment groups. We considered the C
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way the authors presented and discussed the baseline differences as adequate. 
Three of the initially 36 randomized participants withdrew before disclosure of 
treatment allocation. The 33 participants starting the trial made 15 matched pairs. 
During the trial one person dropped out because of knee problems. Because of 
the matched pair design only complete pairs were analyzed, thus eventually 28 
of the initial 36 randomized participants were analyzed. Follow-up was therefore 
incomplete and analysis was not by intention-to-treat. However, the flow path of 
participants was well documented. 
Dermatomyositis and polymyositis trial
In the dermatomyositis and polymyositis trial (33), nine people with 
dermatomyositis and five with polymyositis were randomly assigned to the training 
or control group using distinct randomization lists. The training group received six 
weeks of bicycle exercises and step aerobics. Participants in the control group did 
not undergo any training and continued their previous way of life. There was no 
published information on allocation concealment and our attempts to obtain further 
information on this were not successful. During the strength measurements, the 
clinical evaluator was blinded to the treatment allocation. The success of blinding 
of assessors was not formally checked as blinding of participants is not possible 
in an exercise study. There was no published information on blinding during the 
other measurements. Baseline characteristics were presented for both groups. 
The authors considered the two groups to be well balanced with respect to most 
baseline characteristics. There was complete follow-up of all participants. 
Facioscapulohumeral muscular dystrophy (FSHD)
In the FSHD trial (31), 65 participants were stratified into two groups based on 
muscle strength. Participants in both strata were randomly assigned to one of the 
four treatment groups according to a computer-generated randomization list. The 
treatments consisted of training plus albuterol, training plus placebo, non-training 
plus albuterol, or non-training plus placebo. Training or non-training was the first 
intervention, starting just after the baseline visit until after the final visit at 52 weeks. 
Information on the assignment to training or non-training was disclosed to the 
participants by the physical therapist (supervising the training program) after 
their baseline visit. The clinical evaluator was blinded for the assignment to both 
interventions. The participants, physical therapist and the neurologist evaluating 
side effects were blinded to the treatment allocation. The blinding of the clinical 
evaluator was considered adequate, although one of the main secondary outcome 
measures, the one-repetition maximum (1RM) measurement for assessing dynamic 
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strength, was performed by the physical therapist who supervised the training, 
and who was therefore not blinded to the allocation to training or non-training. 
Allocation to the training or non-training group was unmasked in three cases, 
due to unintentional remarks. The success of blinding was not formally checked. 
Baseline characteristics were presented for all treatment groups. One participant 
stopped training but still attended all trial visits, resulting in complete follow-up 
of all participants. Data analysis was by the intention-to-treat principle.  As no 
statistically significant interactions between the two interventions (that is, training 
versus non-training) could be detected, the effect sizes, being the differences 
in mean change from baseline, were presented for each intervention. In the 
mitochondrial myopathy trial (29), 20 participants were randomly assigned to the 
training or control group. There was no published information on the method of 
randomization, allocation concealment, or blinding of the evaluators. The author 
(Cejudo) informed us that participants were randomly assigned according to a 
computer generated randomization list. The evaluators were not blinded to the 
intervention allocation, but knew to which group each participant was assigned. 
One participant in each group failed to finish the study for personal reasons. 
Baseline characteristics were presented for both groups, except for the participants 
lost to follow-up. Follow-up was therefore incomplete and analysis was not done 
by intention-to-treat. No flow path of participants was documented. The authors 
considered both groups as comparable with respect to age and gender, as well as 
to each measured variable at baseline. 
Combined aerobic exercise and strength training trial in myotonic 
dystrophy type 1 
In the second myotonic dystrophy trial (30), the median value of the results of 
the six-minute walk test was used to divide the 35 participants into two strata 
from which they were divided into the training or the control group. The lots 
consisted of folded pieces of paper with the name of the participant and were 
drawn by a person not involved in any part of the study. Since participants were 
recruited before randomization, concealed allocation procedures were applied. 
An intention-to-treat analysis was applied. Three participants had missing data for 
perceived exertion at baseline and one person in the control group did not attend 
the measurement after the intervention but still completed the questionnaires. 
There was no significant difference in sex or age of participants between groups 
in the study; however, the mean muscular impairment scale (MIRS) grade was 
higher in the exercise group, indicating that participants in the exercise group were 
more severely impaired than participants in the control group. The training group 
received a comprehensive group exercise training program, they were also asked C
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to perform an active 30min walk every week. The participants in the control group 
were advised to live their normal lives and to maintain their degree of physical 
activity during the study period. 
The degree of activity of both groups was not objectively checked. 
We ranked each criterion using the Cochrane ’Risk of bias’ tool. The review 
authors’ judgements about each risk of bias item for included studies are presented 
in Figure 1.
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Kierkegaard 2011 + + + + + +
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Van der Kooi 2004 + ? + + + +
Wiesinger 1998 ? ? ? + - +
Figure 1 Risk of bias summary: review authors’ judgements about each risk of 
bias item for each included study
QUALITY OF DIAGNOSTIC CRITERIA 
This assessment took into account if and how diagnoses were verified. In the 
first myotonic dystrophy trial (14), participants were recruited via neurologists, 
physiatrists and the Dutch association for neuromuscular diseases (Vereniging 
Spierziekten Nederland) on clinical grounds and without genetic verification. 
We therefore considered the quality of the diagnostic criteria as inadequate. In 
the second myotonic dystrophy (type I) trial (30), the diagnosis was genetically 
confirmed in all participants and the diagnostic criteria are therefore adequate. 
In the dermatomyositis and polymyositis trial (33), all the participants had an 
established diagnosis of primary inflammatory muscle disease as defined by 
the established criteria of Bohan and Peter, with a disease duration of at least 
six months (34, 35). In all participants, muscle biopsies, electromyograms and 
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laboratory studies had been performed to establish the diagnosis. We therefore 
considered the quality of the diagnostic criteria to be adequate. 
In the FSHD trial (31), participants or a first-degree relative had the associated 
deletion at chromosome 4 (36). The quality of the diagnosis was therefore 
adequate. In the mitochondrial myopathy trial (29) participants were recruited 
from a larger group of patients followed at the university hospital of Sevilla, Spain. 
Diagnosis was based on clinical and muscle biopsy data. Biopsy findings were 
determined by biochemical and histological techniques without genetic verification. 
One participant in each group had only a probable diagnosis of mitochondrial 
myopathy. The quality of the diagnostic criteria is therefore uncertain. 
QUALITY OF TRAINING PROGRAM  
The training programs of the first myotonic dystrophy (14), FSHD (31), 
mitochondrial myopathy (37) and dermatomyositis and polymyositis (33) trials 
fulfilled most of the minimum requirements as defined by the American College of 
Sports Medicine (ACSM) Position Stand (22). In the second myotonic dystrophy 
type I trial (30), the intervention consisted of a comprehensive group exercise 
training program supported by music. The author could not give the exact training 
load of each strength training exercise as a percentage of repetition maximum (RM) 
as it was not tested that way. However, all major muscle groups were trained: arm, 
back, leg and abdominal muscles (30). The training scheme for the other strength 
training trials was inadequate only with respect to the number of muscle groups 
trained, as the ACSM recommends eight to 10 exercises of all the major muscle 
groups. Only four muscle groups were trained in the first myotonic dystrophy trial 
(14), two in the FSHD trial (31) and three in the mitochondrial myopathy trial (29). 
All studies except the combined aerobic exercise and strength training in myotonic 
dystrophy type I trial (30), focused on a limited number of muscle groups for 
reasons of effect evaluation, safety and time restraints per training session. In the 
dermatomyositis and polymyositis trial (33), the training frequency was only twice 
a week in the first two weeks, but increased to three times a week in the remaining 
four weeks. In the mitochondrial myopathy trial (29), there was no published 
information regarding supervision. 
In the other trials (14, 30, 31), a physiotherapist supervised training. A description 
of the training programs is given in the Characteristics of included studies (Table 1). 
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EFFECTS OF INTERVENTIONS 
See: Summary of findings for the main comparison (Table 3); Strength training 
compared to usual care for facioscapulohumeral muscular dystrophy; Additional 
Summary of findings 2 (Table 4). Aerobic exercise and strength training compared 
to usual care for mitochondrial myopathy. We intended to combine trial results for 
appropriate pairings of treatments by calculating a mean of the difference between 
their effects using the Cochrane statistical package RevMan. Because we could not 
obtain the original data for the mitochondrial myopathy (29), dermatomyositis and 
polymyositis (33) and myotonic dystrophy trials, we describe the results of these 
trials as published in the article. We were unable to produce MDiffs and 95% CIs 
for the myotonic dystrophy trial (14) because of the matched pair design. We report 
the findings of the study as given in the paper.
Primary outcome measure for strength training: muscle strength, 
expressed in measures of static (i.e. isometric) or dynamic strength
Muscle strength was the primary outcome measure for the first myotonic dystrophy 
(14) and FSHD trials (31). In the first myotonic dystrophy trial (14), differences in 
muscle strength were measured isokinetically on a dynamometer as maximum 
concentric knee torques at three velocities, and isometrically as maximum 
voluntary contraction. Knee torques of the myotonic dystrophy group did not show 
any statistically significant difference between the training and control groups, as 
found with a paired t-test. After 24 weeks, mean change in isokinetic knee torque 
extension was 1.4 Nm (SD 8.2) for the control group and 5.3 Nm (SD 12.9) for the 
training group, p = 0.34. Mean change in isokinetic knee torque flexion was 3.7 Nm 
(SD 8.6) for the control group and 7.4 (SD 11.4) for the training group, p = 0.34 and 
mean change in maximum isometric voluntary contraction was 6.6 Nm (SD 11.0) for 
the control group and 8.7 Nm (SD 14.71) for the training group, p = 0.67. 
The primary outcome measure in the FSHD trial (31) was a change in maximum 
voluntary isometric strength of the elbow flexors and ankle dorsiflexors, measured 
on a Quantitative Muscle Assessment fixed myometry testing system. After 
52 weeks the isometric strength of the elbow flexors did not differ significantly 
between the training and non-training group, for the right side the difference in the 
means was 0.54 kgF (95% CI - 0.38 to 1.46), with the better score being for the 
training group. Dynamic strength was evaluated using the one repetition maximum 
(1RM), the weight a person can lift once, but not twice, at a steady controlled 
pace through the full range of joint motion. The 1RM of the elbow flexors showed 
a significantly larger increase in the training group compared to the non-training 
group (for the right side the difference in the means was 1.17 kg (95% CI 0.18 to 
99
2.16). Both strength measures of the ankle dorsiflexors decreased significantly 
and markedly in all treatment groups. This decrease was not influenced by training 
(on the right side the difference in the means in maximum voluntary isometric 
contraction (MVIC) was 0.43 kgF (95% CI -1.62 to 2.48) more for the training group, 
in 1RM the difference was -0.44 kg (95% CI -1.77 to 0.89) less for the training 
group). Differences between groups for the left sided trained muscles did not 
materially differ from those for the right side. 
Muscle strength was a secondary outcome in the mitochondrial myopathy trial (29). 
In this trial, weight-lifting capacity was measured as the heaviest weight that could 
be lifted throughout the complete range of movement (1RM test). After the study 
period, all participants showed increases in all 1RM tests. After 12 weeks, weight-
lifting capacity did not differ significantly between the training and non-training 
group. The differences in mean 1RM between groups were -5.00 kg (95% CI -14.71 
to 4.71) less for the training group for the shoulder press exercise, 6.40 kg (95% CI 
-2.89 to 15.69) in favor of the training group for the butterfly exercise and 7.30 kg 
(95% CI -2.91 to 17.51) in favor of the training group for the biceps curls exercise. 
Primary outcome measure for aerobic exercise training: aerobic 
capacity, expressed in measures of work capacity 
This outcome was published in the mitochondrial myopathy trial (29) and was a 
primary outcome in the combined aerobic exercise and strength training trial in 
myotonic dystrophy (30). 
In the inflammatory muscle disease trial (33), no primary outcome measure was 
defined and aerobic capacity was not measured. 
In the mitochondrial myopathy trial (29), work capacity was measured in a cycle 
test and in the shuttle walking test. Endurance time was measured in a submaximal 
cycling test at a constant workload of 70% of the maximum power output achieved 
during the baseline incremental cycle test. After 12 weeks, the differences in 
mean time and distance cycled till exhaustion and leg fatigue or breathlessness 
exhaustion differed significantly between groups. The differences in mean time and 
distance cycled till exhaustion between groups were 23.70 min (95% CI 2.63 to 
44.77) and 9.70 km (95% CI 1.51 to 17.89), respectively. The distance walked until 
exhaustion was measured in the shuttle walking test and was 78.00 m more for 
the training group (95%CI -144.86 to 300.86). The primary outcome in the second 
myotonic dystrophy type I trial (30) was the distance walked in the six-minute walk 
test. A difference above or equal to 6% in distance walked between the baseline 
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measurement and the measurement after the intervention period of 14 weeks 
was considered as a minimally clinically important change. After 14 weeks, the 
differences in mean distance walked in the six-minute walk test was 11.00 m (95% 
CI -66.92 to 88.92), in favor of the training group. 
Secondary outcome measures for aerobic exercise or strength training, 
or both Aerobic capacity, expressed in measures of oxygen uptake (i.e. 
VO2 max) 
This outcome was available for the mitochondrial myopathy (29) and inflammatory 
muscle disease trial (33). In the inflammatory muscle disease trial (33), work 
capacity was measured during an incremental cycle test on a cycle ergometer. 
Maximal oxygen uptake (VO2max) was defined as the highest O2 consumption 
obtained during the symptom-limited exercise test. After six weeks, the difference 
in mean VO2 max (ml/ min/kg) was 14.6% higher for the training group (95% 
CI -0.96 to 30.16). In the mitochondrial myopathy trial (29), VO2 max was 
noninvasively determined in a maximal incremental cycle exercise test. After 12 
weeks, the difference in mean VO2 max was 400 ml/ min (95% CI 61.97 to 861.97) 
in favor of the training group. 
Muscle strength, expressed in measures of endurance or fatigue  
This outcome was published for the first myotonic dystrophy (14) and FSHD (31) 
studies. In the myotonic dystrophy trial (14) endurance was measured as maximum 
duration of contraction at 80%ofMVIC on an isokinetic dynamometer. After 24 
weeks, the difference in MVIC for the control group was -7.4 s (SD 12.0) and for 
the training group 5.7 s (SD 17.0), p = 0.09. This difference was mainly due to a 
decrease in endurance in the non-training group. 
In the FSHD trial (31), muscle endurance was expressed as a Force-Time 
Integral (FTI30) of a sustained 30 s maximal isometric contraction measured on a 
Quantitative Muscle Assessment fixed myometry testing system. After 52 weeks, 
the FTI30 of the elbow flexors did not differ significantly between the training and 
non-training group. The FTI30 of the ankle dorsiflexors decreased significantly and 
markedly in all treatment groups. This decrease was not influenced by training (for 
the right side the difference in the means was -1 kgF.s (95% CI -42 to 41). Changes 
in FTI30 for the left-sided trained muscle groups did not differ significantly from the 
right-sided results. 
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(Time-scored) functional assessments of muscle performance 
This outcome was available for all trials (14, 30, 31, 33) except the mitochondrial 
myopathy trial (29). In the first myotonic dystrophy trial (14), functional assessments 
comprised the following time-scored activities: ascending and descending stairs, 
rising from a chair, rising from supine, walking 50 m as fast as possible, and 
walking 6 m at natural speed. In the inflammatory muscle disease trial (33), the 
modified Functional Assessment Screening Questionnaire was used for evaluating 
disability (38). 
In the FSHD trial (31) the functional tests consisted of the assessment of a 
functional upper extremity grade and functional lower extremity grade (39), and 
the following timed-scored tasks: standing from lying supine, standing from sitting, 
walking 30 feet (9.14 m), and climbing three standard stairs (39). In the combined 
aerobic exercise and strength training trial in myotonic dystrophy type 1 (30), the 
timed-stands test, and the timed up-and-go test were used for evaluation of effects 
of the exercises. 
In all trials (14, 30, 31, 33), no differences between groups in functional 
assessments were reported. 
Quality of life  
This outcome was assessed in the FSHD trial (31) using the Sickness Impact Profile 
(SIP) and the Symptom-Checklist (SCL-90-R). The mean total of the SIP and its 
subscales did not demonstrate relevant or significant changes for either the training 
or non-training groups. In addition, for both groups the mean SCL total did not 
change between the baseline and final visit. 
In the mitochondrial myopathy trial (29), the Nottingham Health Profile (NHP) 
questionnaire was used. Scores ranged from 0 (no problem) to 100 (maximum 
problem). The MDiff in overall mean score between both groups was -9.80 (95%CI 
-25.70 to 6.14). 
In the aerobic exercise and strength training trial in myotonic dystrophy type I 
(30), quality of life was measured by the SF-36 Health Survey. The scores on all 
subscales of the SF- 36 did not demonstrate relevant or significant changes for 
either the training or non-training group.
Parameters of muscle membrane permeability (serum creatine kinase 
level, serum myoglobin level, serum aldolase level) 
This outcome was available for the first myotonic dystrophy trial (14), mitochondrial 
myopathy trial (29) and inflammatory muscle disease trial (33). In the myotonic 
dystrophy trial (14), serum myoglobin levels were assessed just before and one 
hour after the measurement session at the baseline visit and at the final visit. 
Changes in serum myoglobin activity one hour after a standardised test should 
reflect changes in muscle fiber permeability due to muscle damage. The mean rise 
in serum myoglobin levels did not differ significantly between the training and the 
non-training group (-21.00 ng/l, 95% CI -48.35 to 6.35). In the inflammatory muscle 
disease trial (33), serum levels of creatine kinase and aldolase were measured 
weekly on Monday after a weekend recovery phase without exercise. There was no 
statistically significant change in serum creatine kinase level and serum aldolase 
level during the observation period either in the control group (mean - 13.9%, 95% 
CI -41.34 to 13.54) or in the training group (mean -6%, 95% CI -22.66 to 10.66). 
In the mitochondrial myopathy trial (29), the authors state that the participants’ 
serum creatine kinase levels remained unaltered after the intervention period. 
However, data for the serum creatine kinase level were not published. In the FSHD 
trial (31), one participant stopped training because of recurring, training-related 
muscle soreness and fatigue. A diagnostic work-up revealed a mitochondrial 
myopathy as well as FSHD. In the mitochondrial myopathy trial (29), cancellations 
of exercise sessions by participants happened because of muscle soreness 
associated with the exercise activity. However, every participant was able to 
tolerate the exercise training regimen without complications. In the first myotonic 
dystrophy trial (14), a few participants complained of muscle soreness and transient 
strength reduction after eight weeks. However, no signs of muscle damage were 
found at the final visit after 24 weeks. In the second myotonic dystrophy trial (30), 
one person had periods of atrial arrhythmia; however, this was not in connection 
with the training and the participant was allowed to complete the study by a 
cardiologist. No other adverse effects were reported. In all trials no other signs of 
overuse, such as a decline in strength measures (14, 29, 31) or training-related 
increase in pain or fatigue (31) were reported. 
Pain 
This outcome was available in both the FSHD (31) and mitochondrial myopathy 
trials (29). In the FSHD trial (31), 11 out of 34 participants in the training group 
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reported pain in the neck and shoulder region to the physical therapist during 
home visits. Five people mentioned a period with elbow complaints. However, 
the number of people with neck-shoulder and elbow complaints did not differ 
between treatment groups at baseline nor at the final visit. Moreover, the number 
of participants with neck-shoulder and elbow complaints slightly decreased in 
both groups. RR at the final visit was 1.02 (95%CI 0.66 to 1.58) for neck-shoulder 
and 1.82 (95%CI 0.17 to 19.13) for elbow complaints in favor of the non-training 
group. Although not formally quantified, the authors mentioned that participants 
experienced no notable muscle soreness after training. 
At the final visit, scores on the VAS for pain and the mean daily rated pain scores 
did not demonstrate significant changes for either group. 
In the mitochondrial myopathy trial (29), participants’ arm and leg myalgia was 
recorded by a simple questionnaire and scored as mild, moderate or severe. Two 
people in the exercise group and three people in the control group reported severe 
myalgia in arms and legs. Seven people in the exercise group and five people in 
the control group reported moderate myalgia in arms and legs. After the 12-week 
training program no participants in the exercise group and five participants in the 
control group still reported symptoms of myalgia. 
Experienced fatigue 
In the FSHD trial (31), experienced fatigue was measured by the subscale “fatigue 
severity” of the Checklist Individual Strength (CIS-fatigue). At the final visit, the 
mean score on the CIS-fatigue did not change significantly between the baseline 
and final visit for either group. The mean daily rated fatigue score of the participants 
in the training group slightly decreased, whereas the score in the non-training group 
showed a small increase. 
In the mitochondrial myopathy trial (29), participants’ usual fatigability was 
recorded in a simple questionnaire and scored as mild, moderate or severe. Three 
participants in the exercise group and five participants in the control group reported 
severe fatigue in arms and legs. At the end of the study period, no participants 
in the exercise group and five participants in the control group reported severe 
fatigue in arms and legs. Six participants in the exercise group and two participants 
in the control group reported moderate fatigue. After the intervention period, five 
participants in the exercise group and two participants in the control group still 
reported moderate fatigue.
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Adverse events 
There were no serious adverse effects related to strength or aerobic training. 
DISCUSSION
Only six out of the 60 identified studies on the effect of training in people with 
muscle disease used a randomized controlled design (7, 14, 29-31, 33). The 
randomized controlled strength training combined with aerobic exercise trial which 
compared eight weeks of walking and strengthening exercises versus no training 
in 20 participants with different muscle diseases (7) has been excluded because 
the outcome measures were not presented separately for each different muscle 
disease. Moreover, no specific details about the exercise program were provided 
and the risk of bias of the trial was judged as ’high’. 
The strength training trial in FSHD participants (31) had minor methodological 
shortcomings. One of the main secondary outcome measures, the 1RM strength 
measurement, was performed by a physical therapist not blinded to the allocation 
to training or non-training. The overall risk of bias was, therefore, judged as ’low’. 
The dermatomyositis and polymyositis trial (33) had several uncertainties regarding 
the generation of the randomization list, allocation concealment and blinding of the 
assessor. No primary or secondary outcome measures were defined. The overall 
risk of bias was, therefore, judged as ’unclear’.  In the myotonic dystrophy strength 
training trial (14) diagnoses were not adequately verified. Furthermore, analysis was 
not by intention-to-treat partly due to the matched-pair design. Because of these 
major methodological shortcomings, we judged the overall risk of bias as ’unclear’. 
In the mitochondrial myopathy trial (29), clinical evaluators were not blinded, which 
may have led to an overestimation of the training effect on muscle strength and 
aerobic capacity. Analysis in this trial was not by intention-to-treat. The overall 
risk of bias was therefore judged as ’unclear’. Most differences in mean muscle 
strength outcomes (isometric, dynamic and endurance) between groups in all trials 
showed small, non-significant beneficial effects in favur of the training groups. 
In the first myotonic dystrophy trial (14), only changes in the endurance measure 
(13.10 s longer maximum duration of an isometric contraction (95%CI 2.20 to 
24.00)) and in the FSHD trial (31) only the dynamic strength measure for the elbow 
flexors (concentric contraction with 1.20 kg heavier weight (95% CI 0.18 to 2.16)) 
reached statistical significance. However, no adjustments were made for multiple 
comparisons. C
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The absent or limited positive effects of strength training on muscle strength could 
reflect the inability of the diseased muscular system to respond with normal neural 
and trophic adaptations to the applied training stimuli. However, part of this lack 
of response could be due to the specificity of the training (14). All adaptations to 
training are specific to the stimuli applied. Specific strength training essentially 
involves exercising the muscles in the same manner as the expected use (40). This 
means that a training program with dynamic exercises increases dynamic strength 
more than isometric strength, and vice versa. This phenomenon of specificity of 
training has implications for the sensitivity of the outcome measures; for example, 
the positive effect of a dynamic strength training program may be captured by 
using a dynamic evaluation technique, but might be missed using an isometric 
strength measure. The size of the carry-over effect from, for example, dynamic 
strength to isometric strength cannot be predicted and it may be that there is a 
diminished ability of the diseased muscular system to transfer effects of a specific 
training program from one strength modality to another (31). 
In the FSHD trial (31), training did not influence strength of the ankle dorsiflexors, in 
contrast to the elbow flexors. 
The authors thought that a difference in grade of muscle weakness at baseline 
between elbow and ankle dorsiflexors might provide the explanation for the 
difference in their response to training. In this study elbow flexors were eligible for 
testing and training when strength according to the MRC scale grade was three 
or more, whereas ankle dorsiflexors were eligible when the muscles moved the 
ankle joint in a position between dorsiflexion and plantarflexion, which potentially 
includes MRC grades less than three (41). Therefore, pre-exercise weakness 
might have been more severe in ankle dorsiflexors compared to elbow flexors. In 
people with a muscle disease, it is assumed that absolute gain in muscle strength 
resulting from strength training is probably related to pre-exercise muscle strength, 
and that severely weakened muscles (< 10% of normal strength) may not be able 
to improve. However, this widely reported assumption is based on one published 
observation only (12). 
In the mitochondrial myopathy trial (29), the MDiff in aerobic capacity as measured 
in a submaximal cycle test differed significantly between the training and non-
training group after the study period. Participants in the training group cycled on 
average 23.70 min (95% CI 2.63 to 44.77) and 9.70 km longer (95% CI 1.51 to 
17.89) than participants in the control group. The distance walked in the shuttle 
walking test did not differ between groups. This could be explained by the 
specificity of training, because training consisted of cycling rather than walking 
exercises. 
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The timed-scored functional assessments did not demonstrate any relevant or 
significant changes between treatment groups in the two myotonic dystrophy 
trials (14, 30), the dermatomyositis and polymyositis trial (33) or the FSHD trial 
(31). This may be due to the small number of muscle groups trained, the absent 
or limited effects on muscle strength, and the specificity of the training stimuli 
applied. In all trials no signs of overuse were reported. This is of major clinical 
importance because these findings do not support the notion of increased risk 
of muscle strain in slowly progressive muscular dystrophies. However, adverse 
events were only mentioned in general and not compared between groups. Only 
in the dermatomyositis and polymyositis trial (33), were serum levels of enzymes 
mentioned for both groups. Moreover, several participants in all trials experienced 
muscle soreness. An enhanced liability for overwork weakness in more severely 
affected FSHD patients cannot be excluded, because patients unable to walk 
independently were not included in the FSHD trial (31). Furthermore, all training 
studies, including the studies included in this review, imposed a controlled strain 
for a relatively short period. Hence, exertion of longer duration may still have an 
undetermined effect on disease progression. 
Based on the evidence of the five selected RCTs in this review concerning 
myotonic dystrophy (14) and myotonic dystrophy type I (30), dermatomyositis and 
polymyositis (33), FSHD (31) and mitochondrial myopathy (29), people with these 
specific disorders can be advised that ’normal’ participation in sports and work 
appears not to harm their muscles. 
Yet there is still insufficient evidence for general prescription of strength training 
and aerobic exercise programs in myotonic dystrophy, polymyositis and 
dermatomyositis and FSHD. Nevertheless, there is some evidence for training 
effects in mitochondrial myopathy. Unfortunately, no clearly defined exercise 
protocols can be drawn from the current research evidence. 
Evidence from non-randomized studies and other designs, such as pre-post 
studies or case-control studies showed that aerobic exercise training appears 
to be safe and effective in adults with various muscle diseases and that strength 
training appears to be safe and effective in adults with slowly progressive muscle 
diseases (42, 43) but limitations in the design of these studies prevent valid 
conclusions. The number of recent studies lacking a randomized controlled design 
is striking. At least for the relatively frequent muscle diseases, one should aim for 
randomized controlled training studies. Preferably, homogeneous groups of people 
with the same muscle disease should be included. When people with different 
neuromuscular disorders but with similar distribution and severity of muscle 
weakness participate in the same study, the data should also be presented for each C
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major type of muscle disease separately to detect possible disease-specific trends. 
Because we cannot pool the results of the trials in different muscle diseases in this 
review, it is not possible to define the optimal exercise duration for people with a 
specific muscle disease. 
Specific diagnostic criteria should be given for all muscle diseases included. 
Information on the severity of the muscle disease in participants should also be 
presented so as to allow readers to assess the generalisability of the results to 
other people with the similar type and severity of muscle disease. In trials with a 
small sample size, participants should be stratified for disease severity. Another 
related characteristic that may influence outcome is the level of activity (sedentary 
versus active) at baseline, because in the healthy population untrained persons 
respond with higher percentages and rates of gain in strength, compared to trained 
individuals (22). Activity level and change in activity level for each participant should 
be monitored objectively during the trial period, for example with an accelerometer. 
Participants in an active training group may experience additional non-specific 
benefits (that is, Hawthorne effects), for instance from regular interaction with a 
skilled therapist, in contrast to those in a non-treatment or usual care group. As it 
is well known that such Hawthorne effects may affect outcome (44), future studies 
should preferably have an appropriate control intervention rather than ’no training’ 
in order to assess the specific benefits of aerobic exercise and strength training. 
For example, the control group might receive weekly counseling sessions with 
general information about exercise. 
In strength training and aerobic exercise intervention studies, the training program 
should be described in detail, just as the prescription of drugs would be. 
Authors should provide information about the type(s) of exercises, the intensity 
(including progression rate), frequency, duration per exercise session, the duration 
of the entire program, as well as the trained muscle groups, and the supervision of 
training. 
The recommendations from the ACSM Position Stand on ’The recommended 
quantity and quality of exercise for developing and maintaining cardiorespiratory 
and muscular fitness, and flexibility in healthy adults’ (22) can be used as 
requirements for an effective, safe and individualized exercise prescription, 
taking into account the pre-training level of fitness. The ACSM recommendations 
were almost all adhered to by most of the included and excluded studies in this 
review. The only criterion that was rarely met was that eight to 10 major muscle 
groups should be exercised in strength training programs. This is probably partly 
due to limitations in time available to evaluate the effects of training by multiple 
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assessments covering the different outcome measures. In addition, expenses for 
(adjusted) training equipment can be high. Thirdly, investigators were perhaps too 
cautious in order not to strain participants too much. Moreover, strength training 
for fewer than eight muscle groups could be adequate in people with a muscle 
disease, who are generally untrained. 
More studies that evaluate the level of basic muscle function and aerobic capacity 
are needed on the effects of aerobic exercise and strength training programs in 
people with specific muscle diseases. There are well-validated outcome measures 
that are able to assess positive and, at least equally important, negative effects on 
the diseased muscular system. The expertise to deliver training programs in healthy 
individuals is already present in sports medicine and experts in exercise physiology 
should be consulted. 
If strength training and aerobic exercise training programs prove to be effective for 
people with a muscle disease, we can then aim to develop and evaluate programs 
adjusted to each different muscle disease. In people with muscular disorders, 
combinations of muscle weakness, fatigue, pain and difficulty exercising can all 
lead to reduced physical activity and a sedentary lifestyle (45). Physical inactivity 
negatively impacts quality of life and health outcomes (45). 
In healthy young adults, in the elderly, and in cardiac patients, increasing physical 
activity and participation by comprehensive exercise programs incorporating 
aerobic activities, strength training and flexibility exercises has been shown to 
reduce the risk of several chronic diseases (for example, coronary heart disease, 
obesity, diabetes and osteoporosis) (22). Therefore, indicators of chronic disease 
risk such as blood pressure, resting heart rate, body mass, glucose tolerance and 
bone density could be useful as additional outcome measures (46), although little is 
known about the risks of comorbidity in people with a muscle disease. Cost-benefit 
analyses are only relevant if the benefit of training is much higher than studies have 
shown so far.
In summary, the authors’ recommendations for future studies are as follows. 
Participants with different muscle disorders can participate in one study, but 
data should be presented for each major type of muscle disease separately. 
Randomized controlled comparisons should be made with participants having 
the same muscle disease. The effect of training in people with a muscle 
disease should be compared to a non-exercising control group of people with
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the same muscle disease and not to healthy individuals, or to contralateral 
nonexercised limbs. 
An appropriate placebo intervention is recommended in order to measure 
exercise-specific benefits. 
Stratified randomization is strongly advised with regard to disease severity, 
particularly in studies with a small sample size. It should also be considered 
for pre-training level of activity (sedentary versus active), particularly in aerobic 
intervention studies. 
The following aspects of the training intervention should be specified: type(s) 
of exercise training, intensity and progression rate, frequency, duration per 
exercise session and of the entire program, trained muscle groups, and 
supervision of training. Duration of the training intervention should be at least 
six weeks. 
Outcomes should at least include measures of muscle function (for example, 
strength, endurance measured by the maximum duration of contraction) and 
aerobic capacity (for example, work capacity measured by an incremental 
cycle test), and functional assessments such as a six-minute walk test. 
Researchers should be aware of the specificity of training effects in their 
choice of outcome measures. The following evaluations are strongly advised: 
measures of quality of life, pain and experienced fatigue. 
Outcomes assessors should be blinded to interventions, to avoid measurement 
bias. 
Activity level of participants in the control group should be monitored 
objectively in order to assess the specific benefits of aerobic exercise and 
strength training exercise. 
AUTHORS‘ CONCLUSIONS
IMPLICATIONS FOR PRACTICE 
Based on the evidence from five RCTs in this review, moderate-intensity strength 
training in myotonic dystrophy (14) and FSHD (31), aerobic exercise therapy in 
dermatomyositis and polymyositis (33) and a combination of strength and aerobic 
exercise training in myotonic dystrophy type I (30) show no harm, but there is 
insufficient evidence to conclude that they offer benefit. A combination of aerobic 
exercise and strength training in mitochondrial myopathy shows no harm and could 
be beneficial for aerobic capacity (29). The small number of included studies and 
limitations in study design of the other studies prevent general conclusions in other 
muscle diseases. 
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IMPLICATIONS FOR RESEARCH 
There is a need for more research to establish whether strength training and 
aerobic exercise training is beneficial in all forms of muscle disease, and to define 
the optimal exercise programs for people with a muscle disease. 
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ABSTRACT
Background: 
In facioscapulohumeral dystrophy (FSHD) muscle function is impaired and declines 
over time. Currently there is no effective treatment available to slow down this 
decline. We have previously reported that loss of muscle strength contributes to 
chronic fatigue through a decreased level of physical activity, while fatigue and 
physical inactivity both determine loss of societal participation. To decrease chronic 
fatigue, two distinctly different therapeutic approaches can be proposed: aerobic 
exercise training (AET) to improve physical capacity and cognitive behavioral 
therapy (CBT) to stimulate an active life-style yet avoiding excessive physical 
strain. The primary aim of the FACTS-2-FSHD (acronym for Fitness And Cognitive 
behavioral TherapieS / for Fatigue and ACTivitieS in FSHD) trial is to study the 
effect of AET and CBT on the reduction of chronic fatigue as assessed with the 
Checklist Individual Strength subscale fatigue (CIS-fatigue) in patients with FSHD. 
Additionally, possible working mechanisms and the effects on various secondary 
outcome measures at all levels of the International Classification of Functioning, 
Disability and Health (ICF) are evaluated.
Methods/Design: 
A multi-centre, assessor-blinded, randomized controlled trial is conducted. A 
sample of 75 FSHD patients with severe chronic fatigue (CIS-fatigue ≥ 35) will be 
recruited and randomized to one of three groups:  (1) AET + usual care, (2) CBT + 
usual care or (3) usual care alone, which consists of no therapy at all or occasional 
(conventional) physical therapy. After an intervention period of 16 weeks and a 
follow-up of 3 months, the third (control) group will as yet be randomized to either 
AET or CBT (approximately 7 months after inclusion). Outcomes will be assessed at 
baseline, immediately post intervention and at 3 and 6 months follow up. 
Discussion: 
The FACTS-2-FSHD study is the first theory-based randomized clinical trial 
which evaluates the effect and the maintenance of effects of AET and CBT on the 
reduction of chronic fatigue in patients with FSHD.  The interventions are based on 
a theoretical model of chronic fatigue in patients with FSHD.  The study will provide 
a unique set of data with which the relationships between outcome measures at all 
levels of the ICF could be assessed. 
Trial registration: 
Dutch Trial Register, NTR1447.
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BACKGROUND
Facioscapulohumeral dystrophy (FSHD) is the third most common inherited 
neuromuscular disorder. It is an autosomal dominant slowly progressive myopathy 
with a variable age of onset, mostly in the second or third decade of life. Its yearly 
incidence rate is approximately 1:20,000 (1). The disease primarily affects the facial 
muscles, the muscles of the shoulder girdle (most typically the scapula stabilizers) 
and various leg muscles, while pelvic and trunk muscles are eventually affected as 
well (2-4). The pattern of muscle weakness is often asymmetrical, and the rate and 
extent of progression may vary considerably with sudden periods of unexplained 
rapid disease progression. In a small percentage of the patients, even respiratory 
insufficiency may occur (5). Only very recently, evidence became available that 
there may be a selective involvement of the central nervous system as well, in 
terms of decreased grey matter volume (6) and reduced intracortical inhibition (7). 
Although FSHD is associated with a partial deletion of a critical number of repetitive 
elements (D4Z4) on chromosome 4q35, to date no causal gene has been identified 
and no curative treatment is available (3, 8).  FSHD may eventually lead to serious 
disabilities of speech, swallowing, reaching, standing and walking, even in early 
adulthood. Twenty percent of the patients become wheelchair bound. Since no 
cure is available, rehabilitation is the mainstay of treatment (2, 3, 9). 
Only recently it was shown by our group that severe fatigue, defined as a score 
equal as or higher than 35 on the subscale fatigue of the Checklist Individual 
Strength (CIS-fatigue), was reported by 61% of the patients with FSHD. These 
severely fatigued patients had more problems with physical and social functioning 
as well as with mental and general health than similar patients without a severe 
fatigue. They also had more problems with concentration, initiating and planning 
(10). As such, experienced fatigue should be clearly distinguished from muscle 
weakness, which is probably the most common and characteristic symptom of 
FSHD (11). In a longitudinal study, we built a model of perpetuating factors for 
fatigue in patients with FSHD (Figure 1). It appeared that lack of physical activity, 
sleep disturbances and pain all contributed to experienced fatigue. In addition, loss 
of muscle strength and pain contributed to fatigue through a lower level of physical 
activity. Ultimately, experienced fatigue and physical inactivity both contributed 
to the level of societal participation (12). Thus, theoretically, in order to improve 
societal participation one should improve muscle strength, reduce pain, optimize 
physical activity and alleviate experienced fatigue. In addition, falling appears to be 
a major problem among FSHD patients. Our group was able to show that 65% of 
the patients reported falling at least once a year (13). Since fall incidents often lead 
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to fear of falling and avoidance behavior, they have a serious negative impact on 
physical activity and participation. 
Improving muscle strength by strength training and/or (anabolic) medication has 
shown not to be successful in patients with FSHD (14). Until now, only one trial 
has investigated low-intensity aerobic exercises, indicating that aerobic training 
is a safe method to increase exercise performance (14, 15). Although, in general, 
physical activity does not appear harmful (16, 17), more research is needed to 
establish whether AET is beneficial in patients with FSHD. Besides improving 
physical (aerobic) capacity, it seems important to optimize physical activity and 
change behavior in daily life. Indeed, symptoms and signs of muscle weakness 
and fatigue as well as the anticipation of a (further) decline in physical capacity 
may elicit an inactive life-style, which may disproportionally affect physical activity, 
fatigue and societal participation. From this perspective, it might be beneficial to 
alter illness cognitions and coping styles by means of CBT. However, evidence for 
the effectiveness of CBT in patients FSHD is not yet available. 
The primary objective of the FACTS-2-FSHD trial is:
to study the efficacy of AET and CBT for decreasing chronic fatigue in patients 
with FSHD. It is hypothesized that both AET and CBT are more effective in 
decreasing fatigue than usual care, which is no therapy at all or occasional 
(conventional) physical therapy. The improvement by AET may be obtained 
through enhancement of physical (aerobic) capacity, whereas beneficial effects 
of CBT may be achieved through changes in daily activities and behavior. By 
changing illness cognitions and improving coping style, the balance between 
actual behavior and physical capacity will be optimized. Since changes 
achieved by CBT are more ‘intrinsic’, possible beneficial effects of CBT may 
last longer than those of AET.  
Secondary objectives of the FACTS-2-FSHD trial are:
to evaluate the effects of AET and CBT on bodily functions and structures 
as defined by the International Classification of Functioning, Disability and 
Health (ICF): lower extremity muscle strength, pain, psychological well being, 
cardiovascular risk factors, aerobic exercise tolerance, sleeping pattern, as well 
as biomarkers in blood and urine and structural and metabolic muscle tissue 
characteristics. 
to evaluate the effects of AET and CBT on the ICF level of activities: physical 
activity in daily life, self perceived functional status, and fall incidence. 
to evaluate the effects of AET and CBT on the ICF level of participation: 
limitations in participation and autonomy and quality of life.C
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to evaluate the effects of AET and CBT on environmental and personal factors 
as defined by the ICF: coping style, illness cognitions, concentration problems, 
motivation, caregiver strain, experienced fatigue of the caregiver, social support 
and coping of the caregiver. 
Figure 1 Model of perpetuating factors of experienced fatigue in patients with 
FSHD
METHODS
STUDY POPULATION
It is intended to include 75 FSHD patients, diagnosed on both clinical and genetic 
grounds, aged 18 years and older. All patients who participated in previous FSHD 
studies at the Radboud University Nijmegen Medical Centre (10, 12, 14, 18) 
are approached by the primary investigator (NV). In addition, all patients known 
at the departments of Neurology and Rehabilitation of the Radboud University 
Nijmegen Medical Centre, University Medical Centre of Utrecht, Amsterdam 
University Medical Centre or any of the affiliated rehabilitation centers are invited 
to participate as well. In addition, patients who are registered in the Dutch 
neuromuscular “computer registry of all myopathies and polyneuropathies” 
(CRAMP) database (19) and/or who are member of the Dutch patient support 
organization “vereniging spierziekten Nederland” (VSN) will be invited by the 
primary investigator (NV) and a member of the VSN, respectively, to take part in the 
study. If the patient is willing to participate, the primary investigator (NV) will check 
the inclusion and exclusion criteria (Table 1) and estimate the disease severity using 
the Ricci score (20). When a patient meets all the criteria, oral and written informed 
consent are obtained according to the declaration of Helsinki. Separate consent is 
asked to (i) obtain blood and urine samples, and/or (ii) undergo magnetic resonance 
imaging (MRI) / spectroscopy (MRS), and/or (iii) undergo muscle ultrasound. The 
study protocol was approved by the Dutch ethical committee CCMO (Centrale 
commissie mensgebonden onderzoek) and all participating centers granted 
(ethical) approval to participate. 
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Table 1 Inclusion and exclusion criteria
Inclusion criteria
(1) age 18 years and older
(2) suffering from severe fatigue (CIS-fatigue ≥ 35) (21)
(3) ability to walk independently (ankle-foot orthoses and canes are accepted)
(4) being able to exercise on a bicycle ergometer
(5) being able to complete either type of intervention
Exclusion criteria 
(1) cognitive impairment
(2) insufficient mastery of the Dutch language 
(3) neurological or orthopedic co-morbidity interfering with the interventions or possibly
 influencing outcomes
(4) pregnancy 
(5) use of psychotropic drugs (except simple sleeping medication) 
(6) severe cardiopulmonary disease (chest pain, arrhythmia, pacemaker, cardiac surgery,
 severe exertional dyspnea, emphysema) 
(7) epileptic seizures
(8) poorly regulated diabetes mellitus or hypertension
(9) clinical depression, as diagnosed with the Beck Depression Inventory for primary 
 care (BDI-PC) (22, 23)
RANDOMIZATION AND BLINDING
Participants fulfilling all inclusion and exclusion criteria are randomized to one of 
three groups by creating computer-generated ‘blocks’ ensuring that the same 
number of participants is allocated to each group. Experimental group 1 (E1) 
receives AET and usual care for 3 times a week during 16 weeks. Experimental 
group 2 (E2) receives CBT and usual care once time a week during 16 weeks. 
Thereafter, both groups are followed up for 6 months.  A third group (C) receives 
usual care only for 16 weeks and serves as a waiting list control group. After 
another 3-months follow-up (i.e. 7 months after inclusion), this group will as yet 
be randomized to either AET or CBT for 16 weeks and followed up until 6 months 
later (total time in study 17 months) (Figure 2). All outcomes are assessed by 
blinded and independent physical therapists. At the beginning of each assessment, 
patients are always instructed not to reveal their group allocation to the blinded 
assessor.C
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Figure 2 Study design
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INTERVENTIONS
Usual care
All participants receive usual care. In the Netherlands, patients with FSHD typically 
receive no therapy at all, or occasional (conventional) physical therapy. Patients are 
not restricted in any activities, but all co-interventions are monitored throughout the 
study by diaries and at every measurement.
Aerobic Exercise Training (AET)
The AET consists of aerobic cycling exercise on a bicycle ergometer. The training 
program has a duration of 16 weeks and comprises home training twice a week 
and a supervised training once a week. Training sessions consist of a 30-minute 
aerobic exercise period with a warming-up and cooling-down period of 5 and 
3 minutes, respectively. The cardiovascular load during the training period is 
individually adjusted and increased from a level of 60% to 75% of the heart rate 
reserve (HRR). HRR is the difference between the predicted maximum heart rate 
and the measured resting heart rate. The HRR is equivalent to the difference 
between the maximum and resting maximal oxygen consumption (VO2max). Each 
participant is learned how to adjust the physical load to the preferred individual 
heart rate. Participants are supplied with a Monark 827E bicycle ergometer, a 
Garmin forerunner 50 heart rate watch with breast belt, and a log book with training 
instructions at home for the duration of the intervention. During each training, the 
heart rate is monitored continuously by the breast belt. The number of training 
sessions, the total time spent on AET, possible adverse effects and the training 
parameters (physical load, heart rate) are recorded in the individual log book.  Once 
a week, individually supervised training is given by trained physical therapists 
during one-hour sessions in small groups in a nearby rehabilitation centre. During 
these sessions, therapy compliance in the home situation is verified by reading out 
the heart rate watches and checking the log books. In addition, instructions for the 
next week are provided. The (unblinded) primary investigator and physician (NV) 
gives instructions to the physical therapists and performs integrity checks at each 
treatment location.  
Cognitive Behavioral Therapy (CBT) 
CBT will be focused on the perpetuating factors of fatigue as established in 
previous research (10, 12, 24) and based on experience in clinical practice. These 
factors encompass insufficient coping with the disease, dysfunctional illness C
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cognitions, catastrophizing, dysregulation of sleep, dysregulation of activity, low 
social support and negative social interactions (see appendix 1 for the various 
modules). Because of large inter-individual differences, CBT will be adapted to the 
needs of each patient. For instance, barriers to become more physically active are 
explored and possibly alleviated in some patients, whereas overactivity is reduced 
in others. To determine which modules are appropriate, each perpetuating factor 
is assessed with specific tests, and within each module, the CBT approach is 
standardized (see appendix 1). The precise number of sessions is dependent on 
the number of modules. 
Each session has a duration of one hour and is given at the most nearby 
participating centre by a registered cognitive behavioral therapist, especially 
trained in CBT for FSHD. The therapists have been specifically trained to use the 
diagnostic tests and indicate the different modules and are regularly supervised by 
one of the investigators (GB). 
COMPLIANCE AND ATTRITION
Therapy compliance is assessed by recording the number of treatment sessions 
(AET and CBT). For the participants randomized to AET, the total time spent on 
the bicycle ergometer at home is recorded as well. When applicable, participants 
are asked for their reasons for poor compliance. In the case of therapy drop out, 
patients are asked for the reason of non compliance and are stimulated to continue 
participation in the assessments until the last follow-up. 
OUTCOME ASSESSMENT
Outcome measures are listed in Table 2. The primary outcome measure is fatigue 
severity as assessed with the CIS-fatigue (21). Secondary outcome measures are 
categorized according to the different ICF levels (25). Outcome measurements are 
obtained at the Radboud University Nijmegen Medical Centre  at the start of the 
study period (T0), immediately after the intervention period of 16 weeks (T1) and 
after 3 (T2) and 6 months of follow-up (T3). Observers of the secondary outcome 
measurements are experienced physical therapists blinded for treatment allocation. 
At the first measurement (T0), demographic data is obtained by the primary 
investigator and physician (NV), as well as a general and FSHD related medical 
history, anthropometric measures (diastolic and systolic blood pressure in mm, 
resting pulse rate in beats per minute and auscultation of heart and lungs), to verify 
eligibility. The baseline (T0) and post treatment (T1) visits consist of muscle strength 
testing of the thigh and aerobic exercise tolerance testing. Participants are asked 
127
to complete the questionnaires and to wear the actometer for 12 consecutive days. 
An actometer is a motion sensing device that can register and quantify human 
physical activity and has to be worn at the ankle (26, 27). Blood and urine analyses 
and MRI, MRS and ultrasound measurements of the thigh muscles are performed. 
Follow-up measurements (T2 and T3) consist of muscle strength testing of the 
thigh, aerobic exercise tolerance testing, questionnaires are completed and the 
actometer is provided.
At the level of bodily functions and structures, patients are asked to give separate 
consent for several ‘invasive’ assessments at baseline and after the intervention 
period. Blood and urine samples are collected by experienced nurses and will be 
explored by nuclear magnetic resonance (NMR) for possible biomarkers of disease 
and response to the interventions. Ultrasound measurements of the thigh muscles 
are made by an experienced ultrasound professional, blinded for the treatment 
allocation, and analyzed for muscle thickness and echo intensity. In addition, 
Magnetic Resonance Imaging (MRI) and 31P and proton (1H) Magnetic Resonance 
Spectroscopy (MRS) are performed by trained professionals, blinded for the 
assignment to the intervention. 
It has been shown that in vivo MRS is able to produce spectra of multiple 
metabolites simultaneously and is well suited to study energy metabolism in 
patients with muscular dystrophies (28, 29). The MR examinations start with 
T1 and T2 weighted images of the thigh for detailed structural analysis. Muscle 
involvement is specifically assessed by the presence of fatty infiltration on T1 
weighted MR images. 1H MRS is used to assess muscle specific creatine as well 
as extramyocellular lipids and intramyocellular lipids levels, whereas 31P MRS is 
applied to get information about tissue pH and the level of high energy phosphates. 
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Table 2 Outcome measures and tests
Tests 
Primary outcome measure
Fatigue severity Checklist Individual Strength (CIS subscale fatigue) (30)
Secondary outcome measures
ICF: bodily functions
Aerobic exercise tolerance Maximal oxygen consumption (VO2 max) using the 
Åstrand protocol (31) 
6-minutes walking test (32) 
Resting heart rate
Muscle strength of 
quadriceps, hamstrings 
and tibialis anterior muscles 
Cardiovascular risk factors
Pain
Psychological well-being 
and sleeping pattern
Metabolic biomarkers
Structural and metabolic 
muscle characteristics
Quantitative Muscle Assessment using fixed myometry 
testing system (QMA) (18)
Blood pressure*
Abdominal circumference
Weight / Body Mass Index (BMI)
Percentage body fat
Visual Analogue Scale (VAS) (33)
Daily Observed Pain (during a period of 2 weeks) (27, 34)
Brief Symptom Inventory (BSI) (35)
Blood and urine analyses for creatine, glucose, creatine 
kinase, sodium, potassium, calcium, phosphorus, 
ureum, ALAT, ASAT, gamma-GT, bilirubine, AF and LDH***
T1 MRI, T2 MRI, 31P and 1H MRS analysis of muscle 
specific creatine, extramyocellular lipids, intramyocellular 
lipids, levels and phosphometabolites in thigh muscles; 
ultrasound of thigh muscles
ICF: activities
Physical activity in daily life
Self perceived functional 
status
Actometer, a motion sensing device (during a period of 
2 weeks) (26, 27) 
Daily Observed Spontaneous physical activity (during a 
period of 2 weeks) (27, 34). 
Checklist Individual Strength (CIS subscale physical 
activity) (30)
Sickness Impact Profile (SIP subscales mobility control 
and mobility range, social behavior) (36)
ICF: participation
Limitations in participation 
and autonomy Quality of life 
Fall incidence
The Impact on Participation and Autonomy 
Questionnaire (IPAQ) (37)
36-Item Short-Form Health Survey (SF-36) (38)
Telephone computer (weekly calls)**
ICF: personal factors
Coping
Illness cognitions
Concentration problems
Motivation
Coping Inventory for Stressful Situation (CISS) (30)
ALCOS-16 (39)
Ziekte cognitie lijst (ZCL) (40)
Checklist Individual Strength 
(CIS subscale concentration) (21)
Checklist Individual Strength 
(CIS subscale motivation) (21)
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Table 2 Outcome measures and tests (Continued)
ICF: environmental factors
Caregiver strain
Experienced fatigue of patient 
from perspective of relative.
Experienced fatigue of partner.
Social support
Coping of partner
Caregiver Strain Index of partner/caregiver (CSI) (41)
Checklist Individual Strength (CIS subscale fatigue, filled 
in by relative about patient) (21)
Checklist Individual Strength (CIS subscale fatigue, filled 
in by relative about him/herself) (21)
Sociale steunlijst-subschaal discrepantie 
(SSL-D verkort) (42)
Coping Inventory for Stressful Situations (CISS) (30)
*Measured only at inclusion
** Participants will be called weekly throughout the study by a telephone-computer to 
obtain fall incidence; in the case of fall incident(s), a subsequent telephone interview is 
held to obtain information about the cause and circumstances of falling, fall direction, 
possible injury and ability to get up from the floor
*** In all groups, three extra urine samples will be obtained at week 4, 8 and 12 of the 
intervention period
An adverse event is defined as any undesirable experience or outcome. Specially 
assigned site investigators are instructed to report all adverse events immediately 
to the primary investigator (NV) and to evaluate each event for its date of onset, 
possible relation to the interventions (based on clinical judgment), possible 
treatment and course in time. In addition, adverse events can be reported by the 
participants directly to the primary investigator and physician (NV). All adverse 
events reported will be carefully monitored and registered until they have abated or 
a stable situation has been reached. 
STATISTICAL ANALYSIS
Generalized estimated equations analysis will be used to investigate differences 
in the effects on primary and secondary outcome measures between the study 
groups and to investigate the influence of possible effect modifiers. When 
necessary, analyses will be adjusted for group differences in fatigue severity and 
physical activity at baseline. Data will be analyzed according to the intention-to-
treat principle. 
POWER
In order to detect a 10% group difference (E1 and E2 versus C) in change in 
fatigue severity between the start and the end of the intervention period (assuming 
difference in standard deviation between the start and the end of the intervention 
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Table 2 Outcome measures and tests (Continued)
(SDdif) = 10%, α = .05, β = .80), 20 participants per group are required. With an 
expected drop-out rate of maximally 25%, 25 participants will be recruited in each 
group (n=75).
DISCUSSION
To the best of our knowledge, the FACTS-2-FSHD study is the first randomized 
clinical trial which evaluates the effect of AET and CBT on the reduction of chronic 
fatigue in patients with FSHD. 
This study has several strengths. First, the selected interventions are based on a 
theoretical model of chronic fatigue in patients with FSHD (12) and are compared 
with usual care in a randomized design.  Until now, only one randomized controlled 
trial has been conducted that could not establish a beneficial effect of muscle 
strength training compared to no training in FSHD (14, 18). In addition, one trial 
has been conducted that investigated low-intensity aerobic exercises in FSHD. 
Although this latter study reported improved maximal oxygen uptake and workload 
as a result of training, this was an uncontrolled and unblinded trial of only 8 
patients (15). The majority of the training studies in patients with muscle disorders 
did not include a (no-training) control group or used healthy subjects as controls. 
In addition, data are often presented for mixed groups of muscle disorder (17). 
Second, the proposed study uses a broad arsenal of secondary outcome measures 
at all levels of the ICF, including ‘invasive’ measurements of possible biomarkers 
in blood and urine as well as measurements of structural and metabolic muscle 
characteristics. 
This approach will provide a unique set of data with which it should be possible 
to accurately assess the relationships between disease characteristics, loss of 
bodily functions, activity limitations and restrictions in societal participation in 
patients with FSHD. Third, all patients will be followed up until 6 months after the 
interventions, which will not only provide information about the maintenance of 
effects, but also about any long-term adverse events. 
A limitation of this study is that the sample size calculation was based on detection 
of a 10% difference between the intervention groups and the control group, 
presuming more or less equal effect sizes of AET and CBT. Detecting more subtle 
differences in the effectiveness between both interventions would require a much 
larger sample size. In the Netherlands alone, such a trial would not be feasible. 
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In conclusion, the FACTS-2-FSHD study will increase our insight into the 
effectiveness of aerobic exercise training and cognitive behavioral therapy to 
reduce chronic fatigue and to optimize physical activity and capacity in patients 
with FSHD. A successful outcome of this study has the potential to change existing 
(inter)national guidelines for physical training and to improve the quality of life in 
patients with FSHD.  
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APPENDIX 1 DIFFERENT MODULES OF
COGNITIVE BEHAVIORAL THERAPY
Perpetuating factors: insufficient coping with the disease
Insufficient coping with the disease is assessed with the Impact of event Scale (43, 
44). A participant can continue to be occupied with the period of being diagnosed 
with FSHD. By means of talking or writing about this experience (which can be 
referred to as ‘exposure’), the participant will acquire better coping skills. Fear of 
progression is assessed with a questionnaire especially designed for FSHD. The 
therapist helps the participant to formulate explicit words to describe the thoughts 
of fear of progression. These thoughts are challenged against reality (reality testing). 
In this way, daily unhelpful thoughts about the disease progression are reduced and 
put into perspective. 
Perpetuating factors: dysfunctional cognitions regarding fatigue, 
activity and other symptoms  
Dysfunctional cognitions relate to a variety of ideas, including a participant’s idea 
of lack of control over symptoms, and dysfunctional cognitions about symptoms, 
such as catastrophizing. The sense of control in relation to fatigue complaints will 
be assessed with the self-efficacy scale (34, 45).  
Perpetuating factors: catastrophizing
Catastrophizing will be assessed with the Jacobsen Fatigue Catastrophizing Scale 
(46). These cognitions are disputed and more helpful ways of thinking are taught. 
Perpetuating factors: dysregulation of sleep
Dysregulation of sleep is based on self-report in a sleep diary (47). An irregular 
sleep-wake rhythm can perpetuate fatigue. To restore the biologic rhythm, 
participants are encouraged to adhere to fixed bedtimes and wake-up times and 
discouraged from sleeping during the day, or they are helped with adapting fixed 
rest period(s). 
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Perpetuating factors:  dysregulation of activity
Dysregulation of activity is based on activity (stepping) monitoring using an 
actometer and a physical activity questionnaire (Physical Activity Scale for 
Individuals with Physical Disabilities (44, 48). Some patients experience fluctuating 
periods of activity with subsequent periods of rest during a longer period. 
Others avoid activity because they are concerned that activity increases fatigue; 
consequently, they are physically inactive. For patients with fluctuating activity 
levels, a base level should be established by alternating rest and activities to 
prevent bursts of activity. Once the participant has set a base level, the physical 
activity program is started, usually twice a day, starting with 5 to 10 minutes of an 
activity such as walking or cycling. The activity is increased by 1 minute a day each 
time the activity is performed (ending at a maximum of 2 times 60 minutes minutes 
per day). The inactive participant will start the activity program immediately. 
Gradually, physical activities are replaced by other activities. 
Perpetuating factors:  low social support and negative social 
interactions
Low social support and negative social interactions are based on the discrepancy 
subscale of the Social Support List (49). If a participant still has unrealistic 
expectations of others or perceives a discrepancy between actual support and 
desired support, the therapist helps to install more realistic expectations toward the 
participant’s social support group. The partner or caregiver will be included in this 
treatment module.
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ABSTRACT 
Objective: 
To investigate the effect of aerobic exercise training (AET) and cognitive behavioral 
therapy (CBT) on chronic fatigue in patients with facioscapulohumeral muscular 
dystrophy (FSHD).  
Methods: 
We performed a multicenter, assessor-blinded, randomized clinical trial (RCT). 
Fifty-seven patients with FSHD type 1 with severe chronic fatigue were randomly 
allocated to AET, CBT, or usual care (UC). Outcomes were assessed before 
treatment, following 16 weeks of intervention, and after a 12-week follow-up. A 
linear mixed model for repeated measurements was used to study the estimated 
group differences.  
Results: 
Following treatment, both the AET (28 participants) and CBT (25 participants) 
intervention groups had less fatigue relative to the UC group (24 participants), with 
a difference of -9.1 for AET (95% confidence interval  {CI} -12.4 to -5.8) and -13.3 
for CBT (95% CI -16.5 to -10.2). These beneficial effects lasted through follow-up, 
with a difference of -8.2 for AET (95% CI -12.4 to -5.8) and -10.2 for CBT (95% CI 
-14.0 to -6.3). The patients who received CBT had an increase in registered and 
experienced physical activity, sleep quality, and social participation. The patients 
who received AET had an increase in registered physical activity only. The increase 
in registered physical activity in both groups and the improvement in social 
participation following CBT were still present at follow-up.  
Conclusions: 
This RCT shows that AET and CBT can ameliorate chronic fatigue in patients with 
FSHD.  
Classification of evidence: 
This study provides Class III evidence that, in patients with FSHD type 1 and severe 
chronic fatigue, AET or CBT reduces the severity of chronic fatigue.
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Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant, 
slowly progressive myopathy, affecting approximately 1:8,000 individuals (1). We 
previously reported that severe fatigue is experienced by 61% of patients with 
FSHD and contributes considerably to reduced social participation (2). We also 
developed a FSHD-specific model of fatigue-perpetuating factors (3). Because the 
patient’s level of physical activity plays a central role in this model, it is a logical 
target for therapeutic intervention. In theory, one can increase physical activity 
either by improving muscle strength or by optimizing aerobic capacity. Althoug h 
strength training in patients with FSHD appears to be safe, its beneficial effects are 
limited (4, 5). In contrast, a pilot study provided evidence that patients with FSHD 
can benefit from aerobic exercise training (AET) (6). Cognitive behavioral therapy 
(CBT) is a different type of intervention that can be used to alleviate individually 
relevant fatigue-perpetuating factors. Several published studies have provided 
evidence that CBT can reduce fatigue in chronic fatigue syndrome, multiple 
sclerosis, and cancer survivors (7-9). However, the effect of CBT on fatigue in 
patients with muscular dystrophy has not been investigated. 
METHODS
STUDY OBJECTIVES
The primary objective of this study was to evaluate the effect of 16 weeks of AET 
or CBT on chronic fatigue in patients with FSHD type 1 compared to usual care 
(UC) (10) (level of evidence: Class III). The secondary objective was to evaluate 
the effects of each intervention on the known fatigue-perpetuating factors in these 
patients (level of evidence: Class III). In addition, we were interested whether CBT, 
as it focuses on all fatigue-perpetuating factors, might provide longer-lasting 
benefits than AET.  
PARTICIPANTS 
All the adult patients with FSHD who participated in any previous study at our 
center, (2-4) who were registered in a Dutch neuromuscular database, (11) or 
who participated in a patient support organization were invited to participate. In 
addition, they were asked to complete the Short Fatigue Questionnaire (SFQ) (12). If 
a patient was willing to participate, N.V. checked the inclusion and exclusion criteria 
(Table 1).  A diagnosis of FSHD type 1 had to be confirmed by DNA testing (13). 
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Table 1 Inclusion and exclusion criteria 
Inclusion criteria
(1) age 18 years and older
(2) suffering from severe fatigue (CIS-fatigue ≥ 35) 
(3) ability to walk independently (ankle-foot orthoses and canes are accepted)
(4) being able to exercise on a bicycle ergometer
(5) being able to complete either type of intervention
Exclusion criteria 
(1) cognitive impairment
(2) insufficient mastery of the Dutch language 
(3) neurological or orthopedic co-morbidity interfering with the interventions or possibly 
influencing outcomes
(4) pregnancy 
(5) use of psychotropic drugs (except simple sleeping medication) 
(6) severe cardiopulmonary disease (chest pain, arrhythmia, pacemaker, cardiac surgery,
severe exertional dyspnea, emphysema) 
(7) epileptic seizures
(8) poorly regulated diabetes mellitus or hypertension
(9) clinical depression, as diagnosed with the BDI-PC
CIS-fatigue: subscale fatigue of the Checklist Individual Strength, BDI-PC: the Beck 
Depression Inventory for Primary Care
Source: adapted with permission from Voet et al. (16)
DESIGN 
The study was a multicenter, assessor-blinded, randomized clinical trial using 
repeated measurements. An independent research assistant allocated each 
participant to 16 weeks of AET, CBT, or UC using a computer-generated 
randomization block list. The block sizes varied randomly in order to prevent 
predictability of the allocation process. After 12 weeks of follow-up, after a total 
of 28 weeks (i.e., period 1), the patients in the UC group were randomly allocated 
to 16 weeks AET or CBT followed by another 12 weeks of follow-up (i.e., period 
2: 28 weeks). The interventions were performed at 9 health care institutions for 
convenience of the patients 
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STANDARD PROTOCOL APPROVALS, REGISTRATIONS, 
AND PATIENT CONSENTS 
The study protocol was approved by the regional medical ethics committee 
(CMO2008/228) and by each institution’s local committee. All patients provided 
oral and written informed consent (14). The design of this study was published 
previously (15) and was registered as the FACTS-2-FSHD trial in the Dutch Trial 
Register (NTR1447). 
INTERVENTIONS  
AET consisted of 3 weekly sessions of aerobic cycling exercises on a Monark 
(Varberg, Sweden) 827E ergometer; 2 sessions were performed in the patient’s 
home, and the third was supervised by a physical therapist. N.V. performed 
integrity checks at each study site. The participants cycled for 30 minutes with 
additional warming-up and cooling-down periods of 5 and 3 minutes, respectively. 
During the training period, cardiovascular load was continuously monitored with a 
heart rate belt and watch (Garmin {Olathe, Kansas} Forerunner 50) and adjusted to 
the individual participant’s level. It was aimed to achieve an increase of 50%–65% 
in heart rate reserve (HRR) (16). Participants who were taking β-blockers were 
instructed to exercise at a perceived exertion level of 12–14 on the Borg scale 
(appendix 1) (17). The number and duration of the sessions, the Borg score, the 
mean and maximum heart rate, and adverse effects were recorded in an individual 
log book. During the weekly supervised sessions, the physical therapist verified 
compliance by reading the data recorded by the heart rate watch and by reviewing 
the log book. In addition, training instructions for the following week were given 
to the participant. Acceptable compliance with the AET program was defined as 
completion of a minimum of 40 training sessions. 
CBT comprised 6 possible modules based on the known fatigue-perpetuating 
factors (3) and previous research (8). These modules were directed at insufficient 
coping with the disease; dysfunctional cognitions regarding fatigue, activity, pain, 
or other symptoms; fatigue catastrophizing; dysregulation of sleep or activity; 
poor social support; and negative social interactions (appendix 2). To account for 
interindividual differences in these factors, the intervention was adapted to the 
specific needs of each participant, including an individually tailored structured 
activity program. Each session was 50 minutes in duration and was conducted 
at the nearest participating center by a cognitive behavioral therapist. The total 
number of sessions for each participant was based on the number of modules to 
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be addressed, which were identified by the therapist by performing an interview 
and specific tests. Acceptable compliance with the CBT program was defined as 
completion of a minimum of 3 sessions.  
The participants in the UC group received no specific treatment for fatigue but 
occasional physical therapy was allowed. Throughout the study, the participants 
were not restricted in their activities. Any cointervention (e.g., physiotherapy 
session) was noted in the log books. 
OUTCOMES 
The primary outcome measure was fatigue severity, assessed with the fatigue 
subscale of the Checklist Individual Strength (CIS-fatigue). This scale consists of 
8 questions regarding fatigue as experienced during the previous 2 weeks; each 
question was scored on a 7-point Likert scale (18). A total score ≥35 indicates 
severe fatigue (3). The CIS-fatigue has good internal consistency (Cronbach a 
0.83–0.92), high discriminative validity, and high sensitivity to change in patients 
with FSHD (3). 
The secondary outcome measures were selected to evaluate each factor of the 
described model (3). 
Maximum voluntary isometric strength for the quadriceps was measured using 
Quantitative Muscle Assessment (19); the highest value of 2 maximal isometric 
contractions was collected and the average value of the left and right quadriceps 
strength was calculated. 
Aerobic exercise tolerance (VO2 peak, in L/min) was estimated with the Åstrand 
test (20). Physical endurance was tested with the distance walked during a 
6-minute walking test (21). 
Participants were asked to wear an ankle actometer for 12 consecutive days 
(throughout the day and night) (22). Registered physical activity was averaged over 
the 12-day period and expressed as the average number of body accelerations 
per 5-minute period. The physical activity subscale of the Checklist Individual 
Strength (CIS-activity) was used as a measure of experienced physical activity. This 
subscale consists of 3 questions regarding activity during the previous 2 weeks; 
each question was scored on a 7-point Likert scale (22). 
Pain intensity was assessed with a Visual Analogue Scale (VAS-pain, range 0–100) 
(23). 
Self-reported sleep disturbances were assessed using the 5- item sleep subscale 
of the Nottingham Health Profile (NHPsleep, range 0–100) (24, 25). C
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Social participation restrictions were assessed with the social behavior subscale of 
the Sickness Impact Profile 68 (SIP68-sb, a weighted score ranging from 0 to 572) 
(26). 
For CIS-fatigue, CIS-activity, VAS-pain, NHP-sleep, and SIP68-sb, a higher score 
indicates poorer outcome. 
All adverse events reported by the participants or observed by the therapists were 
recorded. Participants were called weekly throughout the study by a telephone-
computer to obtain fall incidence (27).  
PROCEDURE 
At baseline, demographic and clinical characteristics were collected, including the 
Ricci score as a measure of disease severity (28) (Table 2). 
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Table 2 Baseline characteristics 
UC (n=24) AET  (n=20) CBT (n=13)
Characteristics n median range n median range n median range
Age (years) 24 52 (20-79) 20 59 (21-68) 13 49 (24-69)
Gender (male) 24 17 (71%) 20 12 (60%) 13 8 (62%)
Ricci score 24 3.0 (1.5-4.0) 20 3.0 (0.5-4.0) 13 2.0 (1.0-4.0)
Duration 
of illness 
(years)
24 16.7 (1.0-49.0) 20 13.0 (1.0-42.0) 13 7.0 (0.0-40.0)
Duration of 
fatigue 
(years)
18 5.0 (0.5-25.0) 17 10.0 (1.7-30.0) 12 4.5 (2.0-28.0)
Physical 
therapy (PT) 
(n/%)
24 10 (42%) 20 8 (40%) 13 4 (31%)
Sessions 
PT/patient/week
24 0 (0-2) 20 0 (0-4) 13 0 (0-2)
CIS-fatigue 24 42 (35-51) 20 41 (35-54) 13 43 (35-56)
UC: usual care, AET: aerobic exercise training, CBT: cognitive behavioral therapy, 
CIS-fatigue: subscale fatigue of the Checklist Individual Strength
The outcome data of the participants in the AET and CBT groups were collected 
immediately before treatment, immediately following the 16-week intervention 
period, and 12 weeks postintervention (period 1 and period 2). The outcome data 
of the UC group were collected at baseline and after 16 and 28 weeks follow-up 
(period 1). All measurements were performed at the Radboud University Medical 
Center by 2 blinded physical therapists. At follow-up, N.V. recorded whether the 
participants had continued their level of activity during the follow-up period. 
POWER 
The primary outcome is change in CIS-fatigue between the start and the end of the 
treatment period (16 weeks). Assuming a difference (in change) between the groups 
of 8 points, a SD of the change of 8 points, α = 0.05, β= 0.80, and applying a 
Bonferroni adjustment for the number of comparisons, 20 patients are needed per 
group using a 2-sided t test. We aimed to include 25 patients per group to allow a 
dropout rate of 25%. We planned to randomize the patients of the UC group (after 
28 weeks) to either intervention group, so that a total of 50 patients (instead of 75) 
would be needed to evaluate 25 patients per group. No further (down) adjustment 
for repeated measurements was applied to the already low number of patients per 
group. 
STATISTICAL ANALYSIS 
A linear mixed model for repeated measurements was used to study group 
differences in the change per week after treatment of each of the primary and 
secondary outcomes. The dependent variable was the specific outcome. The 
independent class variables were treatment (3 levels: AET, CBT, UC) and period 
(2 levels: first, second). The independent continuous variables were time (weeks 
since baseline) and the value of the specific outcome at baseline. The intercept 
of each patient was treated as a random variable. This allows different levels for 
different individuals. In addition, all first-order and second-order interaction terms 
between group, time, and period were included in the linear part of the model. At 
first, we found that, for all outcomes, the factor period and all interaction terms, 
except the interaction term between time and treatment, never reached the level of 
statistical significance and that the models were never significantly reduced when 
these terms were omitted from the model (likelihood ratio test). Second, we also 
used time as a class variable and found that this never significantly improved the 
fit of the model to the data (likelihood ratio test). Consequently, in the final model, 
period and the period-related interaction terms were omitted and time was treated 
as a continuous variable, as presented above. Finally, the regression per week in C
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the UC group was estimated using the data of all 3 points of measurement, and 
the estimated mean group differences with 95% confidence intervals (CIs) were 
calculated at 16 and 28 weeks. The difference in percentage of patients with 
severe fatigue (CIS-fatigue score ≥35) was used as an endpoint to calculate the 
absolute risk reduction (ARR) for both intervention groups compared to the UC 
group. The number needed to treat (NNT) was calculated as the reciprocal of the 
ARR. Statistical analyses were performed with SAS version 9.2 for Windows (SAS 
Institute, Cary, NC). p < 0.05 was considered statistically significant.
RESULTS 
The flowchart of the patients in the study is shown in the Figure. 
In total, 377 patients were invited to participate. The most commonly cited reason 
for unwillingness to participate (n = 199) was unknown (n = 153) or the long 
distance required to travel to the training location (n = 33).
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1 drop-out (trial too time consuming) 
Invited to participate (n=377)
Excluded (n= 37) 
- No severe fatigue  (n= 25)  
- Wheelchair-bounded (n=8) 
- Illiteracy (n=2)  
- Other reasons (n=2)  Included n = 57 
Randomization 
FU (n=19) 
Not willing to participate (n= 199)  
No reaction (84) 
 
Assessed for eligibility n = 94 
FU (n=13)  FU (n=24)  
Discontinued trial (n = 4)  
 
Randomization 
Period 2 
Period 1 
Pre-Treatment (n=20) 
UC (n=24)  AET (n=20 ) CBT (n=13)  
Pre-Treatment (n=24) Pre-Treatment (n=13) 
Post-Treatment (n=19) Post-Treatment (n=24) Post-Treatment (n=13) 
FU (n=8) 
Pre-Treatment (n=8) 
AET (n=8 ) 
Post-Treatment (n=8) 
FU (n=12) 
Pre-Treatment (n=12) 
AET (n= 12) 
Post-Treatment (n=12) 
Of the 94 patients who were willing to participate, 57 met the inclusion criteria 
and were enrolled from January 2009 through February 2012. The nonparticipants 
were more often female than the participants (50% vs 35%, respectively) and were 
slightly less fatigued based on their SFQ scores (17.2 vs 19.7, respectively) (12). 
One participant in the AET group withdrew due to time constraints. 
In the UC group, 4 participants withdrew just before the second randomization 
because they thought that the intervention would be too time-consuming. Thus, 
after periods 1 and 2, the AET, CBT, and UC groups contained 28, 25, and 24 
participants, respectively. During the entire study period, the number of participants 
receiving co-interventions (physiotherapy only) and the number of physiotherapy 
sessions remained constant in all groups. 
In Table 2, the baseline characteristics are presented. Groups were similar 
at baseline with respect to demographics, clinical characteristics, amount of 
physiotherapy, and experienced fatigue. A Kruskal-Wallis one-way analysis of 
variance indicated that there were no differences between groups either for 
duration of fatigue (p = 0.37) or for duration of FSHD symptoms (p = 0.30). Post-
intervention, the median number of received AET sessions was 42 (range 0–48). 
Eleven AET participants (39%) did not achieve the level of acceptable adherence. 
The primary reason for non-adherence was time constraints. Across all AET 
sessions, the mean exercise time was 30 minutes (SD 1), the mean Borg score was 
12.8 (SD 0.3), the mean heart rate was 123 beats/min (SD 12), mean cardiovascular 
load was 53% HRR (SD 10), and mean work load was 71 Watt (SD 28). Eight 
participants reached the target training intensity of 65% HRR at the last session. 
The median number of received CBT sessions was 5 (range 1–13). Six CBT 
participants (24%) did not achieve the level of acceptable adherence. The most 
commonly applied modules concerned dysregulation of activity and dysfunctional 
cognitions.16 At follow-up, 20 AET and 19 CBT participants (71% and 76%, 
respectively) reported that they had continued their level of activity during the 
follow-up period.  
In Table 3 the observed medians and ranges are presented by group and point 
of measurement. Note that similar results are observed in period 2 compared to 
the first period. Especially, the baseline values are similar irrespective of group 
or period. Post-treatment, the mean experienced fatigue was lower in each 
intervention group compared to the UC group (AET: mean difference -9.1 {95% CI 
-12.4 to -5.8}, CBT: mean difference -13.3 {95% CI -16.5 to -10.2}). The beneficial 
effects were still present at follow-up (AET: mean difference -8.2 {95% CI -12.1 to 
-4.2}, CBT: mean difference -10.2 {95% CI -14.0 to -6.3}) (Table 4). 
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Post-treatment, 19 participants (76%) in the CBT group and 14 participants (50%) 
in the AET group were no longer severely fatigued, as reflected by a CIS-fatigue 
score, 35. The NNT for AET was 2.3 (95% CI 1.4– 3.1) with an ARR of 50% (95% 
CI 32–69%). The NNT for CBT was 1.3 (95% CI 1.1–1.7) with an ARR of 76% (95% 
CI 59–93%). Post-treatment, the mean sleep disturbances, the mean registered 
physical activity, and the mean experienced physical activity were significantly 
improved in the CBT group compared to the UC group. In the AET group, only 
mean registered physical activity was improved compared to the UC group at post-
treatment. The beneficial effects regarding mean registered physical activity in the 
AET and CBT groups were still present at follow-up. The level of social participation 
restrictions had significantly decreased in the CBT group compared to the UC 
group post-treatment and at follow-up (Table 4). 
Fifteen participants who had received AET reported 1 to 5 adverse events: 4 
participants had experienced knee pain, 9 saddle soreness, 7 neck and shoulder 
pain, and 6 back pain. All these complaints resolved spontaneously during the 
study period. No adverse events were reported by the participants who had 
received CBT. For the AET participants, mean fall rate was 0.11 (SD 0.23) times per 
week during the intervention period, and 0.08 (SD 0.16) times per week during the 
follow-up. For the CBT participants, mean fall rate was 0.10 (SD 0.21) times per 
week during the intervention period compared with 0.15 (SD 0.24) times per week 
during the follow-up. For the UC group, mean fall rate was 0.15 (SD 0.27) times per 
week. None of the falls occurred during an intervention session. No major injuries 
occurred as a result of falling.
DISCUSSION 
Consistent with our hypothesis, 16 weeks of CBT or AET was more effective than 
UC for reducing fatigue in patients with FSHD. After a 12-week follow-up without 
supervision, these beneficial effects remained, probably due to the fact that more 
than 70% of the AET and CBT participants continued their adjusted level of activity 
during the follow-up period. Remarkably, these 2 discrete interventions produced 
quantitatively similar beneficial effects on fatigue, even though the median number 
of therapy sessions was much lower in the CBT group than in the AET group. This 
result suggests that CBT is potentially more feasible and cost-effective than AET. 
As we expected, in the CBT group, all known fatigue-perpetuating factors (with the 
exception of pain) were positively modified. This finding might explain the higher 
social participation reported in the CBT group compared to the UC group. 
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In the AET group, the only change in fatigue-perpetuating factors was an increase 
in registered physical activity. Unexpectedly, we found no improvement in 
aerobic capacity. This lack of improved aerobic capacity might have been due to 
insufficient therapy compliance or to the fact that VO2 peak data were not available 
for the 6 and 14 participants who did not reach the target heart rate or were taking 
β-blockers, respectively. In addition, the absence of any significant change in 
isometric quadriceps strength or distance walked in the 6-minute walking test is 
most likely due to the fact that these capacities were not specifically trained in 
either treatment group (29). 
In this study, only mild adverse effects were found, which, together with an 
absence of pain increase during the intervention period, suggests that both AET 
and CBT are safe interventions in patients with FSHD.  
A limitation of this study is the potentially low generalizability as only 74 of the 
377 invited patients took part. Nevertheless, our study sample was sufficiently 
heterogeneous with respect to age, disease severity, physical endurance, and level 
of social participation.  
The adherence rate was lower than expected. Especially for AET, practical factors 
like travel time to the study sites and the fit of the exercise regimen in daily life 
accounted for the adherence rate being less than 100%. This study provides 
evidence that AET and CBT can effectively reduce chronic fatigue in patients with 
FSHD. Future research should focus on the specific factors that contribute to this 
beneficial effect to optimize patient selection. These studies may also include AET 
or CBT as part of a more comprehensive treatment program for patients with FSHD 
and use a longer follow-up period. Tailoring such an intervention program to the 
specific needs of each patient would meet one of the primary research priorities as 
identified by patients with a neuromuscular disease (30, 31).
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APPENDIX 1: PROTOCOL AEROBIC EXERCISE 
TRAINING  
The aerobic exercise training (AET) consisted of cycling exercise on an ergometer. 
The training program had a duration of 16 weeks and comprised home training 
twice a week and a supervised training by a physical therapist at the most nearby 
healthcare institution once a week. A cycle ergometer (Monark 827E), a pulse watch 
with breast belt (Garmin forerunner 50 heart rate), and a log book with training 
instructions were provided to each participant for home use. Training sessions 
consisted of a 30-minute aerobic exercise period with warming-up and cooling-
down periods of 5 and 3 minutes, respectively. The cardiovascular load during the 
training period was individually adjusted. Every four weeks, the level was increased 
with 5% from 50% to 65% of the heart rate reserve (HRR). HRR is the difference 
between the predicted maximum heart rate and the measured resting heart rate. 
Resting heart rate was measured during the baseline assessment. Maximum heart 
rate (MHR) was estimated using the formula: MHR = 220 - age. Each participant 
was taught how to adjust the physical load to the preferred individual heart rate. 
During each training, the heart rate was monitored continuously by the breast 
belt. Participants who were taking beta-blockers were instructed to exercise 
at a perceived exertion level of 12-14 on the Borg scale. Level of exertion was 
monitored by heart rate and the Borg visual analog scale. For patients with beta-
blocker medication, level of exertion was monitored by the Borg scale alone. The 
number and duration of the sessions, the Borg score, the mean and maximum 
heart rate, and any adverse effects were recorded in the individual log book. During 
the weekly sessions at the healthcare institution, therapy compliance in the home 
situation was verified by the physical therapist by reading out the heart rate watch 
and checking the log book regarding the previous week. In addition, individually 
tailored instructions for the next week were given. The primary investigator (NV) 
gave instructions to the physical therapists and performed integrity checks at each 
location. Acceptable compliance with the AET program was defined as a minimum 
of 40 completed training sessions. 
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APPENDIX 2:  THE VARIOUS MODULES OF 
COGNITIVE BEHAVIORAL THERAPY BASED 
ON THE FATIGUE-PERPETUATING FACTORS IN 
FSHD 
Insufficient coping with the disease 
Insufficient coping with the disease is assessed using the Impact of Event Scale 
(33, 34). A participant can continue to be mentally occupied with the diagnosis 
facioscapulohumeral muscular dystrophy (FSHD). By talking and writing about 
this experience (‘exposure’), the participant can acquire better coping skills. Fear 
of progression is assessed using a questionnaire designed specifically for FSHD 
patients. The therapist helps the participant formulate his or her thoughts regarding 
fear of progression. These thoughts are then challenged against reality (‘reality 
testing’), thereby reducing daily unhelpful thoughts regarding disease progression 
and putting these thoughts into perspective.  
Dysfunctional cognitions regarding fatigue, activity, pain, and other 
symptoms 
Dysfunctional cognitions are related to a variety of unhelpful thoughts, including 
the participant’s feeling of a lack of control over the symptoms and inappropriate 
thoughts regarding the symptoms. The sense of control in relation to fatigue 
complaints is assessed using the self-efficacy scale (35, 36). 
Catastrophizing  
Catastrophizing is assessed using the Jacobsen Fatigue Catastrophizing Scale 
(37). These thoughts are challenged, and more constructive thoughts are taught. 
Dysregulation of sleep  
Dysregulation of sleep is assessed using a self-reported sleep diary (38). An 
irregular circadian rhythm can be a perpetuating factor of fatigue. To restore normal 
biological rhythm, the participants are encouraged to maintain a fixed bed-time and 
wake-up time and are discouraged from sleeping during the day.
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Dysregulation of activity
Dysregulation of activity is based on activity (e.g. steps) and is monitored using 
an actometer and a physical activity questionnaire (Physical Activity Scale 
for Individuals with Physical Disabilities) (34,39). Some patients experience a 
fluctuating activity pattern, with highly active periods followed by periods of 
prolonged inactivity. Other patients avoid physical activity because they are 
concerned that it will increase their fatigue. For participants with fluctuating 
activity levels, a stable baseline level of alternating resting and active periods is 
first established. Once the participant has achieved this baseline level, a physical 
activity program is introduced, beginning with 5-10 minutes of walking or cycling. 
This activity is gradually increased by 1 minute a day each time the activity is 
performed, reaching a maximum of two 60-minute sessions per day. Inactive 
participants are instructed to commence this activity program immediately. 
Gradually, some physical activities can be replaced with other (preferred) physical 
activities. 
Poor social support and negative social interactions
Poor social support and negative social interactions are determined using the 
discrepancy subscale of the Social Support List (40). If a participant still has 
unrealistic expectations of others or perceives a discrepancy between actual 
support and desired support, the therapist will attempt to instill more realistic 
expectations with respect to the participant’s social support group. The partner or 
caregiver is included in this treatment module.  
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ABSTRACT
Facioscapulohumeral muscular dystrophy (FSHD) is an untreatable disease, 
characterized by asymmetric progressive weakness of skeletal muscle with fatty 
infiltration. Although the main genetic defect has been uncovered, the downstream 
mechanisms causing FSHD are not understood. The objective of this study was 
to determine natural disease state and progression in muscles of FSHD patients 
and to establish diagnostic biomarkers by quantitative MRI of fat infiltration and 
phosphorylated metabolites. MRI was performed at 3T with dedicated coils on 
legs of 41 patients (28 men/13 women, age 34–76 years), of which eleven were 
re-examined after four months of usual care. Muscular fat fraction was determined 
with multi spin-echo and T1 weighted MRI, edema by TIRM and phosphorylated 
metabolites by 3D 31P MR spectroscopic imaging. Fat fractions were compared 
to clinical severity, muscle force, age, edema and phosphocreatine (PCr)/ATP. 
Longitudinal intramuscular fat fraction variation was analyzed by linear regression. 
Increased intramuscular fat correlated with age (p<0.05), FSHD severity score 
(p<0.0001), inversely with muscle strength (p=0.0001), and also occurred 
subclinically. Muscles were nearly dichotomously divided in those with high 
and with low fat fraction, with only 13% having an intermediate fat fraction. The 
intramuscular fat fraction along the muscle’s length, increased from proximal to 
distal. This fat gradient was the steepest for intermediate fat infiltrated muscles 
(0.07±0.01/cm, p<0.001). Leg muscles in this intermediate phase showed a 
decreased PCr/ATP (p<0.05) and the fastest increase in fatty infiltration over 
time (0.18±0.15/year, p<0.001), which correlated with initial edema (p<0.01), if 
present. Thus, in the MR assessment of fat infiltration as biomarker for diseased 
muscles, the intramuscular fat distribution needs to be taken into account. Our 
results indicate that healthy individual leg muscles become diseased by entering a 
progressive phase with distal fat infiltration.
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INTRODUCTION 
Facioscapulohumeral muscular dystrophy (FSHD) is the third most common 
hereditary muscular disorder (1). The disease is characterized by progressive 
asymmetric weakness and fatty infiltration of skeletal muscles. In recent years it 
was demonstrated that FSHD is associated with a contraction of D4Z4 repeats 
on chromosome 4q35 (2), leading to lost repression of DUX4, a protein that exerts 
toxic effects on muscle cells (3). 
Even though the most important genetic event for the disease seems to be 
identified, a causative treatment is not yet available (4). Progress is hampered 
because the trigger for DUX4 expression and the further unfolding of disease 
processes leading to fatty infiltration and muscle weakness are not known. 
Thus clarification of the underlying mechanisms is expected to offer clues for 
a more targeted approach in the search for treatment (5). Understanding these 
mechanisms first requires that some key questions concerning the process of fatty 
infiltration are addressed. What is the natural distribution of fatty infiltration? How is 
this related to clinical severity, to muscle weakness and to energy metabolism? Is 
there prevalence for specific muscles to be affected and does fatty infiltration vary 
within muscles? What is the natural progression over time and what are predictive 
signs of progression? To answer these questions and to evaluate treatment 
effectiveness, the use of a non-invasive quantitative imaging method, such as MRI, 
is essential. Unlike biopsies, MRI is not limited to a single location, and longitudinal 
data can be collected without risk for the patient. MR of fatty infiltration in muscles 
has been used to study muscular disorders like Duchenne muscular dystrophy (6, 
7). We have introduced a quantitative MRI measure of fatty infiltration in muscles 
based on T2 relaxation time analysis and demonstrated its value in a preliminary 
study of FSHD patients (8). Phosphorus MR spectroscopy has been used 
extensively to investigate the energy status of diseased muscles (9-15). Recently it 
was also introduced in a pilot study with FSHD patients (16). 
Until now quantitative MR imaging studies were performed in limited numbers 
of patients. However, because of the variability in age of onset and in degree of 
disease severity (17), a study of its pathophysiology requires the participation of 
a relatively large number of well described patients. The main aim of this study 
was to determine natural disease state and progression by quantitative MRI of 
skeletal muscles in the legs of a large, well-characterized cohort of genetically 
confirmed FSHD patients. In particular we wanted to address the aforementioned 
pathophysiological questions to ultimately uncover clues on disease mechanism 
and to establish MRI biomarkers with prognostic and predictive value for 
personalized assessments. 
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MATERIALS AND METHODS 
PATIENTS AND STUDY DESIGN 
We recruited 41 FSHD patients from the local neurology department (28 men/13 
women, age 21–81 years, see Table 1 for patients’ demographics). Of 36 patients 
the upper leg (‘thigh’) was examined, they were selected from a group of patients 
that were entering a clinical trial to assess the effects of rehabilitation intervention 
(18). In addition we included the MR exams of the lower leg of five patients from a 
previous study (8), which were reanalyzed in the exact same way as the MR exams 
of the aforementioned patients (vide infra). 
Eleven patients (8 men/3 women, age 34–76 years) were randomly selected, 
from the group that underwent an MR examination of the thigh, for a follow-up 
measurement after a period of four months. During this period these patients were 
instructed to maintain a normal level of activity (‘usual care’). 
All patients were clinically and genetically diagnosed with FSHD and able to walk 
independently (ankle-foot orthoses and canes were accepted). Patients were all 
unrelated except for one mother and son (patients #7 and #37). Disease severity 
was assessed with the Ricci score (19) and maximum voluntary isometric extension 
(quadriceps) and flexion (hamstrings) of the knee were measured with a quantitative 
fixed myometry testing system (20). Ethical approval was obtained from the 
Radboud university medical center review board, and written informed consent was 
obtained from all subjects. 
Table 1 Patient demographics
Patient nr. Ricci score Sex Age (years) FSHD duration (years)
1 0 F 21 15
2 1.5 F 25 2
3 1.5 M 31 5
4* 2 M 34 3
5* 3 M 34 9
6 1.5 M 38 17
7 2 M 38 16
8* 3 M 38 19
9 1 F 39 5
10 3.5 M 42 32
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11* 2 M 44 14
12 4 M 48 40
13 3.5 M 49 14
14 1.5 F 50 1
15 1.5 F 50 6
16* 4 M 51 19
17* 3.5 M 52 9
18 4.5 F 53 24
19* 3 F 54 1
20* 1.5 M 55 21
21 2 F 55 2
22 2 F 56 22
23 3.5 M 56 17
24 4 M 57 41
25 4 M 57 41
26* 2 F 58 22
27 3 M 59 41
28 4 M 60 9
29 3 M 61 22
30 3.5 M 61 17
31 4 F 63 31
32 4 M 64 15
33 4 M 66 30
34 3 M 66 9
35* 4.5 F 66 49
36 3 M 66 6
37 3 F 68 12
38 2 M 69 Na
39 3 M 69 19
40 3.5 M 76 4
41* 3.5 M 81 3
*Underwent two MR exams four months apart, na = not available,
MR METHODS 
MR measurements were performed on a 3T MR system (TIM Trio, Siemens, 
Erlangen, Germany). Subjects were positioned feet first supine inside the magnet 
bore. Images were acquired with a home-built proton birdcage radiofrequency coil 
(inner diameter 25 cm). 
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In 36 patients, the least affected thigh, according to the subject’s own experience 
was examined, unless there were contraindications (e.g. a previous fracture or 
recent injury). A fish oil capsule was positioned at one third of the distance between 
the spina iliaca anterior superior and the patella and served as a landmark for exact 
matching of the imaging slices between the baseline and follow-up measurements. 
For the MR examinations of leg, the upper end of the proton coil was positioned at 
the center of the patella.  
MR imaging
Scout images were made in three orthogonal directions to position MRI slices for 
subsequent scans. The transmit frequency was set on the water resonance and the 
transmitter voltage was adjusted to the load. 
All imaging was performed in the transversal plane centered on the middle femur 
for the thigh, or the largest circumference for the leg. 
T1 weighted spin echo (SE) MR images were acquired first (field of view (FOV) 175 
x 175 mm; base resolution 384; repetition time (TR) 530 ms; echo time (TE) 16 ms; 
slices 23; slice thickness 4 mm; gap 0.4 mm). 
Turbo Inversion Recovery Magnitude (TIRM) images were collected with an 
inversion time (IT) to null the fat signals (FOV 175 x 175 mm; base resolution 256; 
TR 4000 ms; TE 41 ms; IT 22 ms; slices 23; slice thickness 4 mm; gap 0.4 mm) to 
visualize edema (21-23). To avoid inflow artifacts from venous and arterial blood, 
saturation bands were placed above the upper and below the lower slice (24). 
Subsequently, multi SE MR images were acquired (FOV 175 x 175 mm; base 
resolution 256; TR 3000 ms; 16 equally spaced TE’s 7.7–123.2 ms; slices 5–8, 
limited by specific absorption rate; slice thickness 6 mm; gap 9 mm). 
Phosphorus MR spectroscopic imaging (31P MRSI).
A 31P quadrature insert surface coil covered the quadriceps muscles of the thigh, 
and for the leg measurements a circularly polarized half volume 31P coil covered 
the calf musculature. A 3D 31P MRSI dataset was acquired after imaging (FOV 150 
x 150 x 200 mm; matrix-size 14 x 14 x 8 quadriceps/10 x 10 x 8 calf, TR 1000 ms; 
BIR45 adiabatic pulse for excitation; 12 averages; weighted k-space acquisition; 
nominal voxel volume 8.6 ml quadriceps/ 16.6 ml calf). Datasets were interpolated 
to a matrix size of 16 x 16 x 8.  C
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DATA ANALYSIS 
MR imaging
Each of the investigated muscles (see Figure 1) was analyzed separately. T1 
weighted images were scored for fatty infiltration using the four grade scale of 
Lamminen (25), by one experienced musculoskeletal radiologist (J.W.J.R). When a 
different score was awarded to the proximal and distal images the average score 
was used. 
Muscle area was assessed by drawing regions of interest (ROI’s) for every muscle 
on the center slice of the T2weighted MRI. Fat and muscle fractions were quantified 
from the multi SE MR images as described earlier (8). Note that normal fat fraction 
for healthy muscle does not exceed 10% (26). This method is not suitable when 
edema is present, as it will affect the tissues transverse relaxation properties. In 
those cases, T1 signal intensity (SI) and TIRM SI of the individual muscles were 
quantified by carefully drawing ROI’s in ImageJ (http://rsb.info.nih.gov/ij/) and 
normalized to bone marrow SI. 
To assess natural progression fat fraction differences were normalized to a period 
of one year for every patient (for every muscle) by dividing these fractions by the 
exact number of days between the baseline and follow up measurement, multiplied 
by 365.25.  
31P MRSI. 
From the middle slice of the 3D-MRSI dataset with the largest circumference, 
representative voxels were assigned to a specific muscle according to the 
corresponding T1weighted image overlaid with the MRSI grid. Only spectra with a 
sufficient signal-to-noise-ratio (SNR) (Cramer Rao Lower Bound (ƔATP) <30%) were 
included for further analysis. 
Free induction decays were zero-filled to double the number of points and 
apodized by 8 Hz with a Lorentzian line shape and manually phased using jMRUI 
4.0 (27). Peak areas were obtained from inorganic phosphate (Pi), PCr (fitted 
to a Lorentzian line shape), and ATP (fitted to a Gaussian line shape), using the 
AMARES algorithm (28) with prior knowledge on the relative line width, frequency 
and amplitude. 
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Figure 1 Typical transversal T1 weighted and TIRM MR images of FSHD 
patients 
(A) Transverse T1 weighted image of the thigh of a male FSHD patient (age 38), showing 
fatty infiltration (hyperintense signal) in the semimembranosus and semitendinosus muscles. 
(B) Transverse T1 weighted image of the leg of a male FSHD patient (age 66 year). Fatty 
infiltration of the soleus muscles is clearly visible. (C) Transverse T1 weighted image of 
the thigh of a 39-year-old male FSHD patient. (D) Corresponding TIRM image. The semi-
membranosus is clearly fat infiltrated (grey striped arrow), this results in a nulled signal on 
the corresponding TIRM image. In contrast, the vastus lateralis and vastus intermedius show 
hyperintense signal in the TIRM images (white arrows) reflecting edema or inflammation. The 
different muscles in the thigh (Figure 1A) and calf (Figure 1B) are indicated by the following 
abbreviations: rectus femoris (RF), vastus lateralis (VL), vastus intermedius (VI), vastus 
medialis (VM), sartorius (S), adductor longus (AL), adductor magnus (AM), gracillis (G), semi 
membranosus (SM), semitendinosus (ST), biceps femoris long head (BFL) and biceps femoris 
short head (BFS), tibialis anterior (TA), extensor digitorum, longus (EDL), peroneus brevis (PB), 
tibialis posterior (TP), soleus medialis (SOM), soleus lateralis (SL), gastrocnemius medialis 
(GM) and gastrocnemius lateralis (GL).C
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Metabolite ratios: PCr/ATP and Pi/ATP were evaluated to avoid coil profile 
variations. The pH was calculated from the Pi- PCr frequency shift (29). The value 
of each parameter was averaged for all analyzed voxels in one muscle and this 
value was used for further analysis.   
STATISTICS 
Statistical analyses were performed with Prism 5.0 (GraphPad Software, San Diego, 
California, USA). Non-parametric one-way-ANOVA (Kruskal-Wallis test) was used 
to investigate differences in the average fat fraction between muscles, with Dunn’s 
Multiple Comparison Test as post-hoc test. One-tailed correlation analyses were 
performed between fat fraction and patients’ age, duration of disease, radiological 
score, Ricci-scores, maximum voluntary force, PCr/ATP, Pi/ATP, and pH. Linear 
regression analysis was used to assess the distribution of fatty infiltration over the 
length of the muscle. Outcome parameters in this analyses are the slope of the 
line, indicating the direction of fatty infiltration over the length of the muscle, and 
the coefficient of determination (R2), indicating to what extent fat fraction increases 
or decreases linearly over the length of the muscle. One-way ANOVA was used to 
investigate dependence of fat fraction progression on initial muscle fraction.  
T1 SI difference was compared between muscles normal and hyperintense TIRM 
images with a one-tailed t-test, and correlation was investigated with linear 
regression.
RESULTS 
MUSCULAR FAT INFILTRATION, EDEMA, CLINICAL GRADING AND 
MUSCLE STRENGTH IN FSHD  
Fat infiltration in skeletal muscles is visible as hyperintense areas on T1 weighted 
MR images (Figure 1A–C). This may be accompanied by edema, which can be 
identified independently from fatty infiltration by TIRM images (Figure 1D). In 41 
FSHD patients we investigated 446 leg muscles, of which 4.3% showed edema, 
which was mostly present in the quadriceps muscles. 
The quantitative assessment of muscular fat fraction revealed that 262 of the 
remaining 427 muscles were normal or mildly fat infiltrated (<0.25 fat fraction), 
54 were intermediately fat infiltrated (between 0.25 and 0.75 fat fraction) and 111 
muscles were severely infiltrated (>0.75 fat fraction). A fat fraction distribution 
plot resulted in a typical hourglass shape (Figure 2A). Significant differences 
were observed in average fat fractions of thigh muscles (p<0.01), in particular the 
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semimembranosus had a significant higher fat fraction than the vastus lateralis and 
vastus medialis (Figure 2B).  
Average fat fraction correlated positively with patients’ age (p<0.05, R2 =0.15) 
(Figure 3A) and FSHD duration (p<0.0001, R2 = 0.54), (Figure 3B). Slopes of the 
correlations were not significantly different between muscles (Figure 4 and 5). The 
average yearly increase in fatty infiltration was 0.8+/-0.4% for age and 1.9+/-0.3% 
for FSHD duration. 
The average fat fraction showed a strong correlation with radiological scores 
(p<0.0001, R2 = 0.70) (Figure 3C) and with overall clinical Ricci score for FSHD 
severity (p<0.0001, R2 = 0.90) (Figure 3D). The fat fraction deviated from normal at 
Ricci score 2 (a subclinical event as this score excludes leg muscle involvement) 
and further increased at higher Ricci scores. Muscle fraction multiplied by the 
muscle area significantly correlated with muscle strength for the quadriceps and 
hamstring (p<0.0001, R2= 0.57) (Figure 3E). 
Figure 2 Distribution of naturally occurring fat fraction of the thigh muscles of 
a large cohort of FSHD patients.
(A) Fat fraction distribution over all muscles. Fat fraction of 0 signifies 100% muscle, 1 
indicates 100% fat. Muscles with an intermediary fat fraction (>0.25 and >0.75) are observed, 
in ~13% of the investigated muscles. (B) Involvement of individual thigh muscles in FSHD. 
Average fat fraction of 36 patients. Error bars (SEM) reflect the high variability in this fraction 
between patients. The SM appears to be the most affected muscle of the upper leg, having 
a significantly higher average fat fraction (0.54±0.41) compared to the VL or VI (0.20±0.29, 
0.20±0.27, respectively). Note that fat fractions are not Gaussian distributed therefore 
reporting only mean±error values is not a good representation of the data.
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Figure 3 Correlation of fat or muscle fraction, determined by quantitative MRI, 
with clinical scores
(A) Correlation between age of the patient and average fat fraction of the thigh (p<0.05, 
R2 = 0.15). (B) Average fat fraction of the thigh and FSHD duration are highly correlated 
(p<0.0001, R2 = 0.54). (C) Fat fraction highly correlates with the radiological Lamminen score 
of the corresponding muscle (p<0.0001, R2 = 0.70). (D)  Quantitative fat fraction of lower limb 
correlates with patients Ricci score (p<0.0001, R2 = 0.90). Fat fraction starts to increase above 
normal levels at  Ricci score 2. The high standard deviation depicted in the error bars signifies 
the large variation in fat fraction determined in the limb and the appointed Ricci score. (E) 
Correlation between muscle fraction (1-fat fraction) and force of quadriceps and hamstring 
muscle groups (p<0.0001 and R2 = 0.76).
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Fat fractions and age
Figure 4 Correlation between fat fractions and age for the individual thigh 
muscles
Solid line gives best linear correlation with 95% confidence interval indicated by the dotted 
lines. Slopes of the lines were statistically tested to identify possible differences between 
the muscles. However analyses showed no significant differences. VL =vastus lateralis, VI 
= vastus intermedius, RF = rectus femoris, VM= vastus medialis, BFS biceps femoris short 
head, BFL= biceps femoris long head, S = sartorius, G= gracillis, ST= semitendinosus, SM= 
semimembranosus, AM= adductor magnus, AL =adductor longus.  
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Fat fractions and FSHD duration
Figure 5 Correlation between fat fractions and disease duration for the 
individual thigh muscles
Solid line gives best linear correlation with 95% confidence interval indicated by the dotted 
lines. Slopes of the lines were statistically tested to identify possible differences between 
the muscles. However analyses showed no significant differences. VL= vastus lateralis, VI= 
vastus intermedius, RF= rectus femoris, VM= vastus medialis, BFS biceps femoris short 
head, BFL= biceps femoris long head, S= sartorius, G= gracillis, ST= semi tendinosus, SM= 
semimembranosus, AM= adductor magnus, AL= adductor longus.  
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INTRAMUSCULAR FAT DISTRIBUTION  
Visual inspection of MR images revealed that the fat fraction was often not evenly 
distributed over the length of the muscle (Figure 6). Muscle with an intermediate fat 
fraction showed the steepest fatty infiltration gradient over the length of the muscle 
(7±1% cm-1, mean±SEM). This value was significantly higher compared to muscles 
that were normal or mildly fat infiltrated (1.3±0.3% cm-1, p<0.0001) and those that 
were heavily infiltrated by fat (1.1±0.1% cm-1, p<0.0001). Overall fat fraction rose 
from proximal to distal.  
Figure 6 Intramuscular distribution and progression of fatty infiltration
Transversal T1 weighted images at different positions of the thigh of a FSHD patient. Baseline 
measurement (left panels) reveals an uneven distribution over the length of the muscle with an 
increasing fat infiltration from proximal (top) to distal (bottom), especially prominent in the VM, 
VI, AM. This fatty gradient was largest in intermediate fat infiltrated muscles, as was shown 
by the linear regression analyses. These intermediately fat infiltrated muscles also showed the 
largest increase in fatty infiltration over time. From the follow-up measurement (right panels) it 
is clear to see that fat is increasing distally. AM= adductor magnus; BFL = biceps femoris long 
head; VI = vastus intermedius; VL = vastus lateris; VM= vastus medialis.C
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NATURAL PROGRESSION OF FATTY INFILTRATION 
The natural progression of fatty infiltration was investigated for 85 muscles of 
eleven patients. An average increase in fat fraction of 0.054±0.12 per year was 
observed. In intermediately affected muscles (n =12) the progression of fatty 
infiltration was much faster (0.18±0.15 per year) as compared to heavily fat 
infiltrated muscles (0.00±0.10 per year, n= 20) and to normal to mildly infiltrated 
muscles (0.043±0.10 per year, n =53). Natural progression in fat infiltration 
depended on the initial muscle fraction (p<0.01) and appeared to increase from 
distal to proximal (Figure 6). 
Six muscles, in two patients, showed hyperintensity on the baseline TIRM images, 
indicating edema. The T1 SI difference between baseline and follow up exam, 
representing fat infiltration, was significantly different in muscles with hyperintense 
signal on baseline TIRM images compared to TIRM normal muscles (n= 14) of 
the same patients (p<0.01) (Figure 7). Linear regression analysis showed a trend 
between the TIRM SI and the difference in T1 SI (p<0.1, R2 = 0.1). 
Figure 7 The presence of edema, as identified by TIRM imaging, correlates 
with increased fatty infiltration, as reflected in changes in T1 
weighted images
(A) TIRM and T1 weighted images of a 76 year-old male FSHD patient. (B) TIRM and T1 
weighted images of a 39 year-old male FSHD patient. (A–B.1) VL(*) and VM(**) muscles of 
two FSHD patients show hyperintensity on TIRM images, indicating edema. (A–B.2) Baseline 
T1 weighted images. (A–B.3) Follow-up T1 weighted images showing an increase of fatty 
infiltration after about 4 months in the VL(*) and VM(**) muscles. (C) SI difference between 
baseline and follow-up T1 weighted images is significantly different in TIRM hyperintense 
FSHD muscles (N = 6) compared to TIRM normal FSHD muscles (n = 14) (p<0.01).
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HIGH-ENERGY PHOSPHATE METABOLITES 
Analysis of phosphate metabolites by 31P MRS revealed that the PCr/ATP ratio 
correlated with the fat fraction of the specific muscle (quadriceps p<0.05, R2  
= 0.06, calf p<0.01, R2 = 0.33). This PCr/ATP ratio is significantly decreased in 
the intermediately fat infiltrated muscles compared to muscles with a normal fat 
fraction (p<0.05), but was not further decreased in muscles with a high fat fraction 
(Figure 8A). The PCr/ATP ratio also correlated with muscle force (p<0.001, Figure 
8B). 
Figure 8 High-energy phosphates in the different stages of fatty infiltration and 
correlation with muscle force
(A) Representative phosphorous MR spectra of VL muscle of FSHD patients, upper with a 
normal fat fraction, lower with a high fat fraction. (B) PCr/ATP decreases with fat fraction 
(mean+/-SD). In intermediately fat infiltrated muscles the PCr/ATP is already decreased 
significantly from 4.15±1.00 to 3.57±0.88. Completely fat infiltrated muscles do not show 
a further decrease of this ratio. (C) Significant correlation between PCr/ATP and muscle 
strength (p<0.001, R2 = 0.29). Pi = inorganic phosphate; PCr = phosphocreatine; ATP = 
adenosine triphosphate.C
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DISCUSSION 
In this study we identified three distinct phases of fat infiltration in lower limb 
muscles of FSHD patients by quantitative MR. An analysis of the average fat 
fraction for all individual muscles uncovered an hourglass pattern of many muscles 
with either very  here  low or high fat, and few muscles with an intermediate fat 
fraction. 
This quasi-binary distribution has not been reported for other muscular dystrophies 
(7) and may be FSHD specific. The intermediate phase is most characteristic, 
showing a relative steep fat gradient over the length of the muscles, an altered 
energy metabolism and rapid progression of fatty infiltration. 
For other dystrophies often average values of all subjects or muscles are 
presented, which obscures the presence of a specific distribution. The average fat 
fraction as calculated over all investigated muscles in this study (0.3±0.1), actually 
only was present in 36 out of 427 muscles. Fat fractions were highest in the semi 
membranosus, semitendinosus and adductor muscles as has been previously 
described by Wattjes et al. (21). The vastus muscles were largely preserved. 
We found that in leg muscles the intramuscular fat fraction increased linearly from 
proximal to distal, as was also observed in a pilot study of only the lower leg (8). 
The steepest fat gradient occurred in the intermediate affected muscles indicating 
that these muscles are progressing towards a complete fat infiltrated state. This 
interpretation is supported by the follow-up measurements, which revealed that 
intermediate affected muscles were most prone to increase their fat-muscle ratio. 
In these muscles the average increase of this ratio was about 10% in four months. 
This may seem fast for a disease that is characterized by slow progression, but 
we observed it in only a relative small fraction of muscles. The quasi-binary fat 
distribution of muscles in FSHD patients mentioned above also indicates that 
relative rapid transitions occur. Moreover, a sudden disease progression within 
individual muscles is in accordance with the often reported observation in FSHD 
patients of periods of rapid deterioration of single muscles or muscle groups, 
interrupting long stable periods (30, 31). In some cases the lower performance of 
a single muscle may be compensated by unaffected synergistic muscles, which 
would clinically mask its dysfunction (32, 33).
Assuming that replacement of muscular tissue by fat occurs at a constant rate 
after entering this intermediate phase, fat replacement of entire muscles will, on 
the average, be completed within approximately three and a half years. This can be 
relevant for prognostication and monitoring therapy effectiveness in FSHD. There 
is no report on fat gradients over the length of muscles in other neuromuscular 
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disorders, which may be FSHD specific. Recently, a muscular fatty content gradient 
was also found in inherited poly-neuropathy, but this was not associated with 
disease progression (34). 
The low percentage of muscles involved in a rapid progression towards complete 
fatty infiltration indicates that this process is triggered by an infrequent event. The 
nature of this event is unknown, but the initial relatively high distal level of fatty 
infiltration and the differences between muscles suggests a local origin. This is in 
agreement with findings that only 0.1% of muscle nuclei express DUX4 in FSHD 
patients (35). A recent paper by Tassin and colleagues (36) describes a model of 
initiation and propagation of a transcriptional cascade, which provides an elegant 
explanation for our observation of a gradient of fatty infiltration and fast progression 
in intermediate fat infiltrated muscles. In this model the activation of the DUX4 
gene in (one or) few myonuclei yields DUX4 protein molecules that diffuse into the 
cytoplasm towards neighboring nuclei where they activate target genes, which 
causes expansion into a transcriptional cascade of dysregulation. Because of the 
multinucleated nature of myofibers this model predicts a gradient of dysregulation 
over the length of muscles. The amplification of DUX4 gene activation into a 
transcriptional cascade may also explain the fast progression observed in the 
intermediate fat infiltrated muscles. Preferential involvement of particular muscles 
(e.g. semimembranosus) and distal initiation may hide clues towards the initial 
DUX4 gene activation trigger. Our finding that MR visible fat content increases 
more in the case of initial edema supports the involvement of inflammation in early 
disease onset, as TIRM positive muscles are associated with muscle inflammation 
(21-23, 37-39). However, whether inflammation is cause or consequence of DUX4 
transcription in the initiation process remains unclear. 
The correlation between increased fat fraction and lower strength of skeletal 
muscles is coherent with the loss of muscle mass and also explains the (weak) 
relation with the age of the patients. Clinical severity scores (Lamminen (25) and 
Ricci (19) strongly correlated with fat fraction, but abnormal high fat fractions were 
also present in lower limb muscles without clinical symptoms, as was observed 
in patients with Ricci score 2 (excludes lower limb involvement). Thus, imaging 
fatty infiltration is a potential tool to predict clinical muscle affliction (32, 33). The 
extent of edema in our study (4.3%) is somewhat lower than reported in two recent 
FSHD studies, that however, included more muscles per patient and more severely 
affected patients (23, 39, 40). 
The lower PCr/ATP ratios observed in intermediately fatty infiltrated muscles 
suggest an early change in high-energy phosphate metabolism in disease C
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development. Lower steady state PCr/ATP ratios were also found in muscles 
of Becker and Duchenne patients (10, 41). This may represent a lower cellular 
(phospho)creatine pool due to a lower energy state. Alternatively, it may represent 
a change in fiber type composition, if the fraction of oxidative fibers, which have 
lower PCr/ATP ratio’s (42, 43), increase due to preferred involvement of type 
II fibers. This is supported by histological findings of biopsies, showing more 
dominant type I fibers among the remaining fibers in FSHD affected muscles (44) 
and is also congruent with the correlation between PCr/ATP and muscle force. 
Taking muscle biopsies remains the gold standard to examine muscular 
dystrophies, but this is invasive, painful, restricted to a limited number of biopsy 
sites and only provides focal information. 
As observed in the present and a previous study (8) fatty infiltration is very 
heterogeneous, both between and within muscles, which demonstrates the need 
to know in advance which (part of a) muscle is affected, to acquire representative 
tissue. Our study indicates that MRI guidance in taking muscle biopsies is needed. 
Other common imaging techniques have disadvantages, such as radiation 
exposure in computer tomography, or poor signal to noise and limited penetration 
depth in ultrasound. In clinical trials muscle strength is often assessed to evaluate 
treatment effects, but this may show a placebo effect (45). Muscular fat fraction 
determined by MRI does not involve a placebo effect.  
A limitation of our study was the lack of including a component for the presence 
of edema in the T2 analysis. However, we identified muscles with edema by TIRM 
and excluded the very small fraction of edematous muscles from this T2 analysis. 
Progression of fatty infiltration in these muscles was then derived from T1 images. 
Furthermore, we chose to investigate lower extremity muscles in these patients 
even though FSHD is a disease known to first involve the facial and scapular 
muscles. However, for this study we aimed for the highest image quality, which 
could be achieved with a dedicated coil for the lower extremity. To compare 
different disease phases we had to introduce fat fraction cut-off values, for which 
we chose 25% and 75% of fatty infiltration. Shifting these values by 65% did not 
change the main results of this study.
In conclusion, this study established fat fraction as assessed by MR imaging as 
an objective quantitative and sensitive biomarker for muscular affliction in FSHD, 
detecting even subclinical muscle involvement. This MR biomarker may serve 
to predict disease progression, to guide biopsies and to evaluate treatments to 
preserve or improve muscle performance. Importantly, in these applications the 
intramuscular fat distribution may have to be taken into account. Our data suggest 
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a specific sequence of events that leads towards full muscle pathology in FSHD, 
in which muscles first progress from normal to being distally fat infiltrated, with an 
altered metabolic profile, after which fat rapidly infiltrates the whole muscles. This 
process of disease unfolding may direct new treatment strategies.  
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ABSTRACT 
Objective: 
To investigate the effects of aerobic exercise training (AET) and cognitive 
behavioral therapy (CBT), directed towards an increase in daily physical 
activity, on the progression of fatty infiltration and edema in skeletal muscles of 
facioscapulohumeral muscular dystrophy (FSHD) type-1 patients by T2-MRI.
Methods: 
Quantitative T2-MRI (qT2-MRI) and fat-suppressed T2-MRI of the thigh were 
performed at 3 Tesla on 31 patients, of whom 13 received usual care (UC), 9 AET, 
and 9 CBT. Muscle-specific fat-fractions (%), derived from qT2-MR images, were 
recorded pre- and post-treatment. Intervention effects were analyzed by comparing 
fat-fraction progression rates of the UC with the treated groups using Mann-
Whitney tests, and intermuscle differences by a linear mixed model. Edematous 
hyper-intense lesions were identified on the fat-suppressed T2-MRI.
Results: 
The intraclass correlation-coefficient for reproducibility of qT2-MRI fat-assessment 
was 0.99.  In the UC group the fat-fraction increased with 6.7/year (95% CI: 4.3 to 
9.1).  This rate decreased to 2.9/year (95%CI: 0.7 to 5.2) in the AET (p=0.03) and 
1.7/year (95%CI:-0.2 to 3.6) in the CBT group (p=0.00015). The treatment effect 
differed among individual muscles. Less new edematous lesions occurred after 
therapy. 
Conclusion: 
Fat-fraction derived from qT2-MRI is a reproducible and sensitive biomarker 
to monitor the effects of increased physical activity in individual muscles. This 
biomarker reports a favorable effect of AET and CBT on the rate of muscular 
deterioration in FSHD as reflected in decelerated fat replacement. 
Classification of evidence: 
This study provides Class II evidence that for patients with FSHD type 1, both AET 
and CBT decrease the rate of fatty infiltration in muscles.
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INTRODUCTION 
Facioscapulohumeral muscular dystrophy type-1 (FSHD) is one of the most 
frequently occurring myopathies (1).  It is characterized by asymmetric progressive 
loss of muscle strength and increased fatigue and proceeds with transient edema 
and fatty infiltration in skeletal muscles (2-4). Although the main genetic origins for 
FSHD are understood and molecular targets for treatment have been proposed, no 
cure is available yet (5, 6).
Recent randomized clinical trials (RCTs) demonstrated a positive effect of aerobic 
exercise training (AET) and cognitive behavioral therapy (CBT) on fatigue and 
physical activity (7) and of AET on physical fitness and walking distance (8) in FSHD 
patients.  However, outcome measures for muscle strength did not show treatment 
effects (7-10). Thus, more sensitive quantitative biomarkers at the level of individual 
muscles are needed to monitor therapies.
Fat infiltration and edema in muscles can be detected by T2-MRI (11-13). We 
presented fat-fraction determined with quantitative T2-MRI (qT2-MRI) as a non-
invasive biomarker for affected muscles in FSHD patients and showed that it 
highly correlates with clinical severity and muscle strength (14). Moreover, this 
biomarker has prognostic value and allows to detect subclinical involvement and 
to follow disease progression in individual muscles (15). Hyperintense areas on 
fat-suppressed T2-weighted MRI’s of muscles, reflecting edema indicative of 
inflammation (16), have been shown to precede fatty replacement in FSHD muscles 
(15, 17). Thus, T2-MRI biomarkers seem to be suited to objectively monitor the 
effects of physical activation therapy in FSHD. Therefore, we examined if qT2-
MRI with fat-fraction as biomarker can detect an effect of AET and CBT on the 
progression of fatty infiltration in individual thigh muscles of FSHD patients.  
METHODS 
STUDY OBJECTIVES 
The primary objective of this study was to evaluate the effect of 16 weeks of AET 
or CBT on the rate of fatty infiltration in thigh muscles of patients with FSHD type 1 
(level of evidence: Class II). 
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STANDARD PROTOCOL APPROVALS, REGISTRATIONS, AND 
PATIENT CONSENTS
We invited all patients included in the FACTS-2-FSHD randomized controlled trial 
to take part in the present MR study. This trial aimed to assess the effects of AET 
and CBT on fatigue in FSHD (18). For all patients, the FSHD type-1 diagnosis 
was confirmed by DNA tests with verification of the 4q35 deletion (19). Exclusion 
criteria, in addition to those for the RCT, were MR contraindications such as 
claustrophobia or the presence of a pacemaker (18).
STUDY SETUP
The RCT was listed in the Dutch Trial Register (NTR1447) and its design was 
published (18).  Each participant was randomly allocated to usual care (UC), 
AET, or CBT using computer-generated randomization by an independent health 
professional who was blinded for the allocation sequence. 
Baseline demographics (age and gender) and FSHD severity (10-grade clinical 
severity scale (CSS)) (20) were collected. All clinical and MRI measurements were 
performed at the Radboud University Medical Center by two experienced physical 
therapists and two experienced MRI technicians, respectively, who remained 
blinded for treatment allocation throughout the study. MRI exams were performed 
at baseline and at follow-up, which is 12 weeks after the baseline MR in the UC 
group and 16 weeks therapy plus 12 weeks of UC after the baseline MR in the AET 
and CBT groups. This ensures that all three groups had equal usual care periods 
before the follow-up MR exam.
INTERVENTIONS 
The therapy interventions were delivered at nine healthcare centers across the 
Netherlands (18). Participants in the AET group were asked to cycle three times 
a week for 30 minutes on an ergometer. During successive training sessions 
exercise intensity was gradually increased from 50 to 65% of heart-rate reserve. 
Cardiovascular load and compliance were continuously monitored. The CBT 
intervention was given by a cognitive behavioral therapist and consisted of six 
modules which were directed at the known perpetuating factors of fatigue in 
FSHD: insufficient coping with the disease; dysfunctional cognitions regarding 
fatigue, activity, pain, or other symptoms; fatigue catastrophizing; dysregulation of 
sleep; poor social support and/or negative social interactions. For every patient, 
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a physical activity program was included, starting with 5 to10 minutes of walking 
or cycling, gradually increasing with 1 minute every day, reaching a maximum of 
two 60-minute sessions per day. The participants in the UC group received care 
as usual which in most patients was no treatment or occasional (conventional) 
physical therapy. 
PHYSICAL CAPACITY MEASURES
Participants were asked to wear an actometer around the ankle for 12 consecutive 
days (21). Physical activity was averaged over the 12-day period and expressed 
as the average number of accelerations per 5-min intervals (22). Aerobic exercise 
tolerance (VO2max in ml/min) was estimated using the Åstrand-Rhyming protocol 
(23). In addition, the distance covered in a six-minute walk test (6MWT) was 
recorded (24).
MRI ACQUISITION
MRI examinations were performed of the least affected thigh on a 3 Tesla MRI 
system (TIM Trio, Siemens, Erlangen, Germany) as described previously (15). A 
fish oil capsule, positioned at one third of the distance between the spina iliaca 
anterior superior and the patella, served as a landmark for slice matching between 
the baseline and follow-up measurements. Scout images were acquired in three 
orthogonal directions to position the MRI slices of the subsequent scans. 
The protocol consisted of transversal quantitative T2 multi-slice, multi-spin-echo 
MR imaging (qT2-MRI) and turbo inversion recovery magnitude (TIRM) imaging 
with an inversion time (TI) to null fat signals. The qT2-MRI was performed with 16 
echo times between 7.7 and 132.2 ms of up to 8 slices with a thickness of 6 mm. 
The field of view (FOV) was set at 175x175 mm for all scans. To determine the 
reproducibility of our fat-fraction measurement procedure, the qT2-MRI exam was 
repeated in eight patients after a minimum of one hour and a maximum of one day 
after the first measurement.
MRI POST-PROCESSING 
The qT2-MR images were analyzed offline with an IDL program (ITT Visual 
Information Solutions, Boulder, USA, v6.2) developed in-house (14). To compute 
separate fat and muscle images, the signal intensity of every smoothed pixel was 
fitted to a bi-exponential function with fixed proton relaxation times for fat (143 
ms) and muscle (40 ms). For each muscle, regions of interest (ROI) were carefully 
drawn on the T2-weighted MR images. ROIs were selected for the rectus femoris 
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(RF), vastus lateralis (VL), vastus intermedius (VI), vastus medialis (VM), sartorius 
(S), adductor longus (AL), adductor magnus (AM), gracilis (G), semimembranosus 
(SM), semitendinosus (ST), biceps femoris long head (BFL) and biceps femoris 
short head (BFS) (Figure 1). Subsequently, the mean fat-fraction (%) for every ROI 
was calculated. To assess the reproducibility of the fat-fraction determination the 
duplicate qT2-MRI acquisitions were subjected to the same procedure. 
To ensure that edema would not interfere with the bi-exponential fitting, TIRM 
images were manually checked for high-intensity zones (MRI signature of edema). 
Muscles images showing such hyperintense areas were excluded from the qT2-
MRI analysis. 
Figure 1 Transversal T2-weighted MR images of the thigh of a 34 year old male 
FSHD patient receiving usual care, obtained at baseline (A) and at 
12-weeks follow-up (B)
AM = adductor magnus; BFL = biceps femoris long head; BFS = biceps femoris short 
head; G = gracilis; RF = rectus femoris; S = sartorius; SM = semimembranosus; ST = 
semitendinosus; VI = vastus intermedius; VL = vastus lateralis; VM = vastus medialis. Regions 
of interest (dashed lines) are drawn on the images of individual muscles to determine muscle-
specific fat-fraction. At baseline infiltrated fat is mostly seen in the BFL (30%), G (45%), ST 
(80%), SM (96%) and AM (16%). The average fat-fraction of the thigh muscles, determined 
by qT2-MRI, increased from 2% at baseline to 9% at follow-up, but the progression rate 
depended on the muscle. For example, the fat-fraction of the ST muscle increased by 11% 
to 91% at follow-up, while no progression was observed in the VI, of which the fat-fraction 
remained stable at 2%. 
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STATISTICS 
Pearson correlation analyses were performed between fat-fraction of the whole 
thigh musculature and the physical capacity measures using Prism 5.0 (GraphPad 
Software, San Diego, California, USA). For the test-retest reliability of the muscle-
specific fat-fraction measurements by qT2-MRI, the intraclass correlation 
coefficient (ICC) was computed (25). 
Treatment effects were assessed in two ways. As they are not Gaussian distributed, 
the average changes in fat-fractions per year in the intervention groups were 
compared to those obtained for the UC group with one-tailed Mann-Whitney tests 
(15). A linear mixed model for repeated measurements was used to assess effects 
on muscle-specific fat-fractions, with treatment (three levels: UC, AET, CBT) as 
the independent class variable and time (weeks since baseline measurement) and 
baseline fat-fraction as the independent continuous variable. In addition, interaction 
terms for treatment x baseline fat-fraction and treatment x time were included. 
Because we found no statistical significance for the interaction between treatment 
and baseline fat-fraction, the latter term was omitted from the model. In the UC 
group, regression per year was calculated using the data of the two measurement 
points. For the AET and CBT groups, the estimated difference in change per year, 
with 95% confidence intervals (CI) and corrected for pre-treatment values, was 
compared to the UC group values. These analyses were performed by using IBM 
SPSS Statistics for Windows, version 20.0 (IBM Corp, Armonk, New York, USA). 
Statistical significance was set at p<0.05.
RESULTS 
SUBJECTS 
Of the 57 patients asked to join 44 finally entered the MR study. The main reason 
for not willing to participate was claustrophobia. Twelve patients were not available 
for the follow-up MRI measurement (5 for personal reasons and 7 because of 
logistic problems).  The data for one patient was discarded because of movement 
artifacts in the MR images. Hence, for 31 patients complete datasets were 
collected, with 13 patients having received UC, 9 AET and 9 CBT. Demographics 
and clinical characteristics of the patients are presented in Table 1. A Kruskal-
Wallis one-way analysis of variance revealed no differences in age and clinical 
characteristics between the participants and non-participants of the (complete) 
MRI study. 
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BASELINE MRI RESULTS
From the MR images of the thigh of each of the 31 included patients 11 individual 
muscles were analyzed (Figure 1). In total 341 muscles were analyzed of which 19 
muscles showed hyper-intense signals on TIRM images, suggestive of edematous 
inflammation (Table 2). 
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Table 1 Demographics and baseline characteristics of FSHD patients
MRI
 All NP/NA All UC AET CBT
Number of patients 57 26 31 13 9 9
Male/female 37/20 15/11 22/9 10/3 7/4 8/3
Age (years) 52±14 50±14 53±14 53±15 56±15 53±12
CSS 2.8±1.0 2.8±1.1 2.8±1.0 3.0±0.9 3.1±1.1 2.3±1.0
Actometer (5 min-1) 39±16 36±16 42±15 43±16 40±16 43±14
6MWT (m) 423±148 416±133 428±167 455±169 386±147 456±190
Fat-fraction (%) NA NA 30±35 30±35 32±36 28±36
Adherence (%) 66 60 78 NA 89 67
UC = usual care, AET = aerobic exercise therapy, CBT = cognitive behavioral therapy, CSS = clinical 
severity score, 6MWT = six-minute walk test, NP/NA = non-participant/not available for MRI study. 
Except for number of patients and male/female all values are mean ± SD. Acceptable adherence with the 
AET program was defined as completion of a minimum of 40 training sessions. Acceptable adherence 
with the CBT program was defined as completion of a minimum of 3 sessions. 
Table 2 Number of hyper-intense lesions identified on TIRM MRI for the usual 
care and intervention groups
Baseline Present at baseline 
and follow-up
New at follow-up Total at follow-up
UC 8 6 7 13
AET 3 2 0 2
CBT 8 5 2 7
TIRM= Turbo Inversion Recovery Magnitude, UC= usual care, AET= aerobic exercise therapy, 
CBT= cognitive behavioral therapy.
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The analysis of the qT2-MR images revealed that fat-fractions of the remaining 
muscles (i.e. those with no TIRM lesions) ranged from 2 to100 percent. Some 
patients presented without any abnormal fatty infiltration of the thigh muscles, 
whilst others showed severe fatty replacement of specific muscles. The baseline 
muscular fat-fractions of all patients (average value of all thigh muscles per patient) 
correlated negatively with the baseline level of physical activity (R2=0.27, p=0.0013) 
as measured by the actometer, and with distance walked in the 6MWT (R2=0.40, 
p<0.0001), but did not correlate with aerobic capacity (R2=0.09, p=0.053) (Figure 2). 
An analysis of the duplicate qT2-MRI data to assess the test-retest performance of 
the fat-fraction determination yielded an ICC of 0.99
Figure 2 Correlations between fat-fraction, derived by qT2-MRI, in the thigh 
and common clinical capacity measures of FSHD patients
The average fat-fraction of the whole thigh musculature correlated negatively with physical 
activity (A) and distance covered in the ‘6-minute walk test’ (B). There was no correlation 
between the average fat-fraction of the thigh and the peak oxygen uptake (C). 
TREATMENT EFFECTS
In the UC group the natural progression of fatty infiltration in all the analyzed thigh 
muscles was on average 6.7% (95% CI: 4.3% to 9.1%) normalized per year (Figure 
3).
Figure 3 Treatment effects of aerobic exercise training and cognitive 
behavioral therapy on MRI derived fat-fractions of the individual thigh 
muscles in FSHD patients 
UC = usual care, AET = aerobic exercise training, CBT = cognitive behavioral therapy.  Bars 
indicate the average change in fat-fraction normalized per year for the thigh muscles of FSHD 
patients receiving no treatment (Usual care), AET or CBT. Values are presented as means±SE. 
The progression of fatty infiltration was lower for the two treatment groups compared to usual 
care (* p< 0.05 and ** p< 0.01). 
The linear mixed model analysis revealed that for individual muscles an increase in 
fatty infiltration occurred on average in all muscles except in the G, S and VL. The 
largest progression was found in the AM with 19% per year (95% CI: 12% to 26%) 
(Table 3). 
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In the AET group the average increase in fat-fraction per year was 2.9% (95% CI: 
0.7% to 5.2%), which was lower than observed in the UC group (p=0.03) (Figure 3, 
Figure 4). 
Figure 4 Baseline and follow-up fat-fractions of all individual muscles 
AET = aerobic exercise therapy, CBT =cognitive behavioral therapy.
The solid line is the line of unity, if no change in fat fraction would occur all point would 
be on this line. The dashed line signifies the 95% confidence interval of the fat-fraction 
determination method. Dots above the unity and upper dashed line indicate muscles in which 
significant progression has occurred. Note that this is more in the usual care group compared 
to the intervention groups and that the baseline to follow-up period was shorter in the usual 
care groups compared to both intervention groups (12 vs 28 weeks).  
The individual muscle analyses by a linear mixed model showed significantly less 
progression of fatty infiltration compared to the UC group in all but the G, S, SM 
and VL muscles (Table 3). The deceleration of progression of fatty infiltration in the 
AET group was largest for the VM muscle. In this muscle fatty infiltration did not 
advance significantly whilst this was obvious in the UC group. 
Compared to the UC fat-fraction values, we also computed a lower progression 
rate for the CBT group: on average 1.7% per year (95% CI: -0.2% to 3.6%) 
(p=0.0015) (Figure 3). The linear mixed model analyses showed that this 
deceleration applied to all muscles except for the G, S and VL (Table 3). In this 
intervention group the effect was largest for the AM muscle. FSHD patients 
subjected to AET and CBT had fewer new hyper-intense lesions in their muscles on 
TIRM images than those in the UC group, respectively 2 in 18 and 7 in 13 patients 
(Table 2), indicating reduced edematous inflammation.  Body weight, body mass 
index and body fat percentage were unaffected by the interventions (Table 4). In 
both intervention groups, mean registered physical activity increased compared to 
the UC group. In the AET group, the average number of accelerations per 5-min 
intervals increased with 2.8 and in the CBT group with 2.9 compared to a decrease 
of -1.3 in the UC group, adjusted for pre-treatment values.
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DISCUSSION 
The main finding of this study is that aerobic exercise therapy (AET) and cognitive 
behavioral therapy (CBT) directed at optimizing daily physical activity slow down 
the progression of fatty replacement of muscle tissue in FSHD as evidenced by 
quantitative T2-MR imaging, demonstrating that the fat-fraction derived by MRI 
can serve as a sensitive and reproducible biomarker to reveal treatment effects in 
FSHD. This is clinically relevant as we also demonstrate that fat-fractions correlate 
with physical activity and distances walked in 6 minutes. 
Previously, we proved that muscular fat-fraction determined by qT2-MRI is 
a sensitive biomarker of disease state in FSHD and that it can detect natural 
progression in individual muscles within the course of four months (15), whilst leg 
muscle strength and MR-detected muscle fat infiltration were shown to be strongly 
correlated (14, 15, 26). With the current qT2-MRI study we substantiate that 
both AET and CBT interventions significantly decelerate disease progression as 
reflected in the fatty infiltration of thigh muscles within a time span of four months. 
Our muscle-specific linear mixed model analyses show that treatment effects are 
not the same for all muscles. For instance, retardation of fatty infiltration is most 
pronounced in the adductor magnus and vastus medialis but absent in the gracilis, 
sartorius and vastus lateralis muscles. This difference can be explained by the 
insignificant fatty progression rates for the latter muscles in the usual care group 
across the trial period. A decreased fat infiltration rate was also detected in two leg 
muscles of boys with Duchenne muscular dystrophy due to corticosteroid therapy 
by determining fat-fractions with single voxel MR spectroscopy (27).  
In the absence of a causal treatment for FSHD it is important to find approaches 
that slow down disease progression (28). Of the studies exploring pharmacological 
and non-pharmacological interventions (7, 8, 10, 28-35), until recently only some 
physical therapy programs showed a beneficial effect, while their application 
remained controversial due to the lack of controlled studies (28). We recently 
reported in an RCT that both AET and CBT significantly reduce chronic fatigue in 
FSHD patients as assessed with the Checklist Individual Strength (CIS-fatigue). In 
another RCT from a different group, physical fitness, workload and walking speed 
improved after 12 weeks of AET (8). However, a positive effect on the muscular 
level has never been described before (7-10). In the present study, using the fat-
fractions derived from qT2-MR imaging, we were able to demonstrate significant 
treatment effects, from which we infer that determining fatty infiltration volumes 
in skeletal muscles is a more sensitive instrument than the mentioned physical 
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capacity measures. The higher sensitivity and reproducibility of fat-fractions 
obtained by qT2-MRI compared to muscle strength measurements in intervention 
trials (36) can be explained by confounding practicalities of the latter method such 
as influence of limb position, motivation and placebo effects (9) and also because 
entire muscle groups are gauged, thus obscuring effects on individual muscles. 
The similar positive effects of AET and CBT on the rate of muscle fat infiltration 
is understandable as both interventions aimed to increase the level of physical 
activity: AET by three-weekly cycling exercises and CBT by a daily physical activity 
program consisting of graded increased cycling or walking exercises. Indeed, 
both AET and CBT increased the level of daily activity, as objectively measured 
by accelerometry (7). The particular physical activity programs may well explain 
the positive effect of both therapies on fatty infiltration of the upper leg muscles 
as these muscles are essential for walking and even more so for cycling. This 
indicates that adopting an overall active lifestyle by an increased level of physical 
activity of sufficient duration slows down the progression of fatty replacement of 
muscle tissue in patients with FSHD by an underlying mechanism common for 
both interventions. In future studies it will be of interest to include qT2-MRI in more 
detailed investigations of the levels of physical activity required to obtain beneficial 
effects in these patients.
Some aspects need to be taken into account in the interpretation of the results. 
A selection bias may have occurred in the specific recruitment of the patients 
for the MR study. However, as there were no significant differences in patient 
characteristics and physical capacities between the 31 patients participating in 
the MR study and the 26 non-participants, a selection bias is not expected to be 
relevant. To correct for the timing difference between the baseline and follow-up 
measurement of the control and intervention groups we normalized the change 
in fat-fractions for all groups to one year. This assumes linear progression of fatty 
infiltration in all groups, which might not reflect its true course. Because the interval 
between the two MR measurements was longer in the intervention groups than in 
the usual care group there is more time for a potential increase in fatty infiltration in 
these intervention groups, in particular during the usual care period inserted before 
the follow-up MR measurement. Hence, it is unlikely that the deceleration of fatty 
infiltration by the interventions is positively biased by the normalization procedure.  
Exercise enhances several capacities that will lead to stronger muscles and less 
fatigue, but may also provide favorable conditions to slow down progression of 
muscle affliction and to regenerate muscles in neuromuscular disorders (37, 38). 
A primary role in the pathophysiology of FSHD has been suggested for a DUX4 
205
induced immune response (39). This is in agreement with the observation of 
hyper-intense signals in TIRM or STIR MR images of muscles in patients, which 
are indicative of edematous inflammation (2, 14, 39). The MR signatures for these 
processes are particularly relevant as they seem to indicate that edema may 
precede the process of fatty infiltration (15-17). Therefore, it is of interest that both 
intervention groups showed less new hyper-intense lesions at follow-up.  
In this study we demonstrate that the rate of fatty infiltration as determined by qT2-
MRI in individual muscles of patients with FSHD is significantly decelerated after 
AET and CBT compared to usual care. We also show that this MRI approach is 
reproducible and can be used to obtain direct, sensitive and objective measures for 
the muscular state in legs of FSHD patients. 
These results reinforce the notion that quantitative MRI may become an 
indispensible endpoint in clinical trials for muscular dystrophies (40). 
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CHAPTER 9
SUMMARY AND GENERAL DISCUSSION
SUMMARY
Facioscapulohumeral muscular dystrophy (FSHD) is the third most common 
muscular dystrophy worldwide with an estimated prevalence of one in 8,000 
persons. It is an autosomal dominant disorder affecting primarily the muscles of 
the face and the shoulder girdle, but later in life many muscles of the trunk and 
the extremities can become affected.  In the last decade, substantial progress 
has been made in the understanding of the molecular genetics of FSHD. More 
than 95% of the cases of FSHD are associated with a partial deletion of a critical 
number of repetitive elements (D4Z4) on chromosome 4q35 and the subsequent 
toxic release of the DUX4 protein in muscle cells. It is, nevertheless, still unknown 
why the weakening of different muscles and muscle groups occurs at different 
rates and times.  Moreover, there are no biomarkers for an objective assessment of 
the severity and progression of FSHD. 
To date, no curative treatment is available for FSHD. As a consequence, although 
life expectancy is normal, 20% of the patients become wheelchair-bound due to 
muscle weakness. In addition, more than 60% of the patients experience chronic 
fatigue and with that, a lower level of social participation. Physical inactivity has 
shown to be the most important perpetuating factor of fatigue in patients with 
FSHD. However, being physically active is difficult for patients because of muscle 
weakness, which may lead to a vicious circle of fatigue and inactivity. 
The two main aims of this thesis were (1) to study the issues of fatigue and           
(in)activity in neuromuscular disorders and (2) to evaluate the effect of model-based 
interventions to optimize the activity level and reduce chronic fatigue in FSHD.
Chapter 1  is the general introduction and provided background information on 
FSHD. Individuals with FSHD show a wide range of clinical manifestations. This 
variability suggests that epigenetic mechanisms play an essential role. Epigenetics 
is defined as heritable changes in gene activity and expression that occur without 
alteration in DNA sequence. To objectively assess the severity and progression of 
FSHD, magnetic resonance imaging (MRI), could provide an objective biomarker 
for individual muscle involvement as it can easily visualize intramuscular fibrosis 
and fatty infiltration. Fatigue is increasingly being recognized as a major clinical 
problem in many conditions and evidence-based treatment programs are now 
being developed for several patient groups. By using the subscale fatigue of the 
Checklist Individual Strength, a multidimensional fatigue scale, it appeared that 
more than 60% of the patients with FSHD were severely fatigued. Lack of physical 
activity, sleep disturbances and pain contributed to experienced fatigue in FSHD. 
Loss of muscle strength contributed to experienced fatigue through a lower level 
of physical activity.  This model of perpetuating factors served as a basis for the C
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treatment protocol used in this thesis. This thesis reports the results of the FACTS-
2-FSHD study (acronym for Fitness And Cognitive behavioral TherapieS for Fatigue 
and ACTivitieS in FSHD), which is the first model-based randomized clinical 
trial that evaluated the effects of aerobic exercise training (AET) and cognitive 
behavioral therapy (CBT) on chronic fatigue in patients with FSHD. 
It was hypothesized that, in order to alleviate chronic fatigue, two different 
therapeutic approaches could be followed: AET to promote physical activity and 
CBT to stimulate an active lifestyle (yet avoiding excessive physical strain). 
Hence, the primary objective of this study was to evaluate the effect of both 
interventions on chronic fatigue in patients with FSHD as assessed with the 
subscale fatigue of the Checklist Individual Strength.  The secondary objective was 
to evaluate the effects of each intervention on the known perpetuating factors of 
chronic fatigue in FSHD. 
The secondary outcome measures covered all domains of the International 
Classification of Functioning, Disability and Health (ICF). In addition, it was aimed 
to find clinically useful magnetic resonance imaging (MRI) biomarkers of disease 
progression and response to therapy in patients with FSHD.
PART 1: PREVALENCE, ETIOLOGY, ASSESSMENT AND
MANAGEMENT OF FATIGUE  
In part 1, an overview is provided of the prevalence, assessment, and treatment 
of fatigue in neuromuscular disorders. The following research questions are 
addressed:
1. What is the prevalence and relevance of fatigue in patients with muscular 
dystrophy?
Chapter 2 shows that fatigue is a frequent and relevant symptom in patients 
with muscular dystrophy. Distinguishing experienced fatigue from muscle 
weakness, the key feature in muscular dystrophy, may be difficult. Although 
experienced fatigue is difficult to define, it still is a valuable concept which 
can be reliably measured by using questionnaires, like the Checklist Individual 
Strength, subscale fatigue (CIS-fatigue). As fatigue in muscular dystrophy is a 
multidimensional concept, it is important to understand factors that contribute 
to fatigue. Based on such an analysis, preventive and therapeutic interventions 
could be developed. Therefore, an overview of the pathophysiological 
determinants of fatigue in muscular dystrophies was provided and the model of 
perpetuating factors of experienced fatigue in FSHD was presented. A critical 
overview of the possible treatment options with respect to fatigue in patients 
213
with muscular dystrophy was presented including physical exercise training, 
drug treatment and cognitive behavioral therapy. 
2. How can we assess fatigue in patients with neuromuscular disorders?
Chapter 3 describes the results of a European Neuromuscular Centre (ENMC) 
care Workshop regarding pain and fatigue in neuromuscular disorders (NMD). 
This workshop aimed to achieve consensus on the definitions of pain and 
fatigue in NMD and to define a core set of measurement instruments for pain 
and fatigue in this group of disorders. Pain as well as fatigue are common 
symptoms in NMD with a strong impact on many activities of daily life. Specific 
types of pain and fatigue, related to the underlying (stages of) NMD could be 
distinguished. These should be differentiated from aspecific pain and fatigue, 
which are not primary related to the underlying disorder. Various methods were 
being used to assess pain and fatigue in NMD. In order to develop effective 
treatment approaches in NMD, both the definitions of pain and fatigue and their 
assessment methods should be internationally agreed upon. Therefore, a core 
set of measurement instruments for use in future research and clinical practice 
in NMD was provided.
3. What is the evidence for exercise in muscle disease?
In chapter 4, an updated Cochrane review (most recent date of search 2 July 
2012) is presented on the safety and efficacy of strength training and aerobic 
exercise training in people with a muscle disease. Strength training or aerobic 
exercise programs might optimize muscle and cardiorespiratory function and 
prevent additional disuse atrophy and deconditioning in people with a muscle 
disease. All randomized or quasi-randomized controlled trials comparing 
strength training or aerobic exercise programs (or both) to no training, lasting 
at least six weeks, in people with a well-described diagnosis of a muscle 
disease were included. Five eligible trials with 170 participants fulfilled the 
inclusion criteria: two trials of strength training in people with FSHD and 
myotonic dystrophy (101 participants), two trials of strength training combined 
with aerobic exercise in people with mitochondrial myopathy (18 participants) 
and myotonic dystrophy type 1 (35 participants), and one trial of aerobic 
exercise in people with polymyositis and dermatomyositis (14 participants). 
These trials showed that moderate-intensity strength training in people with 
myotonic dystrophy or FSHD, and aerobic exercise training in people with 
dermatomyositis or polymyositis appeared not to harm muscles. Strength 
training combined with aerobic exercise appeared to be safe in myotonic C
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dystrophy type 1 and might be effective in increasing physical endurance 
in people with mitochondrial myopathy. Finally, strength training was not 
harmful in people with FSHD, myotonic dystrophy, mitochondrial disorders 
or dermatomyositis / polymyositis, but there was insufficient evidence to 
determine its potential benefit. Limitations in the design of studies in other 
muscle diseases prevented more general conclusions.
PART 2: THE FACTS-2-FSHD STUDY
In part 2, the results of the FACTS-2-FSHD study are presented. The following 
research questions are addressed:
4. What are the effects of aerobic exercise therapy and cognitive behavioral 
therapy on chronic fatigue in patients with FSHD? 
 
In chapter 5 the protocol of the FACTS-2-FSHD trial is described. The FACTS-
2-FSHD study was the first theory-based randomized clinical trial which 
evaluated the effect and the maintenance of effects of AET and CBT on the 
reduction of chronic fatigue in patients with FSHD. The interventions were 
based on a theoretical model of perpetuating factors of chronic fatigue in 
patients with FSHD. The primary objective of the FACTS-2-FSHD trial was to 
study the efficacy of AET and CBT for decreasing chronic fatigue in patients 
with FSHD type 1 compared to usual care. It was hypothesized that both 
AET and CBT would be more effective in decreasing fatigue than usual care, 
which is no therapy at all or occasional (conventional) physical therapy. The 
improvement by AET might be obtained through enhancement of physical 
(aerobic) capacity, whereas beneficial effects of CBT might be achieved 
through changes in daily activities and behavior. Secondary objectives were to 
evaluate the effects of AET and CBT on the known fatigue-perpetuating factors 
in FSHD. The AET consisted of aerobic cycling exercise on a bicycle ergometer. 
The training program had a duration of 16 weeks and comprised home training 
twice a week and a supervised training once a week. CBT was focused on 
all known perpetuating factors of fatigue and adapted to the needs of each 
patient. Each session had a duration of one hour and was given by a registered 
cognitive behavioral therapist.  At baseline, patients were randomized to either 
an AET group, a CBT group, or a control group receiving usual care. After an 
intervention period of 16 weeks and a follow-up of 3 months, the control group 
was as yet randomized to either AET or CBT (28 weeks after inclusion). It was 
intended to eventually include 25 adult patients in each of the three groups: 
AET, CBT, or usual care. Because patients in the control group received AET 
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or CBT in second instance, the minimal number of patients to be included 
was 50 at baseline. Outcomes were assessed at baseline, immediately post 
intervention (and control period), and at 12 en 24 weeks of follow-up. A linear 
mixed model for repeated measurements was used to study the estimated 
group differences. 
Chapter 6 describes the results of the FACTS-2-FSHD randomized controlled 
trial for which the protocol has been described in chapter 5. Fifty-seven 
ambulant patients with FSHD type 1 and severe chronic fatigue were 
randomly allocated to AET, CBT, or UC. Following treatment, both the AET (28 
participants) and CBT (25 participants) intervention groups had significantly 
less fatigue relative to the UC group (24 participants), with a difference of -9.1 
for AET (95% CI: -12.4 to -5.8) and -13.3 for CBT (95% CI: -16.5 to -10.2) 
on the CIS-fatigue. These beneficial effects lasted through follow-up, with a 
difference of -8.2 for AET (95% CI: -12.4 to -5.8) and -10.2 for CBT (95% CI 
-14.0 to -6.3). Post-treatment, 19 participants in the CBT group (76%) and 14 
participants in the AET group (50%) no longer had scores indicative of severe 
fatigue. The number needed to treat (NNT) for AET was 2.3 (95% CI 1.4– 3.1) 
with an absolute risk reduction (ARR) of 50% (95% CI 32–69%). The NNT for 
CBT was 1.3 (95% CI 1.1–1.7) with an ARR of 76% (95% CI 59–93%). In the 
CBT group, all known fatigue-perpetuating factors (with the exception of pain) 
were positively modified, including a higher level of social participation. The 
patients who received AET showed an increase in registered physical activity 
and maximal isometric quadriceps strength only. The increase in registered 
physical activity in both groups and the improvement in social participation 
following CBT were still present at follow-up. More than 70% of the AET and 
almost 80% of the CBT participants continued their adjusted level of activity 
once the study had ended. No improvement in aerobic capacity was found 
in both intervention groups. Only mild adverse affects were found in the AET 
group. The median number of therapy sessions was much lower in the CBT 
group, i.e. five, than in the AET group (40 sessions). It was concluded that both 
AET and CBT are able to ameliorate chronic fatigue in patients with FSHD. 
5. Can we discover structural abnormalities in skeletal muscle of FSHD patients 
that may serve as biomarkers for disease progression and response to therapy?
Even though the most important genetic event for the disease has been 
identified, the underlying mechanisms causing FSHD are unknown. 
Understanding these mechanisms first requires a better knowledge of the 
process of fatty infiltration of the skeletal muscles.C
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In the study described in chapter 7, fat fraction as assessed by quantitative 
MRI (Q-MRI) appeared to be  an objective and sensitive biomarker for muscular 
affliction in FSHD, detecting even subclinical muscle involvement. An analysis 
of the average fat fraction for all individual muscles uncovered an hourglass 
pattern of many muscles with either a very low or high fat fraction, and few 
muscles with an intermediate fat fraction. This quasi-binary distribution had 
not been reported for other muscular dystrophies and may be FSHD specific. 
The intramuscular fat fraction increased linearly from proximal to distal. Fat 
replacement of entire muscles would, on the average, be completed within 
approximately three and a half years. The steepest fat gradient occurred in the 
intermediately affected muscles indicating that these muscles were quickly 
progressing towards a complete fat infiltrated state. This can be relevant for 
prognostication and monitoring therapy effectiveness in FSHD.
The primary goal of the study presented in chapter 8 was to examine the 
effects of AET and CBT on the progression of fatty infiltration and edema in 
individual leg muscles of FSHD type 1 patients by T2-MRI. Quantitative T2-MRI 
(qT2-MRI) and fat-suppressed T2-MRI images of the thigh were obtained at 
baseline and follow-up in 31 patients who were included in the FACTS-2-FSHD 
study, of whom 13 received usual care (UC), nine AET, and nine CBT. In the 
UC group the fatty infiltration in the affected muscles progressed on average 
with 6.7% per year. Progression occurred on average in all muscles except 
in the gastrocnemius, sartorius and vastus lateralis. Overall, the adductor 
magnus showed the largest progression. This rate was significantly lowered 
by both interventions to (on average) 2.9% per year in the AET group (AET – 
UC, p<0.05) and 1.7% per year in the CBT group (CBT – UC, p<0.01). In both 
intervention groups fewer muscles developed edema than was observed in the 
UC group. The baseline muscular fat fractions of all patients (average value of 
all thigh muscles per patient) were negatively correlated with the baseline level 
of physical activity (R2=0.27, p=0.0013) as measured by the actometer and 
with the maximum walking distance (R2=0.40, p<0.0001), but they were not 
significantly correlated with aerobic capacity. It was concluded that qT2-MRI is 
a reproducible and sensitive quantitative biomarker for monitoring the effects 
of increased physical activity in individual muscles in FSHD and that both AET 
and CBT slow down the progression of fatty replacement of muscle tissue in 
FSHD.
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GENERAL DISCUSSION 
Mr. C, a 58-year old man with facioscapulohumeral dystrophy (FSHD) who was 
briefly introduced in the general introduction of this thesis, was encouraged by 
his wife to take part in the FACTS-2-FSHD study, hoping to achieve a reduction 
of his fatigue. He hoped to be randomized to aerobic exercise training to resume 
his cycling exercises. He had given up those exercises a couple of years ago for 
fear of further deterioration of his muscle strength. However, in the study he was 
randomized to cognitive behavioral therapy (CBT). Initially he was disappointed, 
as he did not really want to talk to a psychologist about his muscle disease 
and the burden of his disease. During the study, he received nine sessions of 
CBT. In the beginning, he was skeptical about this treatment, and therefore did 
not expect CBT to have any effect. He regarded his experienced fatigue as an 
untreatable problem. Several measurements that were conducted during the first 
treatment session with the psychologist showed that the CBT should be directed 
at unhelpful thoughts and beliefs about fatigue, improper coping strategies, 
sleep disturbances, physical inactivity and unhelpful social interactions. After 
nine sessions of CBT and homework assignments, his physical activity had 
increased substantially. Together with his partner, he went out on an electric bike 
again to visit his family and friends. He was no longer afraid of muscle damage 
from physical activity because he noticed that he felt more fit by being physically 
active. He resumed his gardening activities, this time in the communal garden 
of the apartment complex where he lived. He no longer slept during lunchtime, 
so the quality of sleep at night became better. He was not seriously fatigued any 
more. His mental and physical capacity increased, and there was room for new 
activities. A few weeks after the end of the CBT, he started a new job. 
A MODEL-BASED TRIAL
The Departments of Neurology, Rehabilitation and Pediatrics of the Radboud 
University Medical Center together with the Expert Center for Chronic Fatigue 
collaborate in the Center of Expertise for Muscular Dystrophy and have worked 
together in research and patient care in muscular dystrophy for over 20 years. 
One of the research successes is the result of cross-sectional and longitudinal 
research on experienced fatigue in facioscapulohumeral dystrophy (FSHD). Cross-
sectional research showed that experienced fatigue is a frequent as well as a 
relevant problem for patients with FSHD. Based on longitudinal data, a model of 
perpetuating factors of experienced fatigue in patients with FSHD was developed 
(1). Muscle weakness, the key feature of FSHD and the result of fatty infiltration C
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of the skeletal muscles, appeared to contribute only indirectly to experienced 
fatigue. However, muscle weakness leads to physical inactivity, the most important 
perpetuating factor of experienced fatigue. Sleep disorders and pain are the other 
proven perpetuating factors of experienced fatigue. This FSHD-specific model was 
of major importance for the development of the evidence-based interventions in the 
FACTS-2-FSHD study, namely aerobic exercise training (AET), aimed at increasing 
aerobic capacity, and cognitive behavioral therapy (CBT), a psychological treatment 
aimed at promoting a physically active lifestyle (1) (Figure 1).
Figure 1 Model of perpetuating factors of experienced fatigue, specifically for 
patients with facioscapulohumeral dystrophy 
Physical inactivity, sleep disturbances and pain are direct and muscle weakness is an indirect 
perpetuating factor of experienced fatigue (1). 
Both interventions in the study are directed at the aforementioned perpetuating 
factors of experienced fatigue. AET focuses primarily on the perpetuating factor 
of physical inactivity. This was expected to reduce the chronic experienced 
fatigue and enhance the degree of social participation. It was hypothesized that 
an increase in aerobic capacity could lead to a lower level of experienced fatigue 
(Figure 2). 
Cognitive behavioral therapy (CBT) is composed of six modules directed at the 
proven and presumed perpetuating factors of experienced fatigue and their 
related (unhelpful) cognitions in FSHD. The modules focus on: (1) unhelpful coping 
strategies; (2) unhelpful cognitions about fatigue; activity, pain or other symptoms; 
(3) catastrophic thoughts about fatigue; (4) sleep disturbances; (5) physical 
inactivity or dysregulation of physical activity; and (6) a discrepancy between 
expected and actual social support and interactions. Additionally, reducing 
restrictions in social participation is an important objective of the CBT. In this way, 
the final aim is to reduce chronic fatigue and social participation restrictions (Figure 
3).
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Figure 2 The expected working mechanism of aerobic exercise training (AET) 
based on a model of perpetuating factors of experienced fatigue in 
patients with facioscapulohumeral dystrophy (Figure 1)
AET focuses primarily on the perpetuating factor physical inactivity. Improved physical activity 
would diminish the level of experienced fatigue and social participation restrictions.
Figure 3 The expected working mechanism of cognitive behavioral therapy 
(CBT) based on a model of perpetuating factors of experienced 
fatigue in patients with facioscapulohumeral dystrophy (Figure 1)
 
CBT focuses not only on the perpetuating factor physical inactivity, but also on sleep 
disturbances, pain, unhelpful cognitions about fatigue and restrictions in social participation. C
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The patient with FSHD described in the case study showed an improvement in all 
domains of the International Classification of Functioning, Disability and Health 
after only nine sessions of CBT (2). Not only did he experience a lower level of 
fatigue and an improvement in sleep quality, he also became more physically 
active. He performed gardening activities again, his social contacts increased 
and he started a new job. CBT broke the downward spiral of physical inactivity, 
experienced fatigue and social participation restrictions.
He became physically active in daily life, and social participation became possible 
again.
The case study illustrates the general conclusion of this thesis: CBT is able to 
reduce severe fatigue in patients with FSHD and improve social participation, by 
increasing physical activity and changing all relevant fatigue perpetuating factors 
(Figure 3). 
In addition, the FACTS-2-FSHD study shows that AET can also achieve a reduction 
of severe chronic fatigue and increase in physical activity in patients with FSHD 
(Figure 2). Although AET, contrary to CBT, did not cause an improved quality of 
sleep or social participation, it did cause an increase in muscle strength of the 
quadriceps. Finally, a deceleration of fatty replacement of muscle tissue in the thigh 
muscles was observed after both interventions.
POSSIBLE EXPLANATIONS FOR EFFECTS: A PHYSICALLY ACTIVE 
LIFESTYLE VERSUS PHYSICAL EXERCISE 
 
Physical inactivity
After both CBT and AET, the level of physical activity in daily life increased. After 
CBT, the level of physical activity remained high compared with the control group, 
even after the follow-up period of 12 weeks. The increase in physical activity 
in everyday life appears to play an important role in the positive effect of both 
interventions on the level of fatigue. Based on the model of perpetuating factors of 
fatigue and additional research, it is known that in FSHD the degree of fatigue is 
not correlated with the severity of muscle weakness (1, 3). Apparently, this fatigue 
seems more a result of unintentional unhelpful behavior associated with the disease 
rather than the result of muscle weakness itself. Conversely, experienced fatigue 
often leads to unhelpful cognitions and behavior that, in turn, further increase 
the level of fatigue. A curative treatment for FSHD is not available yet; however, a 
treatment aimed at the aforementioned unhelpful cognitions and behavior, namely 
CBT and AET, now is.
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A physically active lifestyle versus physical exercise: ‘Dutch standard for 
healthy exercise’ versus  ‘ the standard for physical fitness’ 
During CBT, a reliable increase in physical activity is an important part of the 
treatment: the module ‘physical-inactivity or a high dysregulation of activity’ was 
applied in each participant. AET focused primarily on physical exercise on an 
ergometer. At first sight, physical activity and physical exercise seem to be similar, 
but on second thought they are substantially different. Physical activity is defined 
as “any effort of skeletal muscles resulting in higher energy consumption than in 
resting conditions (4).” Physical (aerobic) exercise is a form of physical activity 
and is defined as “planned, structured and repetitive exercises with an increasing 
magnitude and intensity in order to maintain or improve physical fitness or aerobic 
capacity (4).”
The recommendations on physical activity for the healthy population have been 
prescribed in the Dutch Standard for Healthy Exercise (Nederlandse Norm Gezond 
Bewegen; NNGB). This standard aims at a physically active lifestyle and comprises 
a total of 30 minutes of exercise of moderate intensity (at a slightly higher heart 
and respiration rate than usual) of at least 4.0 MET a day, in blocks of at least 10 
minutes at least five days a week. 
The MET value or the metabolic equivalent is a unit of measurement within 
physiology expressing the amount of energy for a certain physical effort compared 
with the amount of energy required at rest. One MET corresponds to the resting 
metabolic rate, the amount of energy consumed during inactivity. One MET is 
equivalent to 3.5 ml of oxygen per kg of body weight per minute. The NNGB leads 
to a total duration of 150 minutes of physical activity per week of 4.0 MET, which 
implies a total increase of 450 MET per week compared to a physically inactive 
lifestyle. Physical activity within the NNGB includes not only sports activities but 
also daily-life activities such as household activities, cycling or walking the dog.
For physical exercise, the Dutch government has issued a standard for physical 
fitness. This standard is aimed primarily at maintaining aerobic capacity through 
physical exercise and requires intense physical activity of at least 6.0 MET for at 
least 20 minutes and at least three times a week. Although the intensity is higher 
than in the NNGB, the total length and the increase in MET per week is less, namely 
300 MET. Thus, one can still have a physically inactive or sedentary lifestyle, in 
spite of meeting the standard for physical fitness. In other words, the NNGB leads 
to a higher level of physical activity than the Dutch standard for physical fitness. 
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The Dutch standard for physical fitness and the NNGB are defined only for healthy 
adults and for healthy elderly. The minimum standard for patients with a chronic 
disease, including FSHD, has not yet been defined. The NNGB not only leads to 
a higher level of physical activity; this standard is probably also more feasible for 
patients with FSHD, because daily-life activities are included. In other progressive 
neurological diseases, such as Parkinson’s disease, there is already growing 
evidence for a positive effect of decreasing the sedentary time (5). The question 
now arises whether physical exercise of minimum intensity and an increase in 
aerobic capacity are really necessary for the treatment of fatigue in patients with 
FSHD. Would an increase in physical activity of moderate intensity and of sufficient 
duration, i.e. a physically active lifestyle, not be much more relevant? 
In order to answer this question, possible underlying mechanisms of the results 
of the FACTS-2-FSHD study will be discusses. The results of the FACTS-2-
FSHD study will be compared with other exercise studies in FSHD and other 
neuromuscular disorders (NMDs). The methodological limitations will be highlighted 
and, finally, recommendations will be given for future research and clinical practice.
UNDERLYING MECHANISMS OF EFFECTS
Aerobic exercise: is an increase in aerobic capacity necessary?
In the FACTS-2-FSHD study, the primary purpose of AET was to treat fatigue in 
patients with FSHD through physical exercise on an ergometer. The hypothesis 
was that such exercise would improve aerobic capacity and, with that, break the 
downward spiral of physical inactivity and fatigue (Figure 2). Indeed, the downward 
spiral was broken: the level of physical activity increased after AET, and the level of 
experienced fatigue decreased. 
However, contrary to our expectations, we found no effect on aerobic capacity. 
Unfortunately, with the results of the FACTS-2-FSHD study, a real absence of 
effect cannot be determined with certainty. The Åstrand submaximal cycling 
test appeared to be unfeasible for relatively severely affected patients. Further 
considerations will be discusses in the Methodological Considerations paragraph 
(see page 233).
The results of the FACTS-2-FSHD study suggest that an increase in aerobic 
capacity is not essential for the reduction of chronic fatigue. Possibly promoting 
physical activity through physical exercise is a more important mechanism.
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Cognitive behavioral therapy: 
FSHD is more than impaired muscle function
Where AET aims at improving physical activity, CBT is aimed at all perpetuating 
factors of the model of Kalkman (Figure 3). This could explain why CBT had a 
lasting positive effect not only on physical activity but also on sleep quality and 
social participation. The CBT intervention was more extensive than AET. The 
treatment protocol of CBT consisted of six modules based on the proven and 
presumed perpetuating factors of experienced fatigue in patients with FSHD. The 
modules aimed to change unhelpful disease cognitions, to better regulate social 
activities, to increase mental activities and to regulate social support. In the first 
treatment session, the psychologist determined which modules were applicable 
by performing an interview and specific tests. Thus, compared with AET, CBT was 
more focused on the individual person with FSHD. In the longitudinal study in which 
the model of perpetuating factors of experienced fatigue has been developed, 
only a limited number of possible perpetuating factors could be explored (1). The 
sample size was too small to reliably test more factors. Therefore, one or more 
of the presumed perpetuating factors of experienced fatigue (discrepancy in the 
level of perceived social support, unhelpful illness cognitions and limited social 
and mental activities) could also be perpetuating factors of experienced fatigue 
in patients with FSHD. For example, unhelpful illness cognitions are a known 
perpetuating factor of experienced fatigue in multiple sclerosis and in chronic 
fatigue syndrome (6). As an essential part of CBT, unhelpful cognitions can be 
changed into helpful thoughts using Socratic dialogues to increase patients’ 
autonomy and self-efficacy.
Although increasing the amount of physical activity is an essential part of CBT 
for Although increasing the amount of physical activity is an essential part of 
CBT for fatigue in FSHD, both scientists and clinicians are astonished about 
its beneficial effect. “Is fatigue all in the mind?” and “How can a psychological 
treatment achieve an effect at a muscular level?” are frequently asked questions. 
The answer to these questions is that a part of the solution is, in fact, literally “in 
the mind.”Psychological factors, such as illness cognitions, coping style and level 
of acceptance of the disease are known to be strongly correlated with the degree 
of social participation in patients with a muscle disease, including FSHD (7). It 
is noteworthy that these correlations, comparable with the level of experienced 
fatigue, are relatively independent of the degree of physical impairments. This is 
also called the “disability paradox:” having physical impairments has little influence 
on the degree of social participation. 
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This paradox can be explained by the perceived burden of disease in patients with 
FSHD (Figure 4). As shown in Figure 4, muscle weakness is not only just an indirect 
perpetuating factor of experienced fatigue, it also constitutes a relatively small part 
of the experienced burden of disease. Fatigue, pain, sleep disorders and physical 
inactivity determine the majority of the experienced burden of disease in FSHD. 
This implies that psychological interventions are not only able to improve the level 
of experienced fatigue, but can also improve the degree of social participation and 
mood of patients with a muscle disease, even when there is progression of the 
disease (8).
.
Figure 4 The imaginative tower of experienced burden of disease in patients 
with facioscapulohumeral dystrophy 
FSHD is more than impaired muscle function. A large part of the experienced burden of 
disease consists of the proven perpetuating factors of fatigue. Not every factor carries equal 
weight. Experienced fatigue and physical inactivity constitute the main part of the disease 
burden. The figure is a visual representation of the results of the study by Johnson et al (9).
The disability paradox seems to explain part of the large observed effects of CBT. 
Psychological well-being improved after CBT, as measured by the Brief Symptom 
Inventory (10) (unpublished data), and the level of social participation increased. 
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This occurred independent of a change in muscle strength, which is often used 
as a measure of disease severity. For many patients, psychological distress is, 
together with a decrease in muscle strength, a significant problem. Stress, fear for 
the future, and fear for fatigue were frequently mentioned in the parallel qualitative 
FACTS-2-PERSPECTIVES study during the interviews before the start of the 
intervention (11, 12). 
 
Effects at the muscular level: epigenetics and/or anti-inflammatory 
effects? 
Both CBT and AET slow down the progression of fatty replacement of muscle 
tissue in FSHD. This raises the question: “How is it possible that an increase in 
physical activity causes a beneficial effect at the muscular level?” Epigenetics and 
the inflammation theory can possibly offer an explanation.
Epigenetics
FSHD is a genetic disorder. More than 95% of cases of FSHD are associated 
with the absence of certain pieces of DNA at the end of chromosome 4 (genetic 
location: 4q35), the so-called D4Z4 deletion. This results in expression of the 
harmful DUX4 gene and production of a toxic protein (DUX4) that causes dystrophy 
(fatty replacement) of the skeletal muscles (13). The conversion of DNA into 
functional products for the cell, such as proteins, is dependent on both the DNA 
code itself (genetics) as well as on factors that may affect the activity of genes 
(gene expression), so-called epigenetic factors (14, 15). Epigenetic phenomena 
determine the “open” or “closed” state of parts of the genome and, thus, control 
the “on” or “off” position of genes. This can take place by means of changes in 
methylation, RNA molecules (intermediates between DNA and protein), or by the 
so-called histone proteins that are involved in the packing (and hence access) of 
the DNA in the chromosomes. FSHD is, therefore, an epigenetic disease (15). In 
FSHD patients, the degree of methylation of the DNA influenced by epigenetic 
factors plays an important role. Sometimes a small molecule group is added to the 
DNA, a so-called methyl group, which carries additional information. FSHD patients 
with a D4Z4 deletion (FSHD-1) show a decreased methylation of the D4Z4 region 
on the chromosomes 4q and 10q (Figure 5).
However, the degree of methylation is not already determined at birth. It varies 
between persons and may change under the influence of environmental factors 
during one’s lifetime. 
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Figure 5 The role of epigenetic factors in facioscapulohumeral dystrophy
If the DUX4 gene is “readable” (i.e. can be transcripted), the DUX4 protein, which is toxic for 
skeletal muscles, is produced. Epigenetic factors can make it an “unreadable” gene by an 
increase in methylation. Figure courtesy of Sylvère van der Maarel. 
Epigenetic factors ensure that the genetic defect in different people, even within 
families, can be expressed differently (16). In recent research, the difference in 
severity of the disease within families with FSHD is, among other phenomena, 
attributed to epigenetic factors (17). 
An increase in physical activity and/or physical exercise can cause changes in 
the DNA methylation of healthy persons (18). It is possible that a physically active 
lifestyle is an epigenetic factor for FSHD and can slow down the progression of 
fatty replacement of muscle tissue by changes in DNA methylation. It is not a 
coincidence that the perpetuating factors of fatigue, i.e. physical inactivity, sleep 
disorders and pain, are known epigenetic factors (19). The degree of methylation 
can be different for every individual cell under the influence of epigenetic factors. 
This could be an explanation for the differences in effect on the fatty replacement 
between different muscles of patients with FSHD after CBT and AET, as measured 
by quantitative magnetic resonance imaging (MRI) (20). To conclude, the first 
hypothesis is that AET as well as CBT influence the fatty replacement of muscle 
tissue by modifying epigenetic mechanisms. 
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Theory of inflammation 
A second explanation can perhaps be found in the beneficial effect of physical 
activity on inflammation. Inflammatory reactions seem to play a role in the 
increase in fatty replacement of muscle tissue in patients with FSHD and also in 
the development of chronic experienced fatigue in various neurological disorders 
(21). In approximately 5% of the muscles of patients with FSHD, edema has 
been observed using MRI (20, 22). There is evidence that an increase in edema 
is preceded by inflammation and is followed by fatty replacement of the muscle 
tissues (23, 24). The inhibition of inflammatory reactions could, therefore, 
theoretically slow down the progression of the disease. In healthy people, the 
anti-inflammatory effect of physical activity has already been proven extensively 
(25). Not only immune cells produce molecules that play a role in inflammatory 
responses (cytokines). Skeletal contracting muscles also release significant 
amounts of interleukin IL-6. IL-6 is a pro-inflammatory cytokine, in this situation 
also called a myokine. IL-6 causes inflammation when it is excreted as a cytokine 
by immune cells, but fights inflammation when it is released as a myokine by 
muscle cells. This is most likely because other cytokines are not produced anymore 
and another, “healthier” environment has been created (26, 27). In healthy adults, 
the production of IL-6 during exercise is for at least 50% related to the intensity 
and duration of the exercise (28, 29). To conclude, the second hypothesis is 
that AET and CBT influence the fatty replacement of muscle tissue by positively 
influencing inflammatory reactions. This again argues in favor of a physically active 
lifestyle beyond physical exercise of limited duration.
COMPARISON WITH PREVIOUS RESEARCH
Aerobic exercise in muscle disease: from a discouraging to an 
encouraging approach
At the time of the design of the FACTS-2-FSHD study, clinicians were reluctant to 
prescribe exercise to patients with FSHD. They often referred to possible muscle 
damage due to overuse. 
This assumption, however, was based on studies in which mdx mice with muscular 
dystrophy had to run in a treadmill for days (30). Because mdx mice constitute a 
model for Duchenne muscular dystrophy only, the results cannot be extrapolated 
to other neuromuscular disorders, including FSHD. However, evidence from human 
exercise studies in FSHD was scarce as well. Only one pilot study was conducted 
with a healthy control group that described the beneficial effect of exercise in C
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patients with FSHD (31).  At the time, there was only limited evidence for a positive 
effect of exercise in other muscle diseases too. The original Cochrane review 
from 2005, which described the effect of AET and strength training in muscle 
disease, contained only two randomized controlled trials (RCTs) and concluded: 
“In myotonic dystrophy and facioscapulohumeral muscular dystrophy moderate-
intensity strength training appears not to do harm, but there is insufficient evidence 
to establish that it offers benefit. Limitations in the design of studies in other muscle 
diseases prevent general conclusions in these disorders (32). “The conclusions 
of the other Cochrane reviews within the neuromuscular disorders group, which 
described the effect of exercise in amyotrophic lateral sclerosis (ALS), McArdle and 
peripheral neuropathies, were also limited because of the low number of exercise 
studies of sufficientquality (33-35).
Throughout the duration of the FACTS-2- FSHD study, the Cochrane review on the 
effect of AET and strength training in muscle diseases compared with no training 
has been updated twice (36, 37). The third update is close to completion and is 
expected to include nine studies including (in addition to the FACTS-2-FSHD study) 
an RCT with a beneficial effect of AET in FSHD (38) and RCTs with positive effects 
of AET in Duchenne muscular dystrophy (39), polymyositis and dermatomyositis 
(40). This expected Cochrane update starts a new era in which exercise is 
encouraged (rather than discouraged) in patients with FSHD and other muscular 
disorders.
Aerobic exercise in FSHD
In the FACTS-2-FSHD study, as previously mentioned, no significant effect was 
observed on aerobic capacity, in contrast to two other studies from Denmark, 
which investigated the effect of cycling exercises in FSHD: the aforementioned 
pilot study with a healthy control group (29) and a recently published RCT (38). 
The absence of an increase in aerobic capacity as observed in the FACTS-2-FSHD 
study could be explained by a limited adherence to the exercise sessions. Many 
participants in the FACTS-2-FSHD study did not participate in all the 48 exercise 
sessions. The participants in the Danish RCT (38) also had a limited adherence. 
In that study, participants with a reduced adherence (6 of 41) were not included 
in the analysis, which may explain the positive result. The FACTS-2-FSHD study 
used an intention-to-treat analysis and had only one dropout, so the risk of bias is 
smaller when it comes to estimating a realistic effect. Another explanation for the 
differences between the studies can be found in the prescription of the exercise 
and the assessment of the outcomes. In the Danish studies, the exercise intensity 
and the aerobic capacity were determined with a maximum test. However, the 
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Danish patients were on average younger and less severely affected than the 
patients in the FACTS-2-FSHD study. 
In the FACTS-2-FSHD study, the exercise intensity was determined using the 
Karvonen method, which uses the resting heart rate and the estimated maximum 
heart rate (41). The aerobic capacity was measured using a (submaximal) Åstrand 
cycling test (42). Both methods use an estimate of the maximal oxygen uptake. 
As the study population in the FACTS-2-FSHD study consisted for a large part of 
relatively severely affected elderly patients, a maximal test was not considered 
appropriate. A possible explanation for the lack of increase in aerobic capacity 
may be that an increase in aerobic capacity is not really possible in this population. 
Moreover, the exercise prescription based on the Karvonen method might not 
have been optimal. Finally, the Åstrand method may not be valid for estimating the 
aerobic capacity in an older, relatively severely affected population of patients with 
FSHD.
Another notable difference between the studies is that, unlike in the FACTS-2-
FSHD study, in the Danish study, in spite of an improvement of aerobic capacity, 
no effect of AET was observed on physical activity (measured with accelerometry), 
experienced fatigue (measured with a visual analogue scale (VAS) score) or muscle 
strength (measured by dynamometry). A VAS-fatigue and dynamometry are less 
valid and sensitive instruments than the Checklist Individual Strength (CIS) and 
Quantitative Muscle Assessment, respectively. Again, the question arises whether, 
in the FACTS-2-FSHD study, adhering to a more physically active lifestyle has 
caused the observed increase in muscle strength and decrease in experienced 
fatigue. Until now, an increase in physical activity or muscle strength has not been 
found in any other exercise trial in FSHD, not even after strength training (31, 38, 
43).
EXERCISE IS MEDICINE
What proved to be impossible in drug trials up to now did succeed in research 
using behavioral interventions. AET as well as CBT did not only reduce the degree 
of disease burden, but also established a beneficial effect at the muscular level 
probably as a result of increased physical activity. Table 1 shows the history of 
interventional research in FSHD. The question arises whether the “number needed 
to treat” and the (minor) side effect profile based on the FACTS-2-FSHD trial can be 
achieved with medication in future studies (44). 
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Nevertheless, the scientific acceptance of AET and CBT as medicine in FSHD 
is still difficult. Although both interventions were examined “lege artis” and were 
based on a theoretical model of perpetuating factors of experienced fatigue, there 
is still uncertainty (and even scepsis) with regard to the underlying mechanisms. 
Figure 6 is a nice illustration of the current situation with regard to believers and 
non-believers.
Figure 6 The scientific acceptance of aerobic exercise and cognitive 
behavioral therapy as medicine is still difficult
In English: Fokke and Sukke know what science is about: “very impressive, colleague, but 
does it also work in theory?” Source: J. Reid, B. Geleijnse, JM van Tol.
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Table 1: Demographics and baseline characteristics of FSHD patients
Intervention Effect NNT
Pilot studies
Prednison (45, 46) No n.a.
Albuterol (47) No n.a.
AET (31) Yes n.a.
Electrical stimulation and exercise (48) Yes n.a.
Randomized controlled trials
Albuterol (49) No n.a.
Albuterol and strength training (50) No n.a.
Salbutamol (51) No n.a.
AET and CBT (52) Yes 2.3 and 1.3
AET (38) Yes 2.1
There is no effect of medication on the primary outcome measure in contrast with a positive effect of 
rehabilitation interventions (in bold letters). AET: aerobic exercise training, CBT: cognitive behavioral 
therapy; NNT: number needed to treat. The NNT is the number of patients who need to be treated to 
prevent one additional bad outcome.
The acceptance of functionally targeted interventions can possibly be accelerated 
by providing more evidence for underlying mechanisms through basic research. 
However, the biggest challenge is to get the scientific and clinical world moving 
forward. This requires a societal change. A change in lifestyle requires a greater 
effort from patients and practitioners than taking or prescribing a drug. And 
even medication adherence is limited (45). In CBT, therapy sessions are usually 
structured by a collaboratively agreed-on agenda. Homework sessions encourage 
active participation. And during AET, patients exercise at home in addition to 
supervised training. Research has shown that a patient-centered approach 
improves treatment adherence in chronic patients and also improves job 
satisfaction in health professionals (53).
Recently, a new definition of health has been introduced by Huber, in which 
health is no longer described simply as the absence of disease (54). Policy 
makers, researchers and clinicians have always had a rather narrow, biomedical 
interpretation of health, paying particular attention to bodily functions, whereas 
patients themselves often strived for a broader definition for the concept of 
health. The new, more positive definition of health is “the ability to adapt and to 
self-manage, in the face of social, mental and physical challenges of life.” This 
means that a patient with FSHD, despite his or her muscle weakness, can still 
be healthy if there is a balance in the demands and personal aims of everyday 
life and if (s)he experiences sufficient self-control and meaning in life. Through 
an increase in autonomy and active participation, which is the aim of both CBT 
and (to a lesser extent) AET, the perceived health status can improve further. 
Although most physicians still tend to adhere to a narrow, biomedical definition of 
health, rehabilitation medicine has already embraced a more functionally oriented 
definition of health since its existence. Therefore, Huber’s definition of health 
corresponds well with the focus of rehabilitation medicine to promote autonomy 
and independence in human beings independent of their disease status.
THE FACTS-2-NMD CONSORTIUM
The FACTS-2-FSHD study was part of a research consortium named FACTS-
2-NMD. Within this consortium, a comparable study evaluating AET and CBT 
was conducted in post-polio syndrome (PPS) and ALS (the FACTS-2-PPS (55) 
and FACTS-2-ALS study (56), respectively). In addition, the qualitative FACTS-2-
PERSPECTIVES study ran parallel to the three intervention trials, making use of 
a responsive assessment methodology. Within the FACTS-2-FSHD study, patient 
perspective data from 28 participants and five practitioners were gathered through 
interviews and focus groups.C
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In the meantime, the results of the FACTS-2-PPS study have been published (57). 
This RCT did not demonstrate any change in fatigue, activities or quality of life after 
AET or CBT, compared with usual care. A possible explanation for the discrepancy 
with the FACTS-2-FSHD study results may lie in a difference in the level of physical 
activity between the two populations. Patients with PPS seem to be on average just 
as active as healthy subjects of the same age (58). They generally are not captured 
in a negative spiral due to physical inactivity, in contrast to patients with FSHD (59). 
For patients with PPS, it is not only difficult to bring about an increase in physical 
activity, but there is also a realistic risk of overload. The results of the FACTS-2-ALS 
and the FACTS-2-PERSPECTIVES studies are expected soon.
METHODOLOGICAL CONSIDERATIONS
The FACTS-2-FSHD study has some methodological shortcomings. Of these, the 
limited adherence and the use of the Karvonen method for the determination of 
exercise intensity have already been mentioned.
Validity and appropriateness of the Åstrand test 
Unfortunately, the submaximal Åstrand test proved not to be suitable for the 
determination of aerobic capacity in patients with FSHD. When performing the 
Åstrand test, muscle weakness instead of aerobic capacity was a limiting factor in 
10% of the participants, so the test results were invalid. Moreover, in 24% of the 
participants, it was not possible to conduct a valid Åstrand test because of the 
use of beta-blocker medication. The Åstrand test is, thus, less valid and has also 
a limited applicability in patients with FSHD. A more reliable test to determine the 
exercise intensity and/or aerobic capacity in patients with FSHD, particularly in 
those who are relatively severely affected, is not yet available.
Blinding
Although physiotherapists who performed the physical tests were blinded, blinding 
of participants was not possible. Especially when using a self-report primary 
outcome measure (CIS-fatigue), this may have led to bias on the basis of a 
Hawthorne or placebo effect. The Hawthorne effect is a psychological phenomenon 
that produces an improvement in human behavior or performance as a result of 
increased attention from therapists or outcome assessors (60). A placebo effect 
can be due to specific expectations that patients may have about the efficacy of 
the treatment they receive (61). This is why the FACTS-2-FSHD trial received only 
a “Class III” label of evidence by the journal Neurology, whereas the results of the 
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MRI study received a “Class II” label by the same journal. Hawthorne or placebo 
effects allow the possibility that the observed effects are not directly related to the 
specific biological or psychological effects of the treatment. However, as the level 
of experienced fatigue was still reduced after 12 weeks of CBT and AET compared 
with the control group and we substantiated our results with MRI parameters, 
it is very unlikely that the observed effects would be solely due to a placebo or 
Hawthorne effect.
Randomization
To obtain sufficient power, the participants in the control group had to be 
randomized again to one of both intervention groups. Fortunately, an analysis 
revealed that there was no difference at the start of the intervention between the 
groups with regard to the primary and secondary randomization. Performing a 
cross-over trial was not a viable alternative, since an adequate wash-out period 
could not be determined due to the possibility of carry-over effects (even after a 
substantial wash-out period). 
Selection bias
In comparison with other studies, the participants in the FACTS-2-FSHD study 
indicated a lower pain score as measured with the VAS. On average, the VAS score 
was 24 on a scale of 0 to 100. In other studies, higher mean VAS scores were 
found: from  44 (62) to 45 (63). Only a small number of patients in the FACTS-2-
FSHD study had a high VAS score. At baseline, 63% of the patients had a VAS 
score lower than 25 and only 14% had a VAS score greater than 50. This may 
have been because the participants were a selected group of patients. When 
patients experience great pain, they are probably less eager to participate in a 
study that requires an increase in physical activity and that is focused primarily 
on the treatment of experienced fatigue instead of pain. Moreover, during the 
qualitative interviews in the FACTS-2-PERSPECTIVES study, participants did not 
mention pain as an important theme. Interviews with the CBT therapists showed 
that the module “unhelpful cognitions regarding pain” had been used infrequently 
(unpublished data). The patient population in the FACTS-2-FSHD study did not 
differ in demographic characteristics from the 139 patients included in the study by 
Kalkman et al. (1). From this perspective, the participants included in the FACTS-2-
FSHD study seem to constitute a representative sample of the Dutch population of 
patients with FSHD.
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RECOMMENDATIONS
It seems that regular physical activity is at least essential to obtain a decrease in 
fatigue in patients with FSHD. In those patients, the statement “I’m too fatigued 
to be physically active” should therefore be changed into: “I’m fatigued, so I need 
to be physically active.” Therefore, both interventions (AET and CBT) should be 
made available to all patients with FSHD and severe experienced fatigue given the 
positive results of the FACTS-2-FSHD study.
In addition, one can expect that both interventions are also beneficial to patients 
with no or relatively minor fatigue for improving and maintaining their functional 
capacities. The favorable effects of physical activity on the slowing down of fatty 
muscular infiltration (CBT and AET) and on muscle strength (AET) will probably also 
occur in patients with much lower levels of fatigue.
AET or CBT?
In the FACTS-2-FSHD study, the effect of AET and CBT was compared with a 
waiting-list condition consisting of usual care. A logical question is whether one 
should prescribe primarily CBT, AET or perhaps both interventions to patients 
with FSHD and severe fatigue? A combination of both could possibly be even 
more effective, but requires a larger investment of both practitioners and patients 
with possibly a negative impact on compliance and costs. Both interventions 
cannot be seen separately from each other. CBT contains a module directed at 
the optimization of physical activities. And in order to maximize the impact of AET, 
unhelpful cognitions regarding physical activity have to be discussed and possibly 
changed. The results of the FACTS-2-FSHD study cannot definitively answer 
the aforementioned question, nor can they answer the question whether AET is 
more effective than CBT (or vice versa), because the study was not sufficiently 
powered for this comparison. Given the small differences in effect size between 
CBT and ART, such a comparison would require many more participants per 
group and an international consortium, given the low prevalence of FSHD in the 
Netherlands. For the time being, both treatments can be implemented in daily 
practice depending on the local facilities. A combination treatment could be helpful 
in individual cases, especially when, in addition to an effect on physical activity 
and fatigue, an effect on muscle strength and/or aerobic capacity is aimed for. The 
departments of Rehabilitation and Neurology of the Radboud University Nijmegen 
Medical Center have developed the ENERGETIC  program (64). This rehabilitation 
program combines AET, supervised by a physiotherapist, and energy-conservation 
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strategies, supervised by an occupational therapist, in a self-management 
group program to improve social participation, physical endurance and alleviate 
fatigue. An RCT that evaluates the (cost-) effectiveness of the “ENERGETIC” 
program has been conducted and the results are awaited soon. In all cases, the 
recommendation for treatment should match with the individual goals, wishes and 
needs of the patient and take into account relevant personal and environmental 
factors.
AET: exercise as medicine
Currently, evidence-based exercise prescriptions do not exist for patients with 
FSHD. Both patients and clinicians experience difficulties in preparing training 
programs (65). The recommendations for an effective aerobic exercise program by 
the American College of Sports Medicine are difficult to adhere to by many patients 
with FSHD: 20 to 60 minutes AET, 3 to 5 days per week at an intensity of 40 to 85% 
of the heart-rate reserve (66). The results of the present study will be used to set up 
an AET standard for patients with neuromuscular disorders for use in rehabilitation 
centers and physiotherapy practices. The results of the FACTS-2-FSHD study and 
the experiences of the physiotherapists showed that the Borg scale, the talk test 
(which means that one can carry on a light conversation while exercising), and the 
rule that activities of daily life should not be negatively influenced by the exercise 
program are useful indicators for a proper exercise intensity (67). Previous research 
from Canada has shown that, in clinical practice, the exercise intensity is frequently 
determined based on simple tests such as the response of participants to the 
training, the Borg scale and/or the talk test (68).
In any case, to maintain the highest possible compliance, it is recommended 
to prescribe exercise as medicine with a clear description of exercise duration, 
frequency, intensity, location and supervision, and to search for a physical activity 
that the patient prefers. The barriers that patients still experience when exercising 
such as costs, shame for their limitations, and lack of facilities should be taken into 
account (69). It is for a reason that the FSHD lifestyle guide (70) refers to “one has 
to move, if possible. “ It is important to realize that a patient does not always have 
to exercise. The results of the FACTS-2-FSHD study emphasize the relevance of 
a physically active lifestyle. Ideally, an intervention for the improvement of chronic 
fatigue would no longer be needed. When adherence to a physically active lifestyle 
is already recommended shortly after the diagnosis, and physical activity and 
exercises are maintained, a patient may not be caught in a downward spiral as a 
result of physical inactivity.
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CBT: part of rehabilitation 
The beneficial effect of CBT was not only larger than expected, but also applicable 
to more domains than expected. In the future, CBT should be implemented as 
part of rehabilitation treatment for patients with FSHD and chronic fatigue. The 
message that AET has a positive effect in FSHD has been expressed increasingly 
in recent communications related to research and healthcare. However, in spite 
of the positive and long-lasting effects of CBT as observed in the FACTS-2-FSHD 
study, it will take more time before CBT will receive the same amount of attention. 
The scientific evidence for the effect of AET in neuromuscular disorders is growing 
steadily. Yet, until now, a positive effect of CBT in neuromuscular disorders has 
been described only in the FACTS-2-FSHD study. Nevertheless, it is expected that 
the promotion of CBT as an intervention for neuromuscular disorders can develop 
equally to AET. Currently, an international study on the effect of CBT with and 
without AET in patients with myotonic dystrophy type 1 is being conducted, the 
OPTIMISTIC study (71). 
Not every rehabilitation center or hospital will have a sufficient number of 
psychologists qualified in CBT. 
Implementing CBT as standard care in rehabilitation can therefore be difficult, 
also because of the costs of a psychological treatment. To solve this problem, the 
principle of “stepped care” could be applied. Stepped care means that the most 
effective yet least resource-intensive treatment is delivered to patients first, only 
“stepping up” to more intensive treatments when clinically required. Step one can 
be the implementation of CBT techniques such as increasing physical activity 
through a graded activity program by physical and/or occupational therapists, 
and help to adhere to regular sleep–wake times and change unhelpful thoughts by 
rehabilitation physicians (72). To further optimize the effect of CBT and in the case 
of psychopathological symptoms, counseling by a psychologist specialized in CBT 
can be administered as a second step. CBT has to be considered as medicine 
too. The psychologist will have to prescribe which specific modules have to be 
followed. Almost always, the dysregulation of physical activity module will be part 
of the treatment. CBT can also be supported by e-health, for example by using an 
interactive application, in order to save costs (73).
GENERALIZABILITY
During the FACTS-2-FSHD study, both interventions were performed at several 
locations by multiple therapists according to the same protocol. This multi-
centeredness implies that the treatment protocols should be implementable in 
other rehabilitation practices in the near future.
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From the results of the FACTS-2-FSHD study, it cannot be concluded that AET and 
CBT will also be effective to reduce fatigue in patients with other neuromuscular 
disorders than FSHD. If epigenetics, inflammation and the downward spiral as 
a result of physical inactivity are important explanatory mechanisms of effect in 
FSHD, it is not justified to extrapolate the results to other neuromuscular disorders. 
The negative results of the FACTS-2-PPS trial confirm this notion. Moreover, it is 
unknown whether the results can be generalized to patients with FSHD without 
severe fatigue. Of course, in daily rehabilitation practice, reducing cardiovascular 
risk factors is often a secondary objective of exercise therapy. Previous studies 
have shown that patients with neuromuscular disorders, including FSHD, are 
at a greater risk of developing metabolic syndrome (74, 75). Thus, a physically 
active lifestyle, taking into account the preventive effect on chronic disease and 
the beneficial effects on fatty replacement in muscles (CBT and AET) and muscle 
strength (AET), can be recommended also to FSHD patients without severe fatigue 
with the aim to improve and maintain their functional capacities and health.
FUTURE PERSPECTIVES
To better interpret and implement the results of the FACTS-2-FSHD study, further 
research is necessary. This research will have to focus both on the underlying 
mechanisms of the observed effects and on improving the methodological 
shortcomings as previously described.
Molecular signature
In order to better explain the positive effects on the fatty replacement of muscles, 
the molecular signature of both interventions (CBT and AET) has yet to be found. 
The aforementioned assumptions regarding the role of epigenetic factors and 
inflammation could be confirmed or refuted by conducting a study with AET and/
or CBT including DNA analysis of muscle tissue and analysis of blood samples for 
the determination of myokines and cytokines before and after the intervention. The 
previously mentioned “OPTIMISTIC” trial already uses an unbiased approach to 
determine the molecular signature of both CBT and AET. This is unusual. Usually, 
an intervention starts with basic research, while in a later stage its impact on 
daily functioning and social participation are measured. Here, basic research may 
explain in a later phase the observed effects of AET and CBT on the functioning 
and participation of patients with FSHD (‘reverse translational research’). The 
long-term effect on fatty replacement of muscle tissue should be observed in a 
longitudinal study. However, such a study will be labor- and cost-intensive because 
of repeated MRI measurements. C
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Optimizing life balance
Within the CBT module directed at dysregulation of physical activity, regaining a 
balance in physical activities throughout the day and week is a key goal. However, 
the concept of activity encompasses more than just physical activity. “Life balance” 
refers to a highly personalized construct that includes balancing both the physical 
demands and the more complex role demands (e.g. as employee, parent, or 
volunteer), while preserving and creating meaning in life. Patients with FSHD often 
experience their lives as “out of balance” due to the perceived burden of disease 
as shown in Figure 4. It is a big challenge for them to balance all their current and 
future activities with their physical and mental capacities. Too many and too heavy 
activities can lead to overload, but having too few meaningful activities also leads 
to an unsatisfactory situation. Of course, the degree of fatigue is an important 
factor herein. The life balance of the patient in the reported case study was better 
after CBT. He was able again to combine social activities with work. Within the field 
of rehabilitation medicine, there is a growing interest in self-management programs 
that are based on the use of energy-saving strategies (64). It is expected that an 
optimal life balance is also of importance for the degree of social participation. 
However, the concept ‘life balance’ is very difficult to measure because it concerns 
the duration and intensity of selected activities as well as the personal meaning 
of these activities. Until now, mainly measurement instruments at the ICF level 
of impairments are available for patients with FSHD. Future research should, 
therefore, focus on validating outcome measures at the ICF levels of activities 
and participation with a focus on the construct of ‘life balance.’ Currently, a new 
outcome measure is being validated to measure the degree of disease burden in 
patients with FSHD: the FSHD Health Index  (HI FSH) (76).
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1H  proton
1RM  one repetition maximum
31P  phosphorous
6MWT  six-minute walk test
ACSM  American college of sports medicine
AET  aerobic exercise training
AFQ  abbreviated fatigue questionnaire
AL  adductor longus
ALS  amyotrophic lateral sclerosis
AM  adductor magnus
AP  action potential
ARR  absolute risk reduction
BDI  Beck depression index
BDI-pc  Beck depression inventory primary care
BF%  body fat percentage
BFL  biceps femoris long head
BFS  biceps femoris short head
BMD  Becker muscular dystrophy
BMI  body mass index
CAF  central activation failure
CBT  cognitive behavioral therapy
CCMO  centrale commissie mensgebonden onderzoek
CI  confidence interval
CIS  checklist individual strength
CIS-activity physical activity subscale of the checklist individual strength
CIS-fatigue fatigue subscale of the checklist individual strength
CK  creatine phosphokinase
CMT  Charcot Marie Tooth
CPEO  chronic progressive external ophtalmoplegia
CRAMP  computer registry of all myopathies and polyneuropathies
CSS  clinical severity score
CT  computer tomography
DM1  myotonic dystrophy type 1
DM2  myotonic dystrophy type 2
DMD  Duchenne muscular dystrophy
DMPK gene dystrophia myotonica protein kinase gene
DN4  douleur neuropathic 4
EDL  extensor digitorum longus
ENMC  European neuromuscular centre
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ESS  Epworth sleepiness scale
FACTS-2-FSHD acronym for Fitness And Cognitive behavioral TherapieS / 
  for Fatigue and ACTivitieS in facioscapulohumeral dystrophy
FACTS-2-NMD acronym for Fitness And Cognitive behavioral TherapieS / 
  for Fatigue and ACTivitieS in neuromuscular disorders
FFM  fat-free mass
FFMI  fat free mass index
FOV  field of view
FSHD  facioscapulohumeral dystrophy
FSS  fatigue severity scale
FTI  force time integral
G  gracilis
HADS  hospital anxiety and depression scale
HI FSH  FSHD health index
HRR  heart rate reserve
ICC  intraclass correlation coefficient
ICF  international classification of functioning, disability and health
IT  inversion time
LGMD  limb girdle muscular dystrophy
MDiff  mean differences
MET  metabolic equivalent
MIRS  muscular impairment scale
MRI  magnetic resonance imaging
MRS  magnetic resonance spectroscopy
MVC  maximal voluntary muscle force
MVIC  Maximum voluntary isometric strength
NHP  Nottingham health profile
NHP-sleep sleep subscale of the Nottingham health profile
NMD  neuromuscular disorders
NMR  magnetic resonance spectroscopy
NNGB  Dutch standard for healthy exercise
NNT  number needed to treat
NP/NA  non-participant/ not available for MRI study
NPSI  neuropathic pain symptom inventory
NRS  numeric rating scale
PCr  phosphocreatine 
Pi  inorganic phosphate
PPS  post-polio syndrome
PROMM proximal myotonic myopathy
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PSQI  Pittsburgh sleep quality index
qT2-MRI quantitative T2-MRI
RCT  randomized controlled trial
REE  resting energy expenditure
REVMan review manager 5
RF  rectus femoris 
RM  repetition maximum
ROI  region of interest
S  sartorius
SCL-90  symptom checklist-90
SF-36  short form 36
SFQ  short fatigue questionnaire
SIP  sickness impact profile
SIP68-sb social behavior subscale of the Sickness Impact Profile 68
SM  semimembranosus
SMA  spinal muscular atrophy
SNR  signal to noise ratio
ST  semitendinosus
TE  echo time
TEE  total daily energy expenditure
TIRM  turbo inversion recovery magnitude
UC  usual care
UNS  Unnalinna narcolepsy scale
VAS  visual analogue scale
VI  vastus intermedius
VL  vastus lateralis
VM  vastus medialis
VO2max maximal oxygen uptake
VSN  vereniging spierziekten Nederland
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NL
Vetfract ie  in  
vastus sp ier
na AET & CGT
Kwal i te i t  
van leven
na AET & CGT
Ef fec t  op
z iekte l as t
af ter
CBT
af ter
AET
before
AET & CBT
SAMENVATTING
SAMENVATTING
Facioscapulohumerale musculaire dystrofie (FSHD) is de op twee na meest 
voorkomende spierdystrofie met een geschatte prevalentie van 1 op de 8.000 
personen wereldwijd. Het is een erfelijke aandoening met autosomaal dominante 
overerving, waarbij allereerst de gezichtsspieren en spieren van de schoudergordel 
progressief verzwakken en later meestal ook de rompspieren en arm- en 
beenspieren. In het afgelopen decennium is al veel inzicht verworven in de 
onderliggende moleculair genetische oorzaak. De oorzaak van FSHD is in meer dan 
95% van de gevallen te vinden in het ontbreken van bepaalde stukjes DNA (D4Z4) 
op chromosoom 4q35. Hierdoor komt er een giftig eiwit, DUX4, in de spiercellen 
vrij. Het is echter nog niet bekend waarom de mate, de verdeling en de progressie 
van spierzwakte van patiënt tot patiënt zo verschillen. Bovendien zijn er geen 
biomarkers beschikbaar om de ernst en progressie van FSHD objectief te kunnen 
beoordelen.
Tot op heden is er geen curatieve behandeling beschikbaar voor patiënten met 
FSHD. Hoewel de levensverwachting niet duidelijk beperkt is, wordt uiteindelijk 
20% van de patiënten rolstoelafhankelijk door de spierzwakte. Bovendien ervaart 
meer dan 60% van de patiënten ernstige en chronische vermoeidheid, wat de mate 
van sociale participatie vermindert en de ziektelast vergroot. Fysieke inactiviteit 
bleek uit eerder onderzoek de belangrijkste in stand houdende factor van deze 
ervaren vermoeidheid bij patiënten met FSHD. Fysiek actief zijn én blijven is echter 
door de spierzwakte moeilijk voor patiënten. Dit kan vervolgens leiden tot een 
vicieuze cirkel van vermoeidheid, inactiviteit en afname van sociale participatie. 
De twee belangrijkste doelstellingen van dit proefschrift waren: 
De beschrijving van vermoeidheid en inactiviteit bij neuromusculaire 
aandoeningen (deel 1).
Het bestuderen van het effect van twee, op een theoretisch model gebaseerde, 
behandelingen die beogen de mate van activiteit te optimaliseren en de ervaren 
vermoeidheid te verminderen bij patiënten met FSHD (deel 2).
Hoofdstuk 1 is de algemene inleiding van het proefschrift en verstrekt 
achtergrondinformatie over FSHD. Het klinische beloop van FSHD is tussen 
personen sterk variabel. Deze variabiliteit doet vermoeden dat epigenetische 
mechanismen een rol spelen. Epigenetica wordt gedefinieerd als de erfelijke 
veranderingen in genactiviteit en genexpressie die plaatsvinden, ook gedurende het 
leven, onafhankelijk van veranderingen in de DNA volgorde. 
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Vermoeidheid wordt in toenemende mate herkend én erkend als een belangrijk 
klinisch probleem bij veel aandoeningen. Voor verscheidene patiëntpopulaties 
worden nu ook evidence-based behandelprogramma’s ontwikkeld. Ook meer dan 
60% van de patiënten met FSHD, gemeten met de subschaal vermoeidheid van 
de Checklist Individuele Spankracht  (CIS-vermoeidheid), een multidimensionale 
vermoeidheidsvragenlijst, bleek ernstige vermoeidheid te ervaren. Fysieke 
inactiviteit, slaapstoornissen en pijn bleken in volgorde van belangrijkheid 
bij te dragen aan het in stand houden van vermoeidheid bij patiënten met 
FSHD. Spierzwakte draagt bij aan fysieke inactiviteit, en daarmee indirect aan 
(toename van) vermoeidheid. Dit model van in stand houdende factoren van 
vermoeidheid vormde de basis voor het in dit proefschrift beschreven en gebruikte 
behandelprotocol van de FACTS-2-FSHD studie (acroniem voor Fitness And 
Cognitive behavioral TherapieS for Fatigue and ACTivitieS in FSHD). Dit betrof de 
eerste, op een theoretisch model gebaseerde, klinische trial naar het effect van 
aerobe training (AT) en cognitieve gedragstherapie (CGT) op ervaren vermoeidheid 
bij patiënten met FSHD.
Er werd verondersteld dat, om ervaren vermoeidheid te verminderen, twee 
verschillende behandelingen toegepast zouden kunnen worden: AT om de mate 
van fysieke activiteit te vergroten en CGT om een actieve levensstijl te stimuleren 
(maar tegelijkertijd overmatige fysieke belasting te voorkómen). Het primaire 
doel van deze studie was dan ook om het effect van beide behandelingen op 
ervaren vermoeidheid bij patiënten met FSHD te evalueren op basis van de CIS-
vermoeidheid. Een secundair doel was het effect van beide behandelingen op de 
bekende in stand houdende factoren van vermoeidheid bij FSHD te evalueren. 
De secundaire uitkomstmaten besloegen alle domeinen van de International 
Classification of Functioning, Disability and Health (ICF). Tevens werd beoogd om 
klinisch relevante biomarkers te vinden om de progressie van de aandoening en de 
respons op de behandeling bij patiënten met FSHD te meten met behulp van MRI 
(Magnetic Resonance Imaging). MRI is namelijk in staat om op relatief eenvoudige 
wijze intramusculaire fibrose en vervetting van de spieren te visualiseren. Er werd 
verondersteld dat het daarom een geschikte en objectieve biomarker zou kunnen 
zijn om de betrokkenheid van individuele spieren vast te leggen en hiermee 
objectief de ernst en progressie van de spieraantasting bij FSHD te meten.
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DEEL 1: VERMOEIDHEID BIJ NEUROMUSCULAIRE 
AANDOENINGEN
In deel 1 wordt een overzicht gegeven van de prevalentie (het vóórkomen), de 
meetinstrumenten en de behandeling van vermoeidheid bij neuromusculaire 
aandoeningen (NMA).
De volgende onderzoeksvragen worden gesteld:
1. Wat is de prevalentie en de relevantie van vermoeidheid bij patiënten met 
een spierdystrofie?
Uit hoofdstuk 2 blijkt dat vermoeidheid een veel voorkomend en ook 
relevant symptoom is bij patiënten met een spierdystrofie. Het onderscheid 
tussen ervaren vermoeidheid en spierzwakte, het kenmerkende symptoom 
van spierdystrofie, kan lastig zijn. Hoewel ervaren vermoeidheid moeilijk te 
definiëren is, kan het met vragenlijsten wel betrouwbaar gemeten worden, 
zoals met de CIS-vermoeidheid. Omdat vermoeidheid bij spierdystrofieën 
een multidimensioneel concept is, is het belangrijk om inzicht te hebben in 
de onderliggende factoren die bijdragen aan deze vermoeidheid. Volgend 
op een dergelijke analyse kunnen namelijk preventieve en therapeutische 
behandelingen worden ontwikkeld. Daarom wordt een overzicht gegeven 
van de onderliggende pathofysiologie van vermoeidheid bij verscheidene 
spierdystrofieën en wordt het model van in stand houdende factoren van 
ervaren vermoeidheid bij FSHD toegelicht. Tot slot wordt een systematisch 
overzicht van de mogelijke behandelopties van vermoeidheid bij patiënten 
met spierdystrofie gepresenteerd bestaande uit fysieke training, medicatie en 
cognitieve gedragstherapie.
2. Hoe kan vermoeidheid bij patiënten met neuromusculaire aandoeningen 
gemeten worden?
Hoofdstuk 3 beschrijft de resultaten van een workshop van het European 
Neuromuscular Center (ENMC) over pijn en vermoeidheid bij patiënten met 
NMA. Deze workshop had als doel overeenstemming te bereiken over de 
definitie voor pijn en vermoeidheid bij NMA en om een eenduidige set van 
meetinstrumenten voor pijn en vermoeidheid vast te leggen voor deze groep 
aandoeningen. Zowel pijn als vermoeidheid komen veel voor bij NMA en 
zijn van grote invloed op veel activiteiten van het dagelijkse leven. Er kan 
onderscheid gemaakt worden tussen verschillende typen pijn en vermoeidheid, S
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gerelateerd aan de onderliggende (stadia van) NMA. Dit moet los gezien 
worden van aspecifieke pijn en vermoeidheid die niet primair gerelateerd 
zijn aan de onderliggende aandoening. Een verscheidenheid aan methoden 
wordt gebruikt om pijn en vermoeidheid bij NMA te meten. Om effectieve 
behandelingen voor NMA te kunnen ontwikkelen moet echter internationaal 
overeenstemming bereikt worden over de definitie van en de meetinstrumenten 
voor zowel pijn als vermoeidheid. Daarom wordt tot slot een eenduidige set 
van meetinstrumenten voor gebruik in toekomstig onderzoek en in de klinische 
praktijk beschreven.
3. Wat is het effect van training bij spierziekten?
Hoofdstuk 4 bestaat uit een Cochrane review waarin de veiligheid en het 
effect van krachttraining en aerobe training bij mensen met een spierziekte 
wordt beschreven. Krachttraining en aerobe training zouden spierfunctie 
en cardiovasculaire functie kunnen optimaliseren en verdere spieratrofie 
door inactiviteit en conditieverlies kunnen voorkómen bij mensen met een 
spierziekte. Er werd in de bekende databases gezocht naar gerandomiseerde 
of quasigerandomiseerde gecontroleerde onderzoeken die krachttraining en/
of aerobe training vergelijken met gebruikelijke zorg. De behandeling moest 
minimaal 6 weken duren en de spierziekte moest op de juiste wijze vastgesteld 
zijn bij de deelnemers. Vijf onderzoeken voldeden aan deze criteria, met 
in totaal 170 deelnemers. Er waren twee onderzoeken naar het effect van 
krachttraining bij FSHD en myotone dystrofie (totaal 101 deelnemers). Twee 
onderzoeken beschreven het effect van krachttraining in combinatie met 
aerobe training bij personen met mitochondriële myopathie (18 deelnemers) 
en myotone dystrofie type I (35 deelnemers). Het laatste onderzoek betrof een 
onderzoek naar het effect van aerobe training bij personen met polymyositis 
en dermatomyositis (14 deelnemers). Deze onderzoeken toonden aan dat 
krachttraining met een matige intensiteit bij mensen met myotone dystrofie of 
FSHD, en aerobe training bij mensen met dermatomyositis of polymyositis niet 
schadelijk is voor de spieren. Krachttraining in combinatie met aerobe training 
bleek veilig te zijn bij myotone dystrofie type I en zou effectief kunnen zijn in 
het verbeteren van de lichamelijke conditie bij mensen met een mitochondriële 
myopathie. Tot slot bleek krachttraining niet schadelijk te zijn bij personen met 
FSHD, myotone dystrofie, mitochondriële myopathie, of dermatomyositis/
polymyositis, maar er was onvoldoende bewijs om een positief effect aan te 
tonen. Door beperkingen in de opzet van de studies konden meer algemene 
conclusies niet getrokken worden.
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DEEL 2: DE FACTS-2-FSHD STUDIE
In deel 2 worden de resultaten van de FACTS-2-FSHD studie beschreven. De 
volgende onderzoeksvragen worden gesteld:
4. Wat is het effect van aerobe training en cognitieve gedragstherapie op ervaren
vermoeidheid bij patiënten met FSHD?
In hoofdstuk 5 wordt het protocol van de FACTS-2-FSHD studie beschreven. 
De FACTS-2-FSHD studie is het eerste, op een theoretisch model gebaseerde, 
gerandomiseerde klinische onderzoek dat het effect en behoud van effect 
van aerobe training (AT) en cognitieve gedragstherapie (CGT) beschrijft 
op het verminderen van ervaren vermoeidheid bij patiënten met FSHD. 
De behandelingen zijn gebaseerd op een theoretisch model van in stand 
houdende factoren van vermoeidheid bij patiënten met FSHD. Het primaire 
doel van de FACTS-2-FSHD studie was om het effect van AT en CGT te 
bestuderen op het verminderen van ervaren vermoeidheid bij patiënten met 
FSHD type 1 in vergelijking met de gebruikelijke zorg. De verwachting was dat 
zowel AT als CGT effectief zouden zijn in vergelijking met de gebruikelijke zorg. 
De gebruikelijke zorg bestaat meestal uit geen enkele behandeling of soms 
reguliere fysiotherapie. Er werd verwacht dat een eventuele verbetering door AT 
verkregen zou worden door het verbeteren van de fysieke (aerobe) capaciteit, 
terwijl de effecten door CGT veroorzaakt zouden worden door veranderingen 
in de activiteiten van het dagelijks leven en in gedrag. Secundaire doelen 
bestonden uit het evalueren van het effect van AT en CGT op de bekende in 
stand houdende factoren van vermoeidheid bij FSHD.
De AT bestond uit fietstraining op een fietsergometer. Dit programma 
duurde 16 weken en bevatte wekelijks één training onder supervisie van 
een fysiotherapeut in een revalidatiecentrum en twee keer per week één 
training thuis. CGT was gericht op alle bekende in stand houdende factoren 
van vermoeidheid bij FSHD en werd aangepast aan de behoeften van de 
individuele deelnemer. Elke sessie duurde een uur en werd begeleid door een 
geregistreerde cognitieve gedragstherapeut. Na de eerste meting werden de 
patiënten door middel van loting toegewezen aan de AT groep, CGT groep, 
of een groep die gebruikelijke zorg kreeg. Na een behandelperiode van 16 
weken en een follow-up van 3 maanden werd de groep met gebruikelijke 
zorg opnieuw door middel van loting toegewezen aan ofwel AT ofwel CGT 
(28 weken na inclusie). De bedoeling was om uiteindelijk 25 volwassen 
patiënten in elk van de drie groepen in te sluiten: AT, CGT, of gebruikelijke 
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zorg. Omdat patiënten in de controlegroep alsnog AT of CGT kregen, was het 
minimum benodigde aantal patiënten 50. Uitkomstmaten werden verkregen 
bij start van het onderzoek, onmiddellijk na beëindiging van de behandelingen 
(en controleperiode) en na respectievelijk 12 en 24 weken van follow-up. 
Een ‘linear mixed model for repeated measurements’ werd gebruikt om de 
verschillen tussen de groepen te analyseren. 
In hoofdstuk 6 worden de resultaten van de FACTS-2-FSHD onderzoek 
beschreven waarvan het protocol in hoofdstuk 5 is toegelicht. In totaal 57 
ambulante patiënten met FSHD type 1 en ernstige ervaren vermoeidheid 
werden door middel van loting toegewezen aan AT, CGT, of gebruikelijke zorg. 
Na de behandeling was de ervaren vermoeidheid voor zowel de deelnemers 
in de AT groep (28 deelnemers) als de CGT groep (25 deelnemers) significant 
afgenomen in vergelijking met de groep deelnemers die gebruikelijke zorg 
kregen. Dit verschil, gemeten met de CIS-vermoeidheid, was -9,1 voor AT (95% 
BI: -12,4 tot -5,8) en -13,3 voor CGT (95% BI -16,5 tot -10,2). Dit positieve 
effect bleef voor beide groepen ook na de follow-up periode bestaan, met een 
verschil van -8,2 voor AT (95% CI -12,4 tot -5,8) en -10,2 voor CGT (95% BI 
-14,0 tot -6,3). Na de behandeling was er bij 19 deelnemers in de CGT groep 
(75%) en 14 deelnemers in de AT groep (50%) geen sprake meer van ernstige 
vermoeidheid. De ‘number needed tot treat’ (NNT), het aantal patiënten dat 
behandeld moet worden om één patiënt te genezen van ernstige vermoeidheid, 
kwam voor AT daarmee op 2.3 (95% BI 1,4 tot 3,1) met een absoluut risico 
reductie (ARR) van 50% (95% BI 32 tot 69%). De NNT voor CGT was 1,3 (95% 
BI 1,1 tot 1,7) met een ARR van 76% (95% BI 59 tot 93%). Bij de CGT groep 
werden alle in stand houdende factoren van vermoeidheid positief beïnvloed, 
met uitzondering van pijn. Ook nam de mate van sociale participatie toe. De 
deelnemers aan de AT groep vertoonden een toename van objectief gemeten 
fysieke activiteit en maximaal isometrische kracht van de quadriceps. De 
toename van objectief gemeten fysieke activiteit bij beide groepen en de 
verbetering van de mate van sociale participatie bij CGT was ook bij de follow-
up meting nog steeds aanwezig. Meer dan 70% van de deelnemers in de AT 
groep en bijna 80% van de deelnemers in de CGT groep bleef fysiek actief, ook 
na beëindiging van het onderzoek. Bij beide groepen werd geen verbetering in 
aerobe capaciteit gevonden. Alleen milde bijwerkingen werden gerapporteerd 
in de AT groep. Het mediaan aantal behandelsessies was veel lager in de CGT 
groep, namelijk 5, dan in de AT groep (40 sessies). Er werd geconcludeerd dat 
zowel AT als CGT in staat zijn ervaren vermoeidheid te genezen bij patiënten 
met FSHD. 
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5. Zijn er structurele afwijkingen aantoonbaar in skeletspieren van patiënten met 
FSHD die kunnen dienen als biomarkers voor het meten van ziekteprogressie 
en behandeleffect?
Ondanks dat het meest relevante onderliggende genetische mechanisme 
van de aandoening FSHD ontdekt is, is het exacte mechanisme nog niet 
bekend. Dit is wel noodzakelijk om het proces dat leidt tot vervetting van de 
skeletspieren beter te begrijpen.
Uit de studie beschreven in hoofdstuk 7 blijkt dat vetfractie, gemeten door 
middel van kwantitatieve MRI (q-MRI), zowel een objectieve als een gevoelige 
biomarker is om betrokkenheid van de spier, zelfs subklinisch, aan te tonen. Uit 
een analyse van de gemiddelde vetfractie van alle gemeten individuele spieren 
bleek dat er een zandloperpatroon bestaat van veel spieren: spieren zijn ofwel 
geheel, ofwel vrijwel niet vervet; weinig spieren zijn gemiddeld vervet. Deze 
quasibinaire verdeling is niet eerder beschreven voor andere spierdystrofieën, 
en zou specifiek kunnen zijn voor FSHD. De intramusculaire vetfractie nam 
lineair toe van proximaal naar distaal. Vervetting van een gehele spier zou, 
gemiddeld gezien, ongeveer 3,5 jaar duren. De meest steile gradiënt van 
vervetting werd gezien in de gemiddeld aangedane spieren, wat een aanwijzing 
kan zijn voor het feit dat deze spieren in relatief korte tijd snel vervetten totdat 
ze volledig aangedaan zijn. Deze bevinding zou relevant kunnen zijn voor het 
stellen van de prognose en het bepalen van behandeleffecten bij FSHD. 
Het belangrijkste doel van de studie die beschreven wordt in hoofdstuk 8 
is het bepalen van het effect van AT en CGT op de toename van vervetting 
en het voorkómen van oedeem in individuele beenspieren van patiënten met 
FSHD type 1 door middel van T2-MRI. Kwantitatieve T2-MRI (qT2-MRI) en 
vetsuppressie T2-MRI afbeeldingen van het bovenbeen werden verkregen bij 
start en follow-up van 31 patiënten. Al deze patiënten waren geïncludeerd in 
de FACTS-2-FSHD studie; 13 van hen kregen de gebruikelijke zorg, 9 AT en 
9 CGT. In de groep met gebruikelijke zorg nam de vervetting in de aangedane 
spieren gemiddeld met 6,7% per jaar toe. Toename van vervetting trad 
gemiddeld gezien in alle spieren op behalve in de gastrocnemius, sartorius en 
vastus lateralis. The adductor magnus spier vertoonde de grootste toename 
van vervetting. Deze toename was significant lager na beide behandelingen. 
Er was nog maar een toename van 2,9% van vervetting per jaar in de AT groep 
(95% BI 0,7 tot 5,2; p< 0,05) en 1,7% per jaar in de CGT groep (95% BI -0,2 
tot 3,6; p < 0,01). In beide behandelgroepen ontwikkelden een kleiner aantal 
spieren oedeem in vergelijking met de groep die gebruikelijke zorg kreeg. De S
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vetfractie in de spieren van alle patiënten bij de eerste meting (gemiddelde 
waarde voor alle bovenbeenspieren per patiënt) was negatief gecorreleerd 
met de mate van fysieke activiteit bij de eerste meting (R2= 0,27; p = 0,0013), 
gemeten met behulp van de actometer, en met de maximale loopafstand (R2= 
0,40; p < 0,0001), maar niet significant gecorreleerd met aerobe capaciteit. Er 
werd geconcludeerd dat qT2-MRI een reproduceerbare en gevoelige biomarker 
is om het effect te meten van een toename van fysieke activiteit in individuele 
spieren van patiënten met FSHD en dat zowel AT als CGT de toename van 
vervetting van spierweefsel bij FSHD afremmen. 
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DANKWOORD
Bij het schrijven van het dankwoord besef ik ineens hoeveel mensen bij het 
onderzoek betrokken zijn geweest. Het zou een tweede deel van het proefschrift 
vergen om iedereen persoonlijk te bedanken. Het onderzoek was uniek door de 
samenwerking op alle vlakken, wat mij ook heeft gevormd als wetenschapper, arts 
én persoon. Dank allen hiervoor!
Allereerst wil ik alle 57 deelnemers aan het onderzoek hartelijk bedanken, zonder 
u was dit proefschrift niet mogelijk geweest. Ik heb u allen als een zeer betrokken 
groep ervaren. De studie vroeg veel inzet én inspanning die als vanzelfsprekend 
werd geleverd. De sleutel tot het succes van dit proefschrift lag bij uw inspanning. 
Door het thuis afleveren van de hometrainers samen met mijn vriend heb ik bij 
een aantal van u letterlijk en figuurlijk een kijkje in huis mogen nemen. De ervaren 
gastvrijheid was uniek. Dit heeft mij extra bagage als revalidatiearts en persoon 
meegegeven en ik heb er heel wat adressen voor een kopje koffie bij gekregen. 
Prof. Geurts, beste Sander, ik had mij geen betere eerste promotor kunnen 
wensen. Je hebt mij de kans gegeven zelfstandig te groeien in mijn carrière als 
wetenschappelijk onderzoeker, maar ook in de academische wereld. Je reactie 
op mijn stukken was altijd snel en adequaat. Ik bewonder je kennis en analytisch 
vermogen. Ik zal niet snel vergeten dat je, om de snelheid van indienen van 
het manuscript bij Neurology te bevorderen, je commentaar op jouw initiatief 
telefonisch met mij besprak, vijf minuten voordat je met de camper op vakantie 
ging.
Prof. van Engelen, beste Baziel, elk gesprek begon allereerst met een persoonlijke 
vraag, hoe gaat het met de mens achter de onderzoeker? Door als filosoof boven 
de stof te staan heb je mij unieke inzichten gegeven en gestimuleerd het geheel te 
overzien. Ik heb vaak driftig meegeschreven om je unieke oneliners te notuleren. 
Je bent een mensenmens en een netwerker waar ik mij graag aan spiegel. De vele 
mails en telefoontjes met de boodschap ‘ik wil je aan (...) voorstellen’  hebben mij 
een uniek (inter)nationaal netwerk van betrokken onderzoekers bezorgd, een van de 
meest plezierige arbeidsvoorwaarden van een promotietraject. 
 
Prof. Bleijenberg, beste Gijs, dank voor je hulp bij de opzet, uitvoering en 
verwerking van de resultaten van het onderzoek, wat ook nog doorging na 
je emiraat. Met cognitieve gedragstherapie hebben we een unieke vorm van 
behandeling in handen die de kwaliteit van leven van veel patiënten fors zal 
verbeteren. Je enthousiasme hiervoor neem ik graag mee in verder onderzoek en 
de implementatie hiervan. Ook in mijn klinisch werk bij mensen met hersenletsel 
ervaar ik nu de grote verbeteringen in de mate van participatie door cognitieve D
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gedragstherapie. Als het gevonden effect was bereikt door een medicijn was er 
minder verbazing geweest, maar ooit zal de medisch-wetenschappelijke wereld 
snappen waarom een psychologische behandeling effect heeft op het niveau van 
de spier…
Jos, wij waren een uniek team! Ik vind het geweldig dat je, door te assisteren 
bij mijn onderzoek, aangestoken bent met het onderzoeksvirus en nu zelf een 
promotietraject bent begonnen. Mede door jou bleven patiënten betrokken bij 
het onderzoek. Je hebt de unieke eigenschap goed om te kunnen gaan met 
uiteenlopende persoonlijkheden, van jong tot oud, uit alle windstreken. Dit heeft er 
zeker voor gezorgd dat er slechts één deelnemer is uitgevallen voor de metingen 
tijdens de studie. Ik wens je alle geluk bij het afronden van je promotieonderzoek 
en hoop nog vaak met je bij te kunnen kletsen, samen met Eva. Omdat ik me 
tijdens het onderzoek altijd erg gesteund heb gevoeld door je medewerking op alle 
vlakken, ben ik ook erg blij dat je mij ook tijdens de bijzondere dag van de promotie 
bij wil staan als paranimf.
Jessica, ook jij dank voor je nauwgezette hulp en betrokkenheid bij de start van 
het onderzoek. 
Barbara, een groot deel van dit proefschrift is door onze samenwerking tot stand 
gekomen. En die verliep zo soepel als een pas gesmeerde ketting, ook nog na de 
publicatie van de artikelen, ondanks dat jouw promotie al was afgerond. Dank voor 
al je hulp! Hetzelfde geldt voor Christine.
Prof. Heerschap, beste Arend, dank voor al je hulp bij het publiceren van de MRI 
artikelen, die voor heel wat beroering in de medische wereld hebben gezorgd, maar 
die je steeds moeiteloos wist te weerleggen. 
Dank aan de leden van het FACTS-2-NMA consortium, met een speciaal woord 
van dank voor Fieke Koopman, Annerieke Groenestijn, Eric Voorn, Minne 
Bakker en Karen Schipper, collega junior onderzoekers. 
 
Elly van der Kooi en Joke Kalkman, dit proefschrift is “model based”, het is 
gebaseerd op jullie onderzoeksbevindingen. Dank voor al jullie steun tijdens het 
traject. Jullie hebben mede de basis gelegd voor gedegen onderzoek en een goede 
band met de patiënten en de patiëntenvereniging.
Alle therapeuten van het onderzoek wil ik hartelijk danken voor hun inzet en 
enthousiasme: Hein, Hans, Marcel, Ralph, Sanne, Liesbeth, Ton, Kevin, 
Jacques, Frank, Bea, Rob en Sandra. 
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Dank aan de revalidatieartsen van de betrokken centra die belangeloos alle 
medewerking hebben verleend bij de inclusie van patiënten en faciliteren van de 
trainingen: Reinout van Vliet, Dirk van Kuppevelt, Erwin Baars, Gerard van der 
Leeuw, Esther Kruitwagen, Manon Janse en neuroloog Anneke van der Kooi. 
Ron Meijer, een speciaal woord voor jou. Onze kennismaking ontstond 
door de keyboardlessen aan je zoon. Je enthousiasme voor het vak van 
Revalidatiegeneeskunde en de wetenschap inclusief de garantie dat ik het zou 
kunnen combineren met een sportcarrière heeft mijn keuze voor een specialisatie 
net op tijd weten te veranderen van de sport- naar de revalidatiegeneeskunde. Hier 
ben ik je nog altijd dankbaar voor.
Mijn collega revalidatieartsen en arts-assistenten van Klimmendaal. Dankzij 
jullie ga ik altijd met veel plezier naar mijn werk, wat ook een van de belangrijkste 
redenen was om jullie collega te blijven. Dank voor alle ruimte die ik krijg om mij te 
ontwikkelen én mijzelf te zijn. Zelfs wanneer ik onverhoopt, doordat mijn kleding 
nog thuis lag, een presentatie geef in mijn fietskleding, waar jullie niets eens van 
opkeken :)
De collega onderzoekers en revalidatieartsen van het RadboudUMC, in het 
bijzonder Imelda de Groot. Dank voor alle gezelligheid en hulp!
De neuromusculaire neurologen van het Radboudumc, Joost Raaphorst, dank 
voor het delen van je kennis tijdens mijn neuromusculaire etalagestage, Nens 
van Alfen en Nicol Voermans, dank voor de samenwerking bij de opzet van 
toekomstig onderzoek, wat ook geldt voor revalidatieartsen Jan Groothuis, Viola 
Altmann, ergotherapeute Edith Cup en logopedist Bert de Swart.
Doordat het proefschrift raakvlakken had met veel medische subspecialismen 
heb ik artikelen kunnen schrijven met auteurs vanuit de radiologie, neurologie, 
revalidatiegeneeskunde, longgeneeskunde, metabolomics en psychologie. Dank 
aan alle mede-auteurs van artikelen, voor zover niet eerder genoemd: 
prof. Padberg, dr. Hendriks, dr. Van Alfen, dr. Wijkstra, prof. Kerstjens, 
dr. Meissner, dr. Deelder, dr. Mayboroda, dr. Morello J, dr. Nevedomskaya, 
dr. Pacchiarotta, dr. Pillen, dr de Rooy, dr. Kan, dr. Nabuurs, dr. Lindeman ƚ, 
dr Riphagen, dr. Van Middendorp, dr Rahbek, dr. Jansen, dr. Van den Engel-
Hoek, dr. Zwarts, dr. Brehm en dr. Beelen. 
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De subsidiegevers ZonMw, Prinses Beatrix Spierfonds, Revalidatiefonds, 
Revalidatie Nederland en Global FSH hebben dit onderzoek financieel 
ondersteund.
Dank aan de FSHD stichting en Spierziekten Nederland, inclusief de leden van 
de FSHD werkgroep, met een speciaal woord van dank voor Anke Lanser, zij 
hebben steeds alle mogelijke medewerking op alle vlakken verleend. 
“Mijn” teamleden van team 4 en Zintens, ik vind het geweldig hoe we samen 
aan het bouwen zijn aan goede behandelproducten. Ik bewonder jullie inzet, kennis 
en betrokkenheid. Een speciaal woord van dank voor “mijn” secretaresse Marian 
Bouwmeester, ik moet het eigenlijk veel vaker zeggen, maar ik ben enorm blij met 
jou als secretaresse, alleen jammer van die frequente buikpijn (van het lachen). Trap 
gerust nog geregeld op de rem, lach om mijn verstrooidheid, app me updates over 
de Olympische Spelen, of stuur me na een lange dag weg. Ik ben ook trots op jou! 
Danke Schön! 
Mevrouw Jensma, beste Ytje, en nu ook mevrouw Agterdenbos, Esther: dank 
voor de geboden mogelijkheid om na mijn opleiding bij Klimmendaal te blijven 
en de ondersteuning op alle vlakken bij mijn promotie en het symposium. Ik vond 
en vind op Klimmendaal een unieke combinatie van een prettige werksfeer en 
een uitdagend werkklimaat, waar ik nog lang mijn steentje aan hoop bij te zullen 
dragen. 
Eveline en Erica, jullie zijn gouden meiden. Met zijn drieën hebben we heel wat 
afgegiebeld tijdens de brainstormsessies. Het is uniek hoeveel uren tijd jullie aan 
de opmaak van dit proefschrift besteed hebben. Erica, je wist altijd precies weer 
te geven wat de kern van mijn boodschap was en hebt hierdoor ook inhoudelijk 
een bijdrage geleverd. Hierdoor heeft mijn proefschrift een geheel eigen uiterlijk 
gekregen. Waar Jos een grote rol had in de opzet en de uitvoering van het 
onderzoek, heb jij dit gehad in de vormgeving van het proefschrift. Super dat je mij 
ook bij staat als paranimf.
Lieve Tessa, een unieke vriendschap, ik weet nog goed hoe we vrienden werden 
tijdens het maken van appelmoes in de kleuterklas! We zijn met elkaar opgegroeid, 
hebben samen alle levensfasen doorlopen. Schreven elkaar wekelijks dikke 
brieven, uren spellen spelen, spraken cassettebandjes vol, samen naar de Efteling 
en Parijs, gingen studeren, koffie rondbrengen als vakantiewerk. Ik hoop hier straks 
als twee omaatjes tevreden op terug te kijken!
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Lieve Mebeline, grappig hoe een vriendschap begint door bij toeval naast elkaar te 
zitten tijdens een eerste hoorcollege. Met jou deel ik een liefde voor geneeskunde 
en sport en nu ook in de zorg voor patiënten met niet-aangeboren hersenletsel. 
Jammer dat je niet bij de promotie aanwezig kunt zijn, maar ik weet dat je dat in 
gedachten wel bent. 
Edwin en José, met Joost kreeg ik er gelijk leuke vrienden bij. In die mate, dat 
Joost een keer verbaasd zei dat ik jullie vaker spreek dan hijzelf ;) Ik hoop dat ik 
samen met José nog vaak afspraken op verzoek van de heren mag maken!
Lieve Mireille, het is alsof we elkaar al ons hele leven kennen, terwijl onze 
vriendschap pas een paar jaar bestaat. Het is zo fijn om geregeld over en weer 
stoom af te blazen tijdens fysieke activiteiten en het wederzijdse begrip te voelen 
en uiten. Ik hoop dit nog heel lang te kunnen blijven doen!
Lieve Debbie, we hebben elkaar leren kennen tijdens geneeskunde. Jammer dat 
je niet meer in de buurt woont, maar als we elkaar bellen, halen we de schade 
ruimschoots in!
Hanneke en Eric, dank voor jullie vriendschap, stiekem hoop ik jullie vaker weer 
in Nederland te zien! Ik waardeer het zeer dat Hanneke een bijdrage levert aan het 
symposium. 
Kaori Muratsubaki and the Muratsubaki family, my forever friend and second 
family. We know each other for already 17 years now since we first met in Izu, 
Japan during a finswimming open water competition. I hope we can continue 
visiting our houses and home countries again and again! Sayonara!
Zoals vermeld in de stellingen: ‘Het leven is als fietsen, om overeind te blijven moet 
je blijven bewegen’. De sport heeft me tijdens dit zware traject overeind gehouden. 
Maar zeker ook mijn medesporters:
Mede triatleten van KIJANI, dank voor jullie vriendschap en sportieve uitdagingen. 
Mijn prestaties voor het team in het laatste seizoen werden sterk gedrukt door alle 
life-events, inclusief de promotie, maar ik heb daarvoor vanuit jullie enorm veel 
begrip ervaren. 
Datzelfde geldt voor de leden van Pontos, ondanks mijn onregelmatige opkomst 
bij de trainingen, met tijdens de dienst mijn waterdichte mobiele telefoon op 
het startblok, was ik altijd welkom in het wedstrijdteam. Tot slot de RZC’ers. 
Onvoorstelbaar hoe Joost en ik ons in zo’n korte tijd  thuis zijn gaan voelen bij deze 
zwemclub. Tegenwoordig zelfs met triatlonafdeling, dus we gaan nog lang niet weg!D
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Lieve grote broers Patrick en Marc. Een klein meisje, maar ook een volwassen 
vrouw, kan niet blijer zijn dan met twee grote broers die trots zijn op, en 
beschermend naar hun kleine zusje zijn. Ik ben ook enorm trots op jullie! Ilonka, 
Mabel, Siméon en Michon, “mede Voetjes” dank voor alle liefde, gezelligheid 
en de onvoorwaardelijke familieband! Dat we nog maar snel en vaak op 
voetenweekend gaan en dan veel onhandige ‘voetjes’ aan de eettafel mogen 
maken!
Jan, Thea, Imke, Magiel, Mats, Jurre en Mare. Ze noemen het de koude kant, 
maar ik voel alleen maar warmte, en dat komt niet alleen door de houtkachel van 
Jan!
Lieve papa en mama, woorden zijn bij lange na niet voldoende om de liefde te 
omschrijven die ik voor jullie voel. Jullie hebben mij zoveel gegeven, dat kan ik 
nooit in gelijke mate teruggeven. Als nakomertje werd ik overstelpt met liefde en 
tijd. Ik weet zeker dat dit in grote mate heeft bijgedragen aan mijn ‘prestaties’ 
in studie, werk en sport. Waar jullie enorm trots op zijn. Van twee kanten heb ik 
leergierigheid, doorzettingsvermogen, het belang van fysieke activiteit maar ook 
eigenwijsheid meegekregen. Dit proefschrift is daar een resultaat van, en daarom 
aan jullie opgedragen.
Lieve Joost, onze relatie duurt net iets langer dan mijn promotietraject. Je kent 
mij bijna niet anders dan als promovenda! Partner van een promovenda zijn is 
als de stoker op een tandem, je hebt wel enig idee waar het naar toe gaat, maar 
onderweg zie je niets en de koers kan ineens veranderen. Takken die de schouder 
van de captain raken treffen de stoker vol in het gezicht. Je trapt maar mee om 
de vaart er in te houden, maar kan zelf niet remmen en sturen. Je kunt alleen 
mee- of tegenhangen. Soms lukt het daarmee de koers te wijzigen of onderuit te 
gaan, en dan blijkt dat je toch nog meer invloed hebt dan je denkt, “achterop”.  
Communiceren is daarbij van levensbelang. Ze zeggen altijd: “wherever your 
relationship is going, a tandem will bring you there faster”. Ik ben ervan overtuigd 
dat minimaal hetzelfde geldt voor een promotietraject. Dat wij dit nu beiden én 
samen hebben doorstaan zegt mij meer dan voldoende! Mijn liefde voor het 
onderzoek gaat verder maar mijn liefde voor jou is niet in woorden te omvatten. 
Schat, we gaan weer naar het grote blad!
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BIOGRAFIE
Nicole Voet is op 15 april 1983 in Nijmegen geboren. Ze groeit op in Wijchen 
en sluit het Gymnasium op het Dominicus college in Nijmegen cum laude af. In 
2001 start zij vervolgens haar studie geneeskunde in Nijmegen. In 2002 behaalt 
zij haar propedeuse cum laude. In 2005 schrijft zij tijdens een keuzevak mee aan 
een wetenschappelijk artikel waarbij haar interesse voor de wetenschap wordt 
gewekt. Tijdens haar coschappen maakt zij per toeval kennis met de revalidatie 
als zij keyboardles geeft aan de zoon van haar latere opleider. Het blijkt dat de 
revalidatiegeneeskunde perfect aansluit bij haar, tijdens het doctoraal examen 
geuite, wens om chronische aandoeningen te “genezen” met sport en bewegen. 
Na het afronden van haar studie in 2007 werkt zij een half jaar als arts in 
revalidatiecentrum Klimmendaal te Arnhem. In 2008 wordt zij aangenomen 
als AIOSKO revalidatiegeneeskunde (arts in opleiding tot specialist en 
klinisch onderzoeker) in het opleidingscircuit Radboud universitair medisch 
centrum (Radboudumc) te Nijmegen en Klimmendaal. Zij start in 2008 met de 
voorbereidingen van het FACTS-2-FSHD onderzoek. 
Het FACTS-2-FSHD onderzoek (acroniem voor Fitness And Cognitive behavioural 
TherapieS/for Fatigue and ACTivitieS in FSHD) werd gesubsidieerd door het 
Prinses Beatrix Spierfonds, ZonMw, het Revalidatiefonds, Revalidatie Nederland 
en Global FSH en was het eerste, op een theoretisch model gebaseerde, 
gerandomiseerde klinische onderzoek naar het effect van aerobe training en 
cognitieve gedragstherapie op ervaren vermoeidheid bij patiënten met FSHD. De 
resultaten hiervan staan beschreven in dit proefschrift. 
Het heeft geleid tot 16 wetenschappelijke publicaties en vele (inter)nationale 
presentaties en deelname in meerdere (inter)nationale werkgroepen. In maart 
2015 heeft zij haar opleiding tot revalidatiearts afgerond, waarna zij werkzaam is 
op de afdeling Na Hersenletsel en Zintens arbeid en gezondheid in Klimmendaal. 
Haar aandachtsgebieden zijn cognitieve revalidatie, bewegen en sport, en arbeid. 
Ze participeert nog steeds, in nauwe samenwerking met het Radboudumc, aan 
wetenschappelijk onderzoek bij neuromusculaire aandoeningen. 
Nicole Voet woont samen met Joost Christiaans in Wageningen. 
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BIOGRAPHY
Nicoline (Nicole) Voet was born on April 15th 1983 in Nijmegen, the Netherlands. 
She grew up in Wijchen. In 2001 she passed secondary school (Dutch Gymnasium) 
summa cum laude after which she commenced her study medicine. In 2002, she 
received her propaedeutics summa cum laude. During her study, she already 
published an article in a peer reviewed journal. During her internships, she switched 
her preference from sports medicine to rehabilitation medicine, because of her 
wish, as she pronounced after receiving her Master’s degree, to “cure chronic 
diseases with exercise”. 
After her graduation in 2007, she worked for 6 months in rehabilitation center 
Klimmendaal in Arnhem. In 2008 she started her PhD project as a primary 
investigator of the multicenter, randomized clinical trial the FACTS-2-FSHD study. 
The FACTS-2-FSHD study (acronym for Fitness And Cognitive behavioral 
TherapieS/for Fatigue and ACTivitieS in FSHD) was funded by the Prinses 
Beatrix Spierfonds (PBF), the Netherlands Organization for Health Research and 
Development (ZonMw), and the FSHD Global Research Foundation and was 
the first theory-based randomized clinical trial that evaluated the effect and the 
maintenance of effects of aerobic exercise therapy  and cognitive behavioral 
therapy on the reduction of chronic fatigue in patients with FSHD. The results of 
this study are described in the present thesis. 
In 2009, she started her residency at the Radboud University Medical Center 
in Nijmegen (Radboudumc). She alternately worked at the Radboudumc and 
Klimmendaal in Arnhem. After finishing her residency in 2015, she started 
working as a rehabilitation physician in Klimmendaal, at the in- and outpatient 
brain injury department and, a couple of months later, at the department 
“Zintens” for vocational rehabilitation. Her specialty is cognitive rehabilitation, 
vocational rehabilitation, and exercise training. She is continuing her research in 
neuromuscular disorders at Klimmendaal, in close co-operation with Radboudumc. 
Nicole Voet lives together with Joost Christiaans in Wageningen. 
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SPORTCARRIERE
Vanaf haar 12e jaar beoefent Nicole topsport. Na het behalen van een 12e plaats 
op de World Games tijdens de 400 meter vinzwemmen in Japan in 2001 krijgt 
ze de Olympische B status bij het NOC*NSF waardoor het mogelijk was een 
topsportcarrière te combineren met haar studie geneeskunde. In 2003 wordt ze 
Europees kampioen met het onderwaterhockeyteam en in 2007 2e op het WK open 
water vinzwemmen. 
In 2010 start zij met het beoefenen van triatlons met vanaf haar eerste wedstrijd 
een reeks podiumplaatsen tot gevolg tijdens zowel triatlons, loopwedstrijden als 
tijdritwedstrijden. Tot haar beste prestaties behoren de winst tijdens het Nederlands 
Kampioenschap tijdrijden voor rijders zonder licentie in 2012 en een top 10 plaats 
tijdens het NK triatlon Olympische afstand in 2013. 
Momenteel neemt ze met triatlonteam KIJANI deel aan de Eredivisie triatlon 
wedstrijden. 
C
ur
ric
ul
um
 v
ita
e
274
SPORTS CAREER
From the age of 12 years, Nicoline is involved in top sport. Because she finished 
12th at the 400 meter finswimming in the World Games in Japan, she received 
support from the Dutch Olympic committee and was able to combine her 
study with top sport. In 2003 she became European champion with the Dutch 
underwaterhockey team and in 2007 she gained a second place at the open water 
finswimming World Championships. 
From 2010 she participates in triathlons and, since her first competition, she 
frequently finishes on the podium during triathlons, running- as well as time 
trial races. Her best results are a first place at the Dutch National time trial 
championships for semi-professional cyclists in 2012 and a top 10 finish during the 
Olympic Distance Triathlon National Championships in 2013. 
Currently, she participates in the triathlon competitions of the primary league with 
her triathlon team KIJANI.  
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DONDERS GRADUATE 
School for Cognitive Neuroscience
For a successful research Institute, it is vital to train the next generation of young 
scientists. To achieve this goal, the Donders Institute for Brain, Cognition and 
Behaviour established the Donders Graduate School for Cognitive Neuroscience 
(DGCN), which was officially recognised as a national graduate school in 2009. 
The Graduate School covers training at both Master’s and PhD level and provides 
an excellent educational context fully aligned with the research programme of the 
Donders Institute. 
The school successfully attracts highly talented national and international students 
in biology, physics, psycholinguistics, psychology, behavioral science, medicine 
and related disciplines. Selective admission and assessment centers guarantee the 
enrolment of the best and most motivated students.
The DGCN tracks the career of PhD graduates carefully. More than 50% of PhD 
alumni show a continuation in academia with postdoc positions at top institutes 
worldwide, e.g. Stanford University, University of Oxford, University of Cambridge, 
UCL London, MPI Leipzig, Hanyang University in South Korea, NTNU Norway, 
University of Illinois, North Western University, Northeastern University in Boston, 
ETH Zürich, University of Vienna etc.. Positions outside academia spread among 
the following sectors: specialists in a medical environment, mainly in genetics, 
geriatrics, psychiatry and neurology. Specialists in a psychological environment, 
e.g. as specialist in neuropsychology, psychological diagnostics or therapy. 
Positions in higher education as coordinators or lecturers. A smaller percentage 
enters business as research consultants, analysts or head of research and 
development. Fewer graduates  stay in a research environment as lab coordinators, 
technical support or policy advisors. Upcoming possibilities are positions in the 
IT sector and management position in pharmaceutical industry. In general, the 
PhDs graduates almost invariably continue with high-quality positions that play an 
important role in our knowledge economy.
For more information on the DGCN as well as past and upcoming defenses please 
visit: http://www.ru.nl/donders/graduate-school/donders-graduate/

